var title_f27_37_28240="Algorithm for management of the red cell alloimmunized pregnancy";
var content_f27_37_28240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F86945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F86945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Algorithm for the clinical management of the red cell alloimmunized pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 724px; background-image: url(data:image/gif;base64,R0lGODlhLQLUAsQeAP///4iIiLu7u0RERCIiIpmZmWZmZt3d3TMzMxEREczMzO7u7lVVVXd3d6qqqt/f319fXz8/P5+fn8/Pzy8vLw8PD+/v76+vr7+/vx8fH39/f09PT29vbwAAAP///wAAACH5BAEAAB4ALAAAAAAtAtQCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//QJ9nSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+AwVyQum8/otHrNbrvf8PiQLK/b7/i8fs/vq+l+gYKDhIWGh4hFgImMjY6PkJGOi5KVlpeYmZpUlJuen6Chonydo6anqKmqU6Wrrq+wsZmtjh22t7i5uru8vb6/wMHCwx2yxlLEycrLzM2+WbSNxcdU09TXStbYT9pV0Yzd20zh4tjk5UjnUd+J6uhF7u+w8fL0TeyI9uj68qn84v+S4DsU0E0AWwcIdAiQJcCALQX7iYpoRkBAix0EDOjwEItDJxQVAcAUEsnGWxYF/ywZwHDJgoweGnQcp3LJRy0lJW6id3KhlJtRLEpBwNBBggVNWDIBuiSnh4GGnBYZYCCK0iUKpjFoSXPpTCxSdV7iWdWigjNCoyRQyVTJVSVtkziFWijsEKrwBKTsUKDBrYO2ChA5cAvBAoW5DjCwZdjD4g4JDNw6AJjAWcAcIYqlRnZIggIsBxA4gMBWVQIMFyRw8FFAAsiCUXsgfKDA64VCZat2UASxZcm5ClS+/PeWcFuWPWD+mg3ayLFdej7MaLFlB953uRoh7CCt0gCNiQYYTQSmggRnGzDIypa5FbubI3Uu0OHAAAQHHFc9gH68cgLKPZQAQ7YdxhBtAzRAhP9QBQDYYBIEKAjTR+eltx5M2XlQYUwXtgeScyRFV1V5elkzXgcGLPDWEAr0VIB3DAFnmgEjDgETfbcQ8GCAmsUnC0/GeXAVYoGpJgACgjlEm40JHVjfkRwpIJSRSBaxgIxVTfgQjsjtmCGXHegIII9NzPWcJfDhRWJaRXyWoBEGIODBSy9O811jQ4yXn428bchiB2cx4F4V8PlYS1I1CtkSA4l6YAABR/E4oHJH4XXQnvqlBV4CRtCHFAJZeuinhhgKqeCoWQU66BFmhsiFmjaWOIRqjC2Ao2BDuBYmXzAO8RhfQtrCKXCU3VIVcAisOkWhhoKD6FQtkTbZbD7xqOv/Zx5gVJp9yEk5zUvazVZamKGSiVlVmClw67mOMqYsPCBC16wHzM5LUCCuIeVHq/I2W6+9dQWCgIKB8Iumvf8CPEjCoxhcCcMTKawKxKE4LAnFoGAssR4ae2KxfAhvjErHO8V78Lwki1xHypl8DAnEHYwrWGijjbvfuNTFDNlZvp2lM7ACIDZeaquFwbLKcCQ83muG7XVcmMTZ8tB9pnnAJboEKNTYY59FCl4ZLj8CM0MBcHpffozOhh4DctJbokqwehAhvWQDOOkQD3r5xdFIu6E0AQsYWJ2G6HGYFW8fDfCQRZh6qqdqwpE3hI5y42q0yQ+bARPjQ+LSIK45D0Hj/5XGum31aPURQaXle/cdcRg3UZUWmGLmObWTteFMWUc60liEQw6MKUbYh4KtUgMAXpU2EQwwQKqsjhrgqQegmv7g3XkiwOnwrlcsxkf81cli4X+qqii1CSnoQH036ain6gkQpTnmF2uOHNzR6q6AQgpBT6O05LIegHTlE3CBrXsZ+94tnMcmdgGHALdDX2XYx7uZCWsIDYjUAbFAF0LArCZQyAqmrpCvDSKwZLB7VxKWl4UVXY6DZ8qc8Z6AkWplYWDzOyEKwRAXtzBmhFZYn75MaIUOLixkOtQE3052BSMKYokyTKKr/EU/kKFMii1DYhNjWL8rYrFfhiKeNLT4xf8uUhGGUwxjGZmoRjSOxRlwjKMc57jGh83xjnjM4zPciEUo1vGPrBKFE70IyELGwY9pGOQZDcnINiASDYpsYyMnmYZHniGSPrIkJaWoyTJgMj6d3OQJQxmGT26GlKJ0HSq/YEqxrDKVKntlF1qpE1nCUmK23AItJZLLW5LRE7vsRy99uchPBLMexEzmFYbJR04q85nLEiQXdchMaPJSmmWspjWRGYpjbmMCEMAAvTyAAQhMYJvoDGQ3p+m6DHSAAu/sQAbSSc/yYDOJEsiFBOpZT216g519s0AFblEBC/CTnv7kBED7BoFbQOCgCL1nEh9wiwdANJ0JZcVC+xaBDkT/4KIYlWgSL9CBC4AUnRmVgjfR8dGTbjOl69ioS2cqSWPKFBx6zKlO70jTH4k0ijXt6SpgCoWVHvKXQvXHT80Y1KSObKlWLKZTn7rOLBJyqlQFhVGTZowelgmrE4Pqy6ZQQwKA8ApxwVDoUlgNsCq1qmmkYeoa0DaPuKdU2VKaCuXi1qza1KpBSV3zsoWYmdlMXFW7GmGqJrrJZMQ3AEQXS1KXq8K2KzCEtUUAxqO1IX61r6Yg6hO2+oaC1HAA+cGWUYTkvFSljT9nwVsHFpDWmqz1tf0xqxFUuz3RyQl7j8MWN0AbWrGKjaz1sc0BFjuZq/CFSHwpgO5qG6u0QFc4/8xhLkLKhpwl2W5yrBsHcRtm3OIFNj90hRy0PLA+xSRqbu39mhGuU93Z6ud37hEutXiDPA8At4JQEO14PwRXMMp1T4oLGnKCpVnEbhc59TkPiopArIwsoDQ1m0xcFBwmBmctW7fZLICHO+AEFpiNrwqXx0psYq3etB1gcOGKWTxjFwO2qTRG8SZI6zek5hiowHxxPsQgYyt4dXhn5euPbxxkJjekI0V2QlqEwhQV1WpBNlxmktOxZCdrgseO9ELsVCxXIzDFPoGTDeGy/J4tq7PLOv6ykO91BNFITSEJyA9gEOAzmTHXAFSbcG9wx9mYHeZ+xfCq/MKn5iGslghZWf8AhwUzabddmAFWhgy84BznWcw5KibZEkxQkypHTaduZFJcXkcoG9oEV3x5JZOZ5dQkuWnnJeoaTQCcx1v/Cma115GfRTxrI053GhNgZgM5lAKjHQVNgKnG3aAlWMEpJ9o9cUIKmLJMFCQZYCvarU9iIFNXv2BvnMZmapPjmiEYlVpQ0JavUrx7F3RRELzDjvWZq3eERucpMv4tnH59DQ/pfkWE9kx3VP/K7vP1as8+U8mDJAxoaWNZZ7sD74XDROWv0G7aRWBPTMbE4QH6xtIIQMD6GFtshY/1xEAGpctfbuOGu3Lmx4W5umWO8zHqfOGZ7LnPa25gJwDGGAJOd9L/mZDsNQTkJW6GQpSvEmU2sInLQofxz2n+hKxgYepkjsPV35x1UG895yuR2qEFnadbPGQ4mf6McWRUAC6BhmyM6TNm6WYEmjmmVksz9N8NzVzDnBzrZTc70Y+dJ8BdOABjP1yANqSefGeIwnKiegBKDWi++4fvU8GPcsKzWcejBjyf4gp3xj7fxNN58TGH04gCYICx78ghHzc3Q67C3Q5r3tkAupHw6twSGaEodjTChQFaZBzWb9r1Hizv0JMwnjRDvhvvHsCoIF2fN3Fn5KbKTvahTb1G8R5PPAof6okQpznxyr5Khv4Rz25eH3JE0uF44NuNVcOq3OokH/Z/eBcz/xF3Ou4HRG/xK0/TAc4zeLzyGgpRABs3fM8nfwUjfc7CBSyUBg6wV/jVBUvHaSGoBE2nBlJxEqIXCEfWVhb4RBiodVLVgnswggLxaQFzVTI4gy84ZEgXdU2Rg/uyg6+3Ei2hFHjlBn4BNTjhg80BhHxAg0hQgpXkBC50hG2wHo7RgGDBhPHnhHkAhUcghWhAD3bHEjJSLEr4XInyGIZHNA4QWQFyEKoWfkegHkXwaH8iaZY1HCiHaSfRW4jnhXgAhkYghmdgD5pnOpTnPAw4a6nnH/6BWwowHipBG/S2IHlmJYDSIJTBa7+GHoVjh8HGEJb3g4L4hUKoeESYITeCC//Bl2TGlyJrUSXXBRQs0QCNcjqxVQTdVgDfFgDh9nHkRgS6Z4qneAeEKBJeVmcEY4R9Qj6x4ogUBilIsYFAETTQeBfo9zsAlwACZznbxxfJEnKUFYjHKAfJSASGmENMIICXhYYTZoUKSC35o2FfMY5FEG4jJHL9lVkdxi4WlnIrx3bmeI5cRX/T1wdG0gfpWGIN+RQ2GH2CQFdBaJArk4o3GIMWGWYImYEauZFOh5ESmQYrKAUJwWbKBpJH1ZEwKAaa4oFPIBOxVloqeZCwt3Nf8JIaSIpL9JDj9ZDrSERh4BuF1hh8qIaVRnfbFiZw6BCX8kI1yZE3CXRgoCmjATn/i0gvDdhr7Jd5POkr+5FbXAgWUdljLMmDZaCTlSOMlZgYvZc8Xyk3nlOSWeCTxAWUETl/aWlf7VMA4VgT+vV9/cVs9mWNMPkeZSmVDFd0XzCBfakcpYMhJedhcDknGAZA9yaUiXmIIqmXOLaZ3HOWQxh0oDmFoqmKpFmanHmaGfmZqukFeLmMtfSaqzmVXJeatAmVi8l4wpSbmilnsnlNvqmb6/ZGO3WcyJkMw0mcO5aXOLicxcWaAGOX0FmBxelM1elX15lE1Jmd6Gab3dOd2RmbXySe1UmefeSdp4Ce2KmerwOequSe5CWdPiafwWkJQTlU9uk99Pmc+2lzyOac/x/5n7HnadlEoDW2m9yJoDukoNTEoErUmf4JobfZnAdKoYxpoDiVnBzaoc2AoZ8Fnxc4SiAqXv15kSRaok0oohWJQOaZVOw5mn3zokIVo6g5oyq6og7amvGZowUJnB4Znj76oxrakj06pNZpoYYATuJUDOV0ThvDpOP0pDn6ABaFbla6nYPgTvAET/OkMlwaT1+qohbgUSR1AR1lUEpqCPmEC/ukMm16C2+aow2FCw+lpYIgUASlpiKjp7ZQUEM6AbkApWtqCHXaAXeKNIeaqD4KT7ZAASy6BxRlC1eKNJPaAZXqo3E6p4VqCB3VUq7zqUhKBANVAScaB2eKQKk6qv8eoAEdoAGnGgeg2j2ziqQUlamdWp4euqu86nridHa8GqwdaqIDCg/CeqzIOQ7Iuqx5pAW0QKM9oqO4Ka2u2XLFWlQLBa04QazVmnD16a3dOlrZ+q3WGq7fOaHgOq3/RK2nxK3qSqTtaozmeg/jiq7l6jdj6QbOR3bsynP9ioxndZJhZ5bN1HqbsK8kQpbyqgRL2XFapjnQg7BYRmDu2q0RYQtnQR9IVgQy+QQ3kTgDSyjOWq9J0LDX5kj5mivxYIXIULGr+IFthgYSewQze69d+AgbcZims60Lyw0BmDB4tRVQ0BZVJ7JVlK5J4EJ0KQczy7JRsLJW0RKMw3+W5Xf/RNAz9CIzIAYbhHEWw1ZpgzEuDOA0j4VoDsYAhYd/FNuzViAjCBB1TpsXUWAUxBaN6ZCyIXqz3FA2AaCxAEQwRBBoN1M1cIiZIMQl3HJ/TjMEf4Z7zWdZatiyR2uzJiG14mYalWa1NtIgtVe1iGFnmYi1OVMa6BF3RWARGBY1yQETJzEAC2CHRCBf8Eq5bmG5ZNJrZwMhEkI2nDIpBYIXacOVvjITg+M21uYY7rF69rC8XOA77bKLcitmq+K0cSu5/9oUx3EQWUg4Z6VqjCOJ4NsRePUdjkcUxRu7HQGynvGJWsmCBZuklauyt8u+uQsPW0m/oqYS/jY3OQM3tQd//6cLKFmYlRlRfY+3Wp0ntHprsE9wFQ6rjy5EOlWzOeK2J0+SZ/Whj1drOWyyVrkBji5Ss+d6vVLgvI6hIMNxhmyIfxZBHyVCul5rWYxrHCk8GaKLty4Lv2UigYhROXfBOvNWH9c1xKDTvTEye/97BB8bQfpYvSQsrk98Pvr2EBCsYjBRxTPJEhIcj/5TFcU4sf/Bls5Ley/RgQ1gG9DLwAtcu/IrXwPnQtNTPTDRX5NSNkiRNR0xcMxDvNaQM0ghFPDmW+4Hazmsxlhgwg5BwGxBesXbv0JSFcLLI4psBPyLw2yrw+MgGDiyvSIXuLizgaDcWuNbN9bHevKVOAQzcP9OvMYqRbIvS2Vt88ZWDJhAHJcsEcehkhYmjHDyW35/acCywQCfcR6AyK/G/MrFQHGT6UIARABZcj9bK1wuXFkLFra2MLZ9LAATKBQANLYQ+H5rG8VPYMIMcMauaDqx2MFdrMHfxZZzgiU7W5eFjL2TUwx/23e4g5nLpT9aM8p3oXasR3EfcSuTucqzi61R7MDJ/Bqdu2AyJpknR5jZ0cy5PA000n8B/EOQOcFwo3aU8im5iMm0O5t5e8gjIhkHEI6Ig37qrMuQHF7fpdJWY19ybMkkrK3yPLkj7K+sLJzzXMKFEVsOhBAK2NIWXRaH910bPWHEMi7OHM8KK87lIBX/z0quOx2vP+3TPd2bOo3TUb3V3JTVXC3VADGyZL0NUFsFIpwFa02wl4zVcsGsci1HZg3WYdDWM2kGS4u0hhxYMpsTmJEaKFi3TxvO89oHtYqnIx1gEUsPeI3XRqazaU0FkK3WYSFEaGYgy2TY73qjucrXlP0Pj40xe73YV4032wMeaSsUnefDfHgEpttqGSy2qLszRXA1VhNiSPB5RCA/1twBKDxZQGTaxA0RtmXTTeFmlW20CanYp30E3Uy2JcfNYrva2mAb2WPdpgZeg7eNkFbdwne2RUnYfV3es4ItgXkdrF1BWUmzACzbisHH/osEnvImSLBYZyW7vtJaa0GJ/1GsMQZdDcoN4GgHnvoQyHllHY2NvNCt3tqgXundHcXQ2u5DertdV4QhcQCC4K9W0seMvsGjISE84RX0cUhQjPBNOb1swlajO1CifUjAy9lGybgyANj11iINBdYNw2cIE78ygJZR29moAGLb47XiGxobPTFxC2nsvkG6o8Xtw71svNPwwZA24mY2ACHOfIGx3uAVi/e9GEiS4Qao4mRi5je9BIQhG+1HJ1Q2QMOcjQhOjvZhb/ENxiwOX+W4gQOgEuujAKQR0oPFHivIvFygvPOtVgJQNvnBEouYEo/8O3UF1corW6KTJdjBs8392VGO4Eb9x8WA4G0OzvkYJjEiJ/9unmhwLhzbOOexG3wzs+Ez8Zg/HQ8GECm6EoHcrDXYwi5rkdETpi2zfc0u/TsQlrjJEbt/MdM5ko/jEtw4DtpSwOWk7juK7ry37IrFPhhiLhjmgeUzfen/gSLkXdj1B+XPvR20nc3bbM+0/c2EzH64Du+7HjPYMo+/ruyYtWcA0s20Hu0U04EJetZJMOqwZu3YUcCmt3nQuO1mFny8YfD5xjiB3iYwHU3n7twjKPAmKNb7wNlkRe9H/Y4BiRwDiCIOv9SCARy2sSsSiGHBEj+yeGVfbaQab9VevdkezgaHcfEy+vNAetBhbdcfv/OVJDVUCfRF+uEkTfBflxmGcGT/hm7VLmhcSRfgsOnxW0C3XKDocFIYyK3UQp/uTf/kN/8G/AFC3KWzCauYY88FpQ0SPui8ktHkHqssUx/ZfRD3bOz0gzgKVW0QtlAT9OHzcu/Ws2sRePYYCnLPTvPa1BIYEEcvnDsYhYF/PO5YsFgj5XzbpTPeS433IN/2cMH2ZTZmUcD3SRuyMOWTgd+8QZKEAjxfNeHbNPsa2KK5prPCRH7NphutPQ3pEBTug74Wg9PeMS3AndeI9+3giX7cOAIgiDwojnOVw6wl/90VNmH6qc/9snYFRdv6gO/KXdB+9CUXtnUbzOG7lZKCJLJ+4lFXpQj8iW8nX6niNj4754y+/wYIAp5AeJ3goagydG0hdKhhlGedyjTKNHiBtDqHwABFKBRIHiKuGWtCS9GUIThsIRS4ACHRQSw8DGw4NQB2aAd0r+DtBGCHoGEQcKMCiGWLoE1xeYHNkSmgMYiRJbYETKE8OUZKTlJSQlZiZmpupgAAOF5yQgW8kXClleGYoCScHCQUpMwdPB7YQZlU0R2MIcQ2dCQ0iuJKhjbBoNwmMyAqmCR7KCT8NTE9azEUreIY7C10vDzNlDg82lDpVNGmEPQ4CDF5HGGLFU0dR+WrntTXbRFYsIBAAD1hEAxT5qyDgmbSWg3ogSKZPDsLYHmANU1LA0SAAg5MOMeBHkBgPP8g5ELrFihiLl+qgilzpiRPLWmO9NBACatYTmwwUJPAXAphSxIsYMnP4Ciez9jB3JdCqogny2KsadEjGp8WOvLcC4BFC7cUArwQCBeNnK456GQEyWKtT7x7RzzoQnBPnyVjJ5JM5Lnk3oAZQdLgYBnurocBL4AMUECRcCMiDkgUOCy4ooEVQQrw+lJAl1dyjRPypam6EtXVrjXZxLeaRQcCAd+cBETHQ9YOEs16wah06okxLsS6gOGVZuvWr59Dn+RcSqQO5upp21LkVQGmUG7B47UQXVCKe07zrt1oYxQm3L15AOdzCcHc9AUSrB59P3X+/mt+Itt/AxLYn4AFIhj/3XSttYWcXLq14JFx4SQWRCO99UCbH8lMkwZLBiCVx24QdoDIWbWFgxyFExawABAJ5HdTgjJNN+NqsaVmo44zNbejj1H1NeBwP/JIpCg1GkkMjsUk2WSQMjoZZY76CYmalJwgGWWWV1KypBNcgvmIMZmUFd2QoLyF4IJhsrllk26yGYWXMcUpZY+SKJamTPIwcSY+AnC1iXEPkvlknVoeymSinMw51aJvjonnMGXOJI8ZVqLpkgMJ0ILAV5iseSilP8JpZKmLNirmo6ZGusVYmbnwhQu8oUEDEWJBRVosZ3hFSBp91kqrVsK2AChWwbrBCB9NzNHIcBgOhquj0v1n/6lLozJnrCankrrqJqka6K2Od6bgTxGKVUZCULxRw4WeMuwxQBFy8HnuQg0500p2NTAj1Aq/LdtEMwggAJUY+Qrg7pfU+mctMdiqFqihi3J7KLiHYZyxxhtz3LHHH4Mcssgat4oCYCKQkKcHgKX1mcNH9YHeLPWiV0ISPjnGGDQxtJwcZNVYc15J7eDc3V7TlgwFtFykZV9jyO6yS7C3hiMrNfP0QRY6vi7WyEUO9LYKbQMsYEiENbRMwD+NAbzwqhXXCS6YcPsYCnbnSrQKYOsCcnR65uwkczxCn9tIeA49IwDiO4vxaQrrhrcFp3idt8N4L4c6BeKtqHTRfI3dm/9CZgvIs+4rCigMwwmF4eDODUEvANje55nAhUApVc7vE7PMAiXF4mYiN5d073iMg1rAmtlfJIQ9hN+N9ZHyhUJ0aECfFhLbgwJNM968hhw5Dv0XQC/9fOZRMOaYPIwpMykSaNRlxGFGTzSOAQuQRgOl3oRxkQC+zMMnudBBAAwQGgAyrn0NCB+d3gY8TAjvSsQb1wMzgYB3XWtiArucXT4HHiG4LjxD4xtY6peD0aFEf29ZWx4QkADLSaN2IIkRfXRXhhFczXeJmiCYIminB/Kwgps4n9LYMBgjeBB7yEnLAarXPHmsxYBoUNvrqoI9cAxjeyhaXQvIpqJYmMBFtUH/gV6StkMhTsKHiAJeENEIKg2Kwk8IOksqVCAETvjPjKJyYyTU6KQ2qomPgWQYTORYIAT8RjlwEEUDcnegRwEySn6EFBu5pBwMDlFbRSKkIAkUyf98skmT9NEEIIABKWAAAhNw4JUQgomTkUJPCaQRHDu5n1DyB5dGGqWPMtABCvyyAxnwli5d0opXmiKHP5FYBjkJk5eZoQPPqwQLppkp/xQTOtn0ES93JAGMSYCYqjnFF9BgjhMJhwgE6M2ndLFOI6qOQiY7Qg6XqDVmPqyWlJhMCaOwqTpm4p/6wGCZSHPBRzBkZZAAgsGoxEpb4qCbOrJABYJQAQuIkyYqaRZe/4pgFDckpWCNYxfQVrE5Y1kJVhJhT0d0xxx9YoJm7bEmJaBZxZ90Qx0JrQ1mnnAWV8I0TNvckUR1BIEgQEBcPJTHKojQuxLYYhg9k+c5AqgMcUDBDZuKBaxiNksgOXMKLTWJHOjAtC+kwleZSYIBRjArt1JVrXAdjRXSprWcPq4HcBBGZmTAgJOFdY8QjWiADvWAIDxAqeO8R1M9WhmksISEOF2cJn1Agmc4gD3EweeRgoqCTXVUDHGIAZ/W6TntPMIjGAHtal/Yt554ALSUcl1Bv8KEFMEhBl/LY2DrNFQdFVVHEehABCqpUcaegAno3NUwmseP7FUlq0qAQXd28//VlxBxCuBwQETcIBnShqWDqL0B14SAMai457yrwJ91V/gVHthsIC1Q6Ij06NvBEvZRF+jABYyLXwV5dgcaScALzdNP9h3xdRgpyudem5HPWUehB1EhXvFyRwrBim31A+iUfvdfDwRXuED8MIB7O4oQeSq61Vvf55hqA7iSAMbjlXFbpkhhKsTlD/JkYkKNgClFQZLEISbxc34ryOwSWTVGVrKQC4uLkUE5ylKeMpU5Zt8kYzfAWMaSYj98sS2vhlxgpqWJx9zZjP73y2Ymsw7XzOUyu7lQaMavmuOcT4fa+c1XthFyBPtQOjvZbXke4p4Hjec2X9MvVcUEODAZBfj/eS3CS9gDMLDgaD1DwQKJHV6TEZ2twTanyqIeNalLreVFK5oTz8gEOJAXg2eUwQCIcGVSQvRSKJSyA5uWYKcfqQmDEjRhNM2kNYZdYm8Vd8SVIE1o0Gq2EjF7Zy/SgoqO1rK2Boe5AxAMaEE36RS4cijEqZA0FxDPBvtOAsAkrlB73eFMmKYKQBu3ktNk01z6F0yr9PRAJ32QguSOGztbXWcibK1ofBSyInXVsBYRBAXAGgWt/sjtRvvjmzxAAxUNQn/n5m4g//q9PbBnDZyaUBiYu2XaFoxdmY0CX7VV5afZNjkJ1gKi3HnOXIJABiSAUZArmjRpOCAYbZDAGcDy/2jJeKoQzsQD7rCCKKAdWg3TkYe2bikGGCg110f2cUGHvG8sRUTtzkWDdbX2aQ1th17tfY+0n4EWG10kC8+s8yttvQMVgMCuVcUac3gHIOU4RxTvhgOEPzYpmBI3KcrWgTK0FL4WBprtQsJZjGv8MB3ntJcD3cBNmEYMDejqGMsuAk4JobxRbQJ7l0Op9B5m9QlubJa7zKZ1tyACm89SW1j0RQubV5Ns6YPSfZrtmpXr8QqheriDwIB5i49sl/e1unPf7s7zWxLxpp4yS24XArzdgylVfoolbRLYXqqftG8mMbvufpAle8k4kOyfU5Drvq8xzZ5HGuhzLCLXC5vJcP+DjA1Jb1BRW5SLF8RczLCEiyVYztUfl+Aece3ejNDGwtlepuHfH33d5xnaG2Ugl+Td3uGf/PGRCbIZoGXfB77bGbEJz/lcC7IgnHkc9vnaDBba9YXJvt0giV1SCsZJKZ2S1qnSYNUZDtJglExABIRTDEhABPCgh/mHIcWUsfXTFAAVEMaJLwETMA2TEe4fQr3fGJKhqT2KFwrTL4VgmNxbJhzTJiXKNx1GOIEhEpqZHAYBHUagJNhVCVwbFlTFtKHH8XQFQ8zV0/SK1CxHpTEEEzBiNbgTtJwbCCYKRVnUz0HUkNmht2yc3uVbJtBWIxjAOrmF6jQGDdiBuSQOg8X/1gvJS1U4zw74i/ndFs4910nBwMWtoJQcVQsklQpuIphxQBBwwCdKQushxvodHSrewXQdAU+o3i3MjF3MzyncDxNYYx2tQvpg1basymG1wAYKkiYG46KAo64ZYySgUPklF3JF0WnczSqiX/ukxxCcB/31hLUsWFVR1vT1YJwMV7IBYzli2QZ0wAYoWyUYIIW52DveAiGqiGSkjeA0kQKGTYegFRFchCKMmyS6CQq+xH5tXh0SJJZt3SmlY0ny36II5ECqJIm15N29pN/NJIGQY02WYU7qpJSdmh2G2k4CZVBujEzc5EyCZEIeWk2GC9C9JN0UZVMq5Ur+Y7+5hj82/8EtQMwg7aJPEmUYRqWcRSWSPddN0YRVJkYjZOVMXaEWgp1RduVX1p4nXdoU9FmSiCW9pSUxmGX65WWxFVkOrsZefoc0UdJLPKVKhkJScCQfzKUlNCbr9WUkyJHKUOKhHU+0oUEsHKIdbJsqsNUhwlUoRORmouUKfQYiDp1ZzUvPEIut2IazHYIHMmUD7MWgQN8mCCYOCNTDBFt0gaVLHGZJhoIt4McwwMpjplomrJpLTKYuAuYlmMvrLBIXPFgrqp0TqFYssFYjBIo8VidoYeW7wMcr0kt4ZcRWxIDptItpwQLVyWZbdtFnTU6KvURuOhhv/ondAadXwqU+udKmwP/DW3SbHaXcrJBcGCEAAyhmMFxlF8kXYjyOEmXNgsLCZ+hKVylP9IWBrFDVUk7JyYyAdC5PNGLKKqjeHQUKYJHoTZECA05PLA5G7yTDVNFPABHde76nPHDUcIxVC3WFHywCGHAIQTybR7wcG6iVLMBPcRTCITBby33GsQwLDAiiVDIKf/anfZWE6rgFDrRaEgwBIrTW2JWDK6FcU1ScxJDCSgTA2J0pPXZDvExKwoCEK02nYJyP4Uma3pDAPiIfvfmpUYgFDninn4anLERY4Ejj4JSQoKbnp7DYR+ColVrKwGCgdf4DA7Tp1XQEUyAEDGxPcjkSDE1DAM4f7STMSeD/zliy3Q0wA8KYIutY6bdgaZa2Gf8AXxC8BUL4gqwFQHmRHgkEQ+UAg1FY3RJgXROYhh0Eq04Eg7MMQ4uOUZ6YRgHdAGB5KMgRYlvwKcq4KC682ETCChDMRQtI5LeWiYZITz2uWBHASloQS/wE0O/NKqWGhdDkznZ1FzUEq9BhXQJIxI0SzVU5jM4IgL/e6Hrlj6vyTNG8Y70GT63aaoetQfh0qeTQAIFpwT5q1iP8wNE8BcVZnmjO0KZC31NExN/oRMrkDZ0W57XiaU9CFHVCYAvyyeTAx/wN2At1bOCpjrHmgWBQlsMMrdME7eCto/6cU3qOx8PSpJJI7MSCXbO+/xylrGLgeOsYqYgKuQgCwMNykJv0JeYUVQYdKBINJI+60leGjs2GLs+kwu1/Iccb6ue7xZ74EEoeoBgB7QaLcEgCWM9pKumwOIwWpQWTHsdp1lgf0IAu9JVH5kDcVkJwEuRRwsRAoBsoySwOitmqhGyCOGXUSi3EClV8zshdIiZgSokiOectveXoViZObu4Mdq5bwgTllqPlrqEMQmVS9q5hii7s6q5MMqXtbiUShi7sgopQMm/zWkLzQq9QGkP0Um8Zvq7yPpAGYO/2+u44Bi/35h/4im+28hHujq/rnq/4Dm90mG/6/qX7cu/6Qkf7wm+Y1e/2yu9z0O/9wiH/Sv9t/r7G/vpvXA6wrQKwawhwAdetAn/lAd/I9zLwgDhwBPsZSVKwXV4wXE4wTSRwBj9v9YJwCIvwCJOhDXrwCWMTCsdJB6swBW9wC4MYBMPwDKsuDScIC9uw/75wC+NwDt/vDqtwD/sw/AIxCgvxEKdvEZ/wESPx+CqxBzNxE4PvE2dwFEsx/l7xj1hxFtuqEKJSEXIxgmxxGPcnFwbTF5KxTcpwGl8wHraAHrKxf4xxHNekJbbARdHxf8xxHr9kL3bAL/LxfuxxIBPkOYojIavGICNyMAbkIrPvGjvy/YpkJOsvJFMy/MbkJc+EImsyNpHwJ1fZDHNyJ6Nvf1Lxlo3/MilrkwGLsiWrshRqcCu/MpGdcvgasSvP8n1laS0nWSrnMpPtsiz/Mn7xcmEGMS4Pcw1GTLHsSBvaLwz7cjKDlXT0waVloX/g08FBKAzQwAJMiETAAwNNJQVHszSznzHEAilIAt3qiDYrXxXQAMGEwf8owwDYWhIWcDmb8wLjQyw8hT3FUxCkjIOeG4qkASDiwCOy08wRQDJ0la0Un0UkgKdEHA7MwfZkLu+SMzLvMwdaQiyMopsu0g1U3qeONN2RYpmYn3qugEil6ONpcxIUUGGEaNA8YA37rz53tDd+sB8EK1esQrUma1U54EegAo2yhEPDD4zWzwGkxQoUXENN/9XaaXQE6/ROxy4ozEfHAnVylWxXz967wIJkJTXPvIO8NnWfxLNLX5DyaRg+D/BVY7WWdejWgrWGgnVRxwduLID3DANF0AVTw6IZqAFtAKysiY5r4TT/yvVcLzbyCrNjI2UDR7Zk767sQjNHWzYFBXNmb3ZKzkbrTvYSa/Zngy4fOh9VUwIVVlAxd6Bp67Ij3IUtBAQnsPZoQ3Fpw/ZqPAAmFu/ARh1eywqQcihz/eh3UVe5xKZxvFAfFvfKvAFqzBUefNuBJgELnMCbVjUDNzZWHxYYt2UTsI8dlPRoZQPZPRY8cioD5KJNB+3ahWINpSwUtNZpDRhHkJ1HsIU4P/8tae/2lQzXL8Ex+SJRUTiAUEcDda6CHDCrZjAT0YUeMlIYYPyPNFWD6llGTwn065zFU42zVev2f9PEflmUBmxaa8x2Z1YeQUQDO66selfD5XGBSgjghMHs/H2Kn85BfnRsFZ2BkX44d4e4FIMy1w0hakdIGbStIomUQK9O2XoFM/2eYS/kjX/P4U0kXtja1lZRgD52/XY39hYzid+xifc3boZCZMaJMxM4iEtzMQc4BQw43EiMmofJK9hikCtwmCsvL393FJKucFZ2Lvu5b4c3ZvPwkDexax+vLdl5914wnwuvow+IVd52vbFlFSs6EjO6ns+EpYs2pk/zMb85pWv/QtuWQGZm7edMJKoLICP0WNQtl24qdgyRTtYcdw24iIIaNk8neql30paUdwmky3fWeoLXKWqwBEI4dQFMQ0Y0AkilwJeuUwA833qTqXWYqVv7Oqknc6dvt7IS0ISv03mZhf1c3VmiQEcYwGVYO9MZDK+OhqYGa7MOawoUa6hL7p5v+hCD+2/TZcneuJ+eexisuLKvFIyIgVEI6j0fRcZSQ8f2eDiUUfKptqfHdb/78L8fumQ66I3L2LQDwUCXmw/MilFEzqwT6ipgLZdzOYJ6bX2xxqDPMsfve+7S/CvbfKBXbs6r8s6fOaJ7+zADfZsLumd/u6mbss+TctEXvVYO//0vO32RU73XIT3RM/DTj6+kj67Wx7aIxzCwF7DXgy/X/2/Wg30naHwOk32bpD0KmP3Etr0Ogn3cs7ICzz322n1nj/3bh33S473f7/3SB/7bD34sF37aHz5lJ37dr70Nd3rVS/77uTngg3b8Vj7W47b6Zr7Ut/YPdz6hf3795n0PPT4NRz7oC7nYX/YUh37Njz4Rv77Oe8sDnDgK2H4Sz/7Pe4sFUCB/DZehw27uUwfxM/bpz3Ax+7Eviq/v6x7wd4Dwu+/ih6W4TADGADr2Lv8f5zPyw7Br4x4FnO/1H0b2wy/1K6Vr4+GAc2/48zvrr0pFVYD7rv/7W763aEAHaP+v+8o/CHjiSJbmiabqyrbuC6cAENf2jef6zpddD7Q9Oo+g8Yi0aTqapPMJXc2i1Kr1SvphkZit95saFsHksmlqTqvJ2rX7Dfd04/Qnuo7P19qojv8PGCg4SFhoeIiYqLjIp+f4iHUHOTnZaGJJaYbpwtjp+Qkaaph5I0l6Grc5ooqKxbry2loVKztiWov79Uqbm8R78ttrFNx6K3wMtYvsikO8rON8avxM3aNcHRUtoo0Nw0053S0ecz2OxP1trpIOGa7+3gebJMCOQz/bfC4A1rGPL+4OnsBV8jj5IeBPxb0TAzocENHwoQIEBwOIaNChQIyFCn8EGJDvBq2Gfiz/suh3IkBGESo1LmDwp4EIBx0M7EmYoh9HkeMCDhRY7qTGAAlY7CTRUOYBPwcOJLDpIQADDwsSDAAJ46iKjyFtjLRJT8FJnCNUIhBBYCUCBAs8CDjr4WqCtt7IptBKrieNn3wvFWyxUoFDlR0IKFjqh+09BQRMQhwwt0HEAHBJFEiw9OGIyyzPwuyg+McBih1kevicgB7imo2pJnAAuKuKAVATFCBs2EPawmL7LUAwtSwBhA4aFhBMd8RSxhqVdxBLbwHu3vtIDmhL+Hm/3QQMYB1gOjbAvX3LewgKS6MBwwnENgjuYamDsAhL0B5wucBgqEhlDnDsmka2UdYWAgHc/8PAVAqkFgABmt3DlQcFECAhheJ51QJtEj7XngfvkUCATB04YGAJDQZgAAP6FSCAhSRQFhVWI2jIgAELujdVPw0u8FsAgiWkkxaZZfZCPY74ZJ446K1zkAL6/WEYSRnRk0B4MxqgHwOqNVjCaoWZOIADFBoAiAH3ENAcfgbwByFWVb3V3EmypSBlAU8etACZftjUQQKVCbdUURkJptkIuzFFggCYOXTnl/2syRKWLp4nAEf/NcDfhdggmSQ2S+YU540jGHDWAlP2kwCAcdmUmmpOBScVjK7B5lxrBI6AoII6OigChJVRVhQnc6KgoQiiiqBfgXwWgICMLFHIgEVqIf/w0FvRQWSlbgSAdOw2Auy4QGM/rlJpB3S12GGRenXa16d9xBnVH2YmUNipHiyYabFuOeQWaQa2JkKKJRgwlwif2TuaH6aRlNoPC9ZEVQeqrjMsQ5lmZ0DChfEpwG9sCZeFRgcwjCl8nFmGUrx7UhqXH9eprF3HFFnYbF7jscuXuz8pmpycPCX5ps3dcIrzMocsgTMC2f61R6cN/CnszUVPbeRP6EztzbpY41z1QFdvrWk1RIOtZJF21RBhLl+TTbHUbJf3S8poY5W2DTSdcKizLbG00iUWVjVp2xjWcLcJeb/Y995+iwC4Hl3jMfbb1MR9dgsR1h0DSXjDWxZoaPX/7cOIGwaeU8UraG4453zDlZbq54muH+lwPF5H5JIbbfZpiS0wkR8MLMCwc3s2mNbH3PVGmup47Ubti8MJUNxKhCHQ21UeNCs7MKavsHxihUb1fPRDJVY9SNibSP55E7JZbwKfKUWaTB+pdMB0Wbt9u9dm32qgrPv2zBK6Oagq8ArReSzCpRLghXHAcR6KVDSo53jAOwd8TWOy55efbUQVv4EP+B64IsGIhYISs2ACjSVBEnpwX/vY1oZOoyAG1UdUH1IX/vIHD8rpaU8HgAkCNIKRVL2IblhBU57kxbIJmWCBAXReoNSnRLdQKCNkCsAJmSa0rLCibg16Ykai2CL1/1XximCcIlkW8p996SZNt8FKozCovRviUB2Uu5WJXESossAlQmhK1vU4VqEltoGCArhOj5x3GmkdR4IMAMmg5nJFwTWtBhwhpCFLBLJoqU+Ep3HkcSA5KU42kmWJ0kIac3UvHWGlW/cbGnnm+A7K6c4Pt/kDi5A4gocZgI8F0Fh3khi4Ok0QJBp7GchWMT7Q9CZOkSydBl8gTAoWs2dXlF76QBfJ6VFHgaa0yD00Jj8ZYayVm3olLM1Bu1huT3LpjIPtzlmLdqJznW+T5xveCc9W2LNsz4TlPteAz3ye4p+eoifbCJqGgAo0EwidnEHJ1tAyKHShlRDo2s4ZUTJMlP+ij8goMi7qT61xtBqiKKlJT4pSkM7Ro1/Y6EgXylIqpHSmNK3pIET60pzaUKeS5GkMXOrTlQbVmUOFAVCLyk6kZlCpLTgqU8EW05w9tanmnKpOo2o1q0qhqlodKVb111UUODWsnfoqUMh6grGiFW5aNSu71LpWqVrVrZ2Ca1zBOlW6Jsmud80hUycAgS78AAMQmEBc+dpXOj41Ax2gQGM7kIG7Ijax49BrNyQQCAlIlquUzZ9lsWGBCvyhAhbYbGfz+VlsQOAPEOjrZE9L0qkOwQ9jOCxnYXtQq0agAxFI7Gtxi7upXqADF/DtbYG7tdR2o7fGRS4OlcsDm0p3uif/xalzcxtceEL3CL+9rtqesd2OWte7yQWvRcdLXqqZF7XoTS/X1qvd9rq3rPDFqHzna57w5gCrmGPoffHbrvrmoHeFmRgK+ktJXsjNGv8FcFazmwOnQEUqLkDwBvnRYAefFcI48N+MXLYAetCjli5zC71sI8WSaMwmxANNuA4yS7YQOEcCmPEO9AuE7mq4ohy+AYruyCMD0cMi4+KKEC9TFcfUKD7t6SIBF8I/K/5JR1Dbb4Z3rNge2yCSkIqKmbQQxY8Q6Txj1g0g2oiWWwasTD0EjUb60eYf3vjKWK6sgG/wKpZEiwA8asxCRAkSIRIlySNYclmKeEvsfOyOpATf/5zlWOcHf7QHb0mMRawT4kEmBiSK6pNGOi0xjQ0G0b/50sFIvBId2fLRrox0knDcT6FC2tV+1bJn6Uxrh9r6drDmgY5zTYdeTzK+swa2nXcdBQvzuNXGxusxuqZsEyA4jc2o3Dlw3WxhCDuLO4g2mBhi4GBjO9vfRXYMVjMvT6OvxC2i5Z1InJuMdGcAu6F3nx4SJIp0yH4MLja5dT1pIEToyAVD4T6MrBEHFCWNNMxRcKynnxZKq1zVsVGHahjdcf9bFtsmZ7eJyS8yb8ZCYg7EyCzyRlKespuUWsiaUt5vZm/82AHvgawEXfBUimWUKJ6RTFiZspVDZOIut7hYhv+BAgvUFhe/nnkZOr5THuiy0z0f1aZT/KUnoRqQcfEmy4MUMBbjMuMlACwRhNF0p2PY3NgVgQQcy9tjpF3tXoB61OL7AA2I9g/FRftx6V7ummMUA9Qt/E3F+nfAx/POz/VA3vfuh75TQhVzV7wV7B42GBAGBtRuoj5J8HY/MHfyMki85VGBeZ/VwFRn67x9AOTtF8T+EuUaltmXLl7En57xuNCGYIgVbtfP3nLO0qLplO5f3e9e8Nq+wW7MtBs72XKHGhH+cFwc40ynxX0K2xAP5QXO+JBGS/3IyHZgPOzel375zO+FNhaCYoV3fWBnsf4BCBhlEesGJPpBmXSwkiD/95Iao9QrEuMtTKR66qd87Od+vGcUomFy1EYUMCZ8iLZDNYFGXichpDFqaQYRExInHAF2sfZ5C8iACth+LgB/8AIe8SE6DUAhFZhmdqRG83cmMkET9QMXAfgjBFiDLWcuJIh663eCgfdsN7AQ7ZZ1tEQSwzF/h+aBp5aBaoQbDqFL4acx5EcupQZHRIWCZ2B6RegIqYdFsmaEJVB5Yoh0bAdRzWeCajhQDphUDfiGcJh8KXhrdJhWYWiH4saGUOWGe9iHQ/iH5aWHYDiIcViIWEOGS4WIiXiHz2Z4k0iJhRCIjwiJy8ZUjaiIgpiJmqhUnEgKlMeHn5gGogiKm0iE/6Y4hnPVVaTIirn3VKhIenUYi6ngim21irdYB5xYib8IjImweLbIi27gi0V1jMRYjGqQjEHVjJi4jLMzjM44jdAYjcZYjTz1jGhYitd4eafwAGOgBeGojdlIAmnojV44CRbAW8N1AbtVWhxFjuchAvMYidyYjm+QeqsFCK01UuwYAe4Ij51ojfn4dKgwAYFgWC/Fj6xFiJ5okKfYCnDXWDqVkICwkKO4ixHJBq2AWX6gWTpFkRRQghDJkR3ZCqJVAT71kR0QkgSJjyd5kK2wBE3gUyrJcRspk1vQiGIQVDWZk8q4kzJVC3PgUz5ZkgU5lN/4iUb5kEq5lESZE8FIlf+FtwdViZU2FUcmGZVMGQ/sxW1mmAU62ZXZ0FNieXf25YgxWZZeuZVq6XFouQ1k2ZZOwAq0qAvpF1JreY7dWJdWpo5ymYB76QN0+ZdHcJfnFZaNx5e24JeHOThfSWxxyZiFKZSQGXNvGQVHsWD3mHlPIINJSRCXiZmsppkuICWduUCcaW3k0JopARKuR5ll+IB/UHxPaAKh+XE3gYC0CYulaZdnmSGZwk0owJrW8Jp0Em6D+ZncE3LgBnxDZHO3qYIqRY+kCZzrFA36kn3csRqh4QPJg3XVV2/b9xDHs0P1kz7ZoQD/QW8f8W562ZwdUShKKH20RH24CT7F0xafERr/2/c+3lcT6IaF4ydi5qeEXSiZY4md2RmZp5khtpl/jSAfnIlAFBJ/C8d/KAEwaCEi+8BJ3jEuENE8XCGbUZeW1fkHipJwC6cqpKKfTjYgHyNkHLqh/hchPDiAMjJkB2idv+mga7ig0MQfF/hlxlInxzkhXuIQQtd1R7QyKFFGUTR0TXSiKTqfdxFyTHpyLEEvXxKaaGKkU3gPzPIH9YNoH4gmuNIGI/igo8mVQUp2Q4qa/EGD1wKjpqJmWbAPSlR1NthNfoQAfAIbgDaiT2iiS4OlzPmAhfKnLSgfHhKDsIdod8pyN+gBOSgrPNgPPiiC5QJAKDqXDSqnosqgmZMp/6fGhZ3WOkpKIQkKqEPnSzahJ+qpTDDTnibBFVonn4zqnPXJHd5XAE04qdK5RrNkL7FahQdwhfEjfr7zqVz4pqMap6UKmHRamaaah5ZZrdYqhNQKl9rKaxAqAui4k4kJlrM5ro1Zro/preQKroQprnPIrVD5rosJp9gwfPgqnEhwpeZ4nd16r+oasCzAMPugMa6TBP+6AvtKsNgqcN+xnM5ZYiqzaJuJCRlrmAO7qPnqAk8DQ5kahFTAsFtBnabZsdNZpRH2GpykNFWAFxpLqhwLrwXrAkv2Gt6CFKRhEyvWdfQ2S0Xhn5mmb06yaiIQfgfKTJwWfR7yBwqAEX5wdP++Kkn0AKDdl7TlB29Ti24DwLMuuDv0ULQnQCiyUjdiyxsqE2/ro4QB4LNeuzLBeqpzy5Y026seuwKxg2/+ADpxoSsKsGRO0Z4lyitRQaMHghIaIps6Wi6qgnCZKii0ch6Sm7JeqH8u1H+M26MNZ6zWoxrOMR+JS5xmhkACVEo7xwCc2wHBIUQG07Pt4bkOEbPwaq4yia6ah6G0smDUJm9nRm1dNkFlUnT6eaxxsadDxKUNUhPSkRYGEKoQW7WX+gNrarwLAXOel0aZ0Z62NLwmEC63sUfOAmVoAghm5IKFcigZkb2yK7P1Wrd2S7C8MBoP0QBCOxU00TNplIOGtrL/XdQZyTG8LUgCnFp73/anI1B1BxyYCUimP0DAf5YuJgIX63sAeZqswDtBFuEUPiJBL8umIjCoQOcPrXsa+aLB7Buq7Wuv8Nuv8ZoCL3EQCCueSPEHGsyBXQoRfiC03KsFkMKrSOusWsEVCVoVu/OlF0ubTNPAz1oaPzhOuUQv3nHCB8CqF5wpE+I7fIN9bOo9MMN1oOa2N0zB0kq3LuyYLHy3ZrwDJXuJlZsJvYmYtOuudnu7QcDGh+jGlADHQlrGZ4zG8auYD9t2fdyufwzI6Tqv9STHhjyveFl3aUyvhOwBtXuSdSyvedyG7DrJc0yzd5mVn5xSVwnKoywKi8zI/1naiqEomn15yqjsOKr4lO/byjWbykhFhkA6y9Ari8i4yn6cy7pcy7wcy6z8y8D8yqo8zL5czO7rmT51yxuby43oyL3Yy4W8zJqMB4AlWHJQWBYZWPRIWBkJCbh8zWqsB4zlWI4VWTyFzo+1zrUosL+MeS0JkiyZWRo5s3+MeaE1WvGoU/zsB6SFz/EczajQkP7oUwcNk8RczngLCbN1dkEF0bg3ztA8y2S4W6MXVBmdzNbc0ObsCO6IVCK90Mrc0I2o0UOV0vC8wgX90VRLyRy5C6RM059ADjWN04tgyi+tM5HsypnMzCZdzj2tyIIM1JIc0xFJ1IP804CoyUltkP9LfdRNbYhB7dEfLdVOnchMbc5QnY9ZXdWYrNVIzckcC9aMyK9xcMfM8NRlPbBnbRDP+cE3YbAT6wuLCQh2XZ08sNYNe7LF6ZsW3cpwzQlns8e054emuhL4uwOHfTp6zQIOG9j5jMaEDRgHd31swR1K+wds0X8TtCZnaj/yJsXnIZ72GceUKT1F4bMNQi8fM7Tf+WJfgiu7EcbdNz8OcTAItJ5Pi9pwO6Dg97WXURJl+qUTo8KyfM2WPRbgc3+2kYQGCLqfDSkooboPJy0X6gEZmtqKnRj7ELhNxmfhImUF4hgVagkkzLgNgtkP8R8hOgCHyt2xi6auy2TtGR73IMD/EErOQ53E0HBwiBbdSGpL1A1IKRd0E1chXMrHn/lIsJG+aLYqRrq9tHQUZUa9+BEhXfYfU+oiXErBfHRmlRbf90DiU+vQ/b3c/71fAZ5m1+JypXIqTTGokyuAKJ7gwLTdCjuni7rY7cG/McJk4JscFpxoJaDeuvItAtRnHLxz8S03jzrFmzq6JbwTQW7GKr7MzM0kHbhGq6oFVVx9fVLjtTpOOS6lryq3QUAMGdscXXTD2REcUkgvrUPGvXLc4RchpZYAttLbUgurFNysZ9qECqDfTdKYWl7MXP5qaZ0Ckg1wZP3SIG2zgtnCJtvobT3plW7V67rVU93Vbn2vjJ5f/45+UIQg2KdM6lBAD52JjUY9DpBODF6djqsenTqASbCQnHetro5dA2zs67tp6sq95SyeA32tAqmRB23+BcAeUbL+U6L+rrZuAu/mnuS7Mi0mY+OnJ/OWZjaWuCCGthHc4FQLIZndM3qO7tm3Gdx7YgV0EBhnuBaL4rl+GjIR21+7qwhB3NJNyy190caOA9Tmtd+TLDIKvnw6TDM4Zd8y3jVacbwuruf+3PCy3gM0o+aNFCZBcACsBfJHQdEC3yTwIRrSZIcb3goAn82z3wusArTujdSemyZBbWbKFLwUZ2+2DxS0RjlPKV2GIt3b3SnbJh5oKGzES0a68ee7DfWpBf+mUhwNcBlOYiFhNAIKB74gXyYRPoG0cuIun+qMLPP2sTAmYUCamqbPwjJcwqIgsytNLvTl/t9FX7wGo+S8RIP9IQI45/F0wQC2sSBFAWhIjhlEMRU0GOSUEXEDXOWUDvCDLfA3oHUSeBBejibZofPxUTwDsmrh3gHXEfdszq90T71AjNtpemooMyXvTgLSOmh/pMXUUwKjpKcGY0uiVt8rUuhgT9ksPPYb9uljTVWb/vu1FvxhPfyTXvzqBOvIzwIwf43Ln2XHj9ZGJe3eKv3z1PzV/wLQH43ZT3Ni7fxbRfyRL/xU69PPf/3WOtM57f6j4A3vL/+H1/3rX6rSnI//3r+M+J+OIAAAHlmaJ5qqK9u6LxzLM13bNw53Oc/vPTAoHBKLNJExqVwym07c70mMSqvWK5aEzHK73m+RCp6Jx+Yzeotes9vXsjsFj9PrQrU9r9+z5nk/X6DgCd6g4eFZh+IiY6PjI2Sk5OQjoqVh4aXmpiEg5ycoS2YoaemYp2nq5qhqq+sS6qvsHuus7W1NLO5u2gjvL3CLbjDxVW0x8uxwMrPScTM058MDyc90NHbTcza3oEVHxEXHRUSHRTf60HY6Ox1EI0S7PM76vP3YROPEPT9MfT/AKxQWUQhoMMW/gwqVSFgkYeHChBAnCqnQoQLFgxIzcryhoYOGjgA3/4osCeNBB2om7ZFc6VIFhpfzWsoERekmzpw6d/LsyajmF5pANy3rVnQoEaFILR3N1nQpEKVQOy18OjWH1KuBrELjqrVG1q96vDIjKzZG2LN1zCJjq7ZF2rdu3K7pIMAKXbkIfeklJUYAowA67t4AfMOuCsQlBgh2EWAACcZk+iaJSznRCcAHPARI4MSwDcUoRHuQ7Bhy6MtFLKsG87fD5gYMSDBQhGCBh9qKBNsFjKBDAgUmCiwywJkAgQ63k3cgkNv2At/AhTMnoMDAogPVhYsmrqiAAOYFPDRYpKC4ZOXfPRz4rYhwtdbq+Mq/9Lr4ggC3PSAI0HlzegIAdtcAxv+hQFx+BBywQALg/aAfbv0NWJqBJBDQgAekeXBhhvCV1liDHjjgWQcOlPBYZLwJFoBzDCBQjYd5tcZafVy8ttkCF2JXnAEGBghaj8O5BxuKGzpIwo6KGACkAQskaRxiThbXoQmSHdDIASx20GSRAXpQgHMEjEdlCTKqRmONWNzoQY7+7UcCiwu02SGTJnDoAJGoiQkYbhCWwCSC/EFpYqAIQOnhABh6ECIKDeqXIpVg5jbbeTGm2QOal1ZxnyIM4KZbBwUs4B4BvAn4Q5AnKpJclnqK+luLixzpQY/trWrcjrY2d+hw34W3KoPQKZDAll5KqkByyVmqKT30MbvVDTn/jonLeZuV+ewNmWLLRFOLoGYLYLudYOZl2m6rBLm7pNuXuecase4t8MrVrrtT6AEaDQN08C269cpAr79BWKVhuPuyqa9yuOWArwwjKkyCd0qymSQDwpEXagzyvgVwwD0M7KEJByTgwAEDyFkqDwzHUGQJklaJwGYHMDAegwPwK0zHL3CcMxQxbJektSZUa0J/JshmwqMBrCqcbrcZhmwACrg3Wwm6NnDlehA7V8LQJxSQwJVB48yzKM6SjcZRHGpoYQeNwfmiCSPSChkDUQdHXt37SdgBsnc9igIDlCYgAMsQM2IAcZGtl+iHOpy9ws6PT/aClBKvTYK0SL5ZwgIl/yb6tQIR73o4YAkoKrNy0xoZWQGFf7k1CV0bifWqjkuOQuS32+5CoYOeYIBgIgfQXoUnMNDgsJ4NazFnmw+YgNvHmRC4B5W67nIJCCBgsaNwM2iiCxqrlbvu4cOgKwG4KhI0mJ1+yQjscCYQoYFKSwzqkcMCL2vI7mF4/eEmtoiKoQxJVBtb+bRgtgTaqCoMVOADXePAB5IvgqOZIAMraEETiO8VHRSLBjcYH4V88CshFGEJVZHCq5xwgys0xQuh0kIL+qSGNrwhDnkSwRmKMA4x7OG/FghEYvxwiDoTohF/UcQklo2JyViiE/cSxWJAcYom4KEVvVDFLHoAi1yswv8EIBCTHWAAAvv4Iha8iMYnZKADAxlIBtaYRiTKMRQNYcRD6lgFNepRCRawiCIqcI4+PoGPhDTCOxQRj0M6wZCMHAJKFKGSRy7BkZQMQjkicEkmWHKTPBDHBTzpDDqK0hCaLKUROonKVZpBlTzLISxjKUsbWtCVOduiJnD5Elt2TJdMqSUpWTnCg/hyJbwMWDEPkcySHNNfyxzEMzvSzHpFE1o7DKYwq8kHbVJkmu7Ki+toEM6xAFOY5jsfIxSFAhSZRpw3W4H92karAJ7onShA2OA88KsOqPOcFMQmK4cRNn0i4IBIs6cMxskCPD0sc/WMQQNehAAM4UlsfSinOS//ik5rnWcBujIOOwPwtbc9J2EDwhicCECs2xgANYxbZ/xYFLLiCIBYjAIcrrYXnochMIMAXaVAYVMmATDAOCJTQEgZNJ7uRSgAgInecU42PNgMdKaiERn4HroowXyNp+9TEEGxA1WN/jOjZHVBVTvKnO+ElDMDcIBzkrQllbk1MsZhTAOKJzShzm2dkKkqX08g05GxibAv4OZEvHmuoG5GAIbKTfHaeiWU+YkEdEWRyMYTnrtV6S54Ek6l1gk36HFmflWDGXk8Y7rqGdafPjXrCoK6iMboKk+No5VpSxqqyw4we++MZ2MGYFCuEWtJNlXdAnRDgLvUVBH97GkCFbst/20yCGRtQCxEpIstbUb0DxiF7QVJ+F3wchCDryXvuMDQThmEy7pZwG5EforKKq43BkWzEyM20z7lEOY3FvXYeNGbIfWO9QX5tJPq8DQm4OkzAfcVAnwVot1n5aVzzFsUydxjVA03zgAwK48iLmy/7e0ofmKa3nNpNbP4ASHCGpFvKWXUH+0UYFiQZU9wiopjBTCmpdXIKtf41lcNrRU2A1BdYR1Q3SG42CATZpaMZGMAuAZgNkXe73cGkACwpXRLD3NZeMhUghOXQMe9mhKEA4xeGQ2rRaQ1M22KlygDgLUENz0P0yBD5ATLk1aPURSf0nxNAZeXCKStKHuGdIDalp9MMHQeFnSQZhvugKzIm+mMIo4sZAsV+DBqJm+T5/Jp8Ib6uqOGbanZkGp+PFlTq0bbqc36aswMmtDDNMisZwJjUc6y177+tSNibethX6LVxD62CoyN7GWXQNnMXrazn33saEt72NSuNqGvjW30anvb4BUBuMMt7nGTu9zmPje6063udbO73e5+N7zjLe9507ve9r43vvOt733zu9/8DgEAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCA: middle cerebral artery; MoM: multiples of the median; EGA: estimated gestational age.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: A systematic review. Obstet Gynecol 2012; 120:1132. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28240=[""].join("\n");
var outline_f27_37_28240=null;
var title_f27_37_28241="Core stability rehabilitation for tennis";
var content_f27_37_28241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Core muscle stability rehabilitation for tennis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Core muscle weakness&nbsp;may contribute to extremity injuries such as epicondylitis. For this reason, exercises to develop core muscle strength and stability are often incorporated into rehabilitation programs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jayanthi N, Subbarao JV. Racket sports injuries. In: Sports Medicine and Rehabilitation: A Sports Specific Approach. Buschbacher R, Prahlow N, Dave SJ (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28241=[""].join("\n");
var outline_f27_37_28241=null;
var title_f27_37_28242="Hyphae candida albicans";
var content_f27_37_28242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyphae of",
"    <em>",
"     Candida albicans",
"    </em>",
"    seen on KOH prep with light microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28242=[""].join("\n");
var outline_f27_37_28242=null;
var title_f27_37_28243="Loss of capture BiV pacing";
var content_f27_37_28243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Loss of LV capture with BiV pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 162px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top line of this tracing shows one lead from the surface electrocardiogram (ECG). The middle portion of the tracing shows the pacemaker event markers obtained by telemetry. The bottom line of the tracing shows the intracardiac electrogram. The arrow above the tracing indicates the time point at which capture of the left ventricle (LV) by the biventricular (BiV) pacemaker is lost. The changes with loss of capture are subtle in the surface ECG tracing. The event markers and the intracardiac electrogram document the loss of capture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28243=[""].join("\n");
var outline_f27_37_28243=null;
var title_f27_37_28244="Lanthanum carbonate: Drug information";
var content_f27_37_28244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lanthanum carbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41812?source=see_link\">",
"    see \"Lanthanum carbonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fosrenol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5594603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fosrenol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphate Binder",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Reduction of serum phosphorous:",
"     </b>",
"     Oral: Initial: 1500 mg/day divided and taken with meals; typical increases of 750 mg/day every 2-3 weeks are suggested as needed to reduce the serum phosphate level &lt;6 mg/dL; usual dosage range: 1500-3000 mg; doses of up to 4500 mg have been evaluated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fosrenol&reg;: 500 mg, 750 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13247742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM271798.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM271798.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or immediately after meals; tablet should be chewed completely prior to swallowing; do not swallow whole. Tablet may be crushed to aid in chewing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of serum phosphate in patients with stage 5 chronic kidney disease (end-stage renal disease [ESRD]; kidney failure: GFR &lt;15 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or dialysis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lanthanum may be confused with lithium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Reported in short-term (4-6 weeks) trials at frequency &gt; placebo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Vomiting (9%), abdominal pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic skin reactions, bowel obstruction, constipation, dyspepsia, fecal impaction, hypophosphatemia, ileus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel obstruction, fecal impaction, ileus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Gastrointestinal (GI) obstruction may occur in patients with altered gastrointestinal anatomy, hypomotility disorders (including constipation, ileus, and diabetes), or concomitant medications (eg, calcium channel blockers); may also occur without history of GI disease. Use with caution in patients with active peptic ulcer, ulcerative colitis, or  Crohn's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use in children is not recommended; lanthanum deposits into developing bone, including growth plates; the consequences on developing bone are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablet: Chew thoroughly to decrease risk of adverse GI effects; do not swallow whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal x-rays: May have a radiopaque appearance in patients taking lanthanum.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Lanthanum may decrease the serum concentration of ACE Inhibitors.  Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: Lanthanum may decrease the serum concentration of Ampicillin.  Management: Administer oral ampicillin at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Lanthanum may decrease the serum concentration of Chloroquine.  Management: Administer chloroquine at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: Lanthanum may decrease the serum concentration of Halofantrine.  Management: Administer halofantrine at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May decrease the serum concentration of Lanthanum. Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Lanthanum may decrease the serum concentration of Quinolone Antibiotics.  Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Lomefloxacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Lanthanum may decrease the serum concentration of Tetracycline Derivatives.  Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Lanthanum may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some, but not all, animal studies. The effect on absorption of vitamins and nutrients has not been studied. Lanthanum is not recommended for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2886994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Take  with or immediately after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Fosrenol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (45): $428.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (15): $142.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (10): $95.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009): CKD stage 5 and 5D: Every 1-3 months",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2886993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Corrected total serum calcium (K/DOQI, 2003): CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Phosphorus (K/DOQI, 2003): CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fosrenol (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, ID, IL, KP, NL, NO, PH, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Foznol (IE, IT);",
"     </li>",
"     <li>",
"      Lanthonate (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disassociates in the upper gastrointestinal tract to lanthanum ions (La",
"     <sup>",
"      3+",
"     </sup>",
"     ) which bind to dietary phosphate resulting in insoluble lanthanum phosphate complexes and a net decrease in serum phosphate and calcium levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;0.002%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Plasma: 53 hours; Bone: 2-3.6 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces primarily; urine &lt;2%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Behets GJ, Verberckmoes SC, D'Haese PC, et al, &ldquo;Lanthanum Carbonate: A New Phosphate Binder,&rdquo;",
"      <i>",
"       Curr Opin Nephrol Hypertens",
"      </i>",
"      , 2004, 13:403-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/37/28244/abstract-text/15199290/pubmed\" id=\"15199290\" target=\"_blank\">",
"        15199290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 13: Treatment of Bone Disease in Chronic Kidney Disease.&rdquo;  Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/37/28244/abstract-text/11774095/pubmed\" id=\"11774095\" target=\"_blank\">",
"        11774095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/37/28244/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10219 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.44.181.18-7163832E31-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28244=[""].join("\n");
var outline_f27_37_28244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186951\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5594603\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186966\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186953\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186954\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160264\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160265\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186934\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186923\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13247742\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186936\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186935\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914236\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186964\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186939\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186925\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299576\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186928\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186930\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186942\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186958\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886994\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186941\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186932\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886993\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539886\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186924\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186938\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41812?source=related_link\">",
"      Lanthanum carbonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28245="Chronic GVHD tongue erosions";
var content_f27_37_28245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28245=[""].join("\n");
var outline_f27_37_28245=null;
var title_f27_37_28246="Management of severe asymptomatic hypertension (hypertensive urgencies)";
var content_f27_37_28246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of severe asymptomatic hypertension (hypertensive urgencies)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28246/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28246/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28246/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28246/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28246/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/37/28246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypertension (often defined as systolic blood pressure &ge;180 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure &ge;120 mmHg) can produce a variety of acute, life-threatening complications, which are considered hypertensive emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These include hypertensive encephalopathy, retinal hemorrhages, papilledema, and acute renal failure (",
"    <a class=\"graphic graphic_table graphicRef54145 \" href=\"UTD.htm?15/43/16060\">",
"     table 1",
"    </a>",
"    ). A review of the manifestations and treatment of hypertensive emergencies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with an equivalent degree of hypertension are relatively asymptomatic (other than perhaps headache) and have no acute signs of end-organ damage. This entity is called hypertensive urgency, and as with hypertensive emergencies, it seems to occur most commonly among patients who have been nonadherent with their chronic antihypertensive regimen or those who are nonadherent with a low sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/3\">",
"     3",
"    </a>",
"    ]. Severe hypertension can also occur in medication-adherent patients following ingestion of large quantities of salt [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the treatment of severe asymptomatic hypertension, or hypertensive urgency. The evaluation of the patient with hypertension, the treatment of hypertensive emergency, and the treatment of the pregnant woman with severe hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations in this topic review only apply to patients without signs of end-organ damage. The evaluation of the patient with severe hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial evaluation of the hypertensive adult\", section on 'The basic workup'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H3#H3\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients with severe asymptomatic hypertension is unclear. The blood pressure reading should be quickly confirmed with a repeat measurement utilizing proper technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood pressure reduction goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapidity with which blood pressure should be brought to safe levels (eg,",
"    <span class=\"nowrap\">",
"     &lt;160/100",
"    </span>",
"    mmHg) is controversial. A relatively rapid reduction in blood pressure (BP) was recommended in the past. However, in the absence of symptoms a more gradual reduction in pressure is suggested.",
"   </p>",
"   <p>",
"    While a variety of oral therapeutic modalities have been used, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , and oral or sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], sublingual nifedipine is now contraindicated in this setting. In many cases, however, blood pressure may decline spontaneously simply with rest in a quiet room.",
"   </p>",
"   <p>",
"    Furthermore, there is no proven benefit from rapid reduction of the blood pressure in patients with severe asymptomatic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/1,2,8-10\">",
"     1,2,8-10",
"    </a>",
"    ]. In fact, cerebral or myocardial ischemia or infarction can be induced by aggressive antihypertensive therapy if the blood pressure falls below the range at which tissue perfusion can be maintained by autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This has been most often described with sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ; the degree of blood pressure reduction cannot be controlled or predicted, and severe ischemic complications have ensued [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/12\">",
"     12",
"    </a>",
"    ]. Given these concerns, as noted above, sublingual nifedipine should not be used in this setting.",
"   </p>",
"   <p>",
"    Thus, in the absence of signs of acute end-organ damage, the goal of management is to reduce the blood pressure to",
"    <span class=\"nowrap\">",
"     &le;160/100",
"    </span>",
"    mmHg over several hours to days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. This is based on the adverse effects observed with faster correction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower achieved blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The individual patient's risk for an adverse event and the probable duration of severe hypertension must be considered when deciding how quickly to reduce the blood pressure. As an example, an elderly patient may be at particularly high risk for cerebral or myocardial ischemia from excessively rapid reduction of blood pressure. In such a patient, who often will have a high pulse pressure (eg, diastolic blood pressure &lt;90 mmHg with systolic blood pressure &ge;180 mmHg), the initial goal blood pressure of",
"    <span class=\"nowrap\">",
"     &le;160/100",
"    </span>",
"    mmHg may need to be achieved even slower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be provided a quiet room to rest; this can lead to a fall in BP of 10 to 20 mmHg or more. The approach varies depending on whether the patient has already been treated for hypertension or is untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Previously treated hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients already treated with antihypertensive medications, the following (depending on the circumstances) may be appropriate interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase the dose of existing antihypertensive medications, or add another agent.",
"     </li>",
"     <li>",
"      Reinstitution of medications in non-adherent patients.",
"     </li>",
"     <li>",
"      Addition of a diuretic, and reinforcement of dietary sodium restriction, in patients who have worsening hypertension due to high sodium intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Untreated hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously untreated patient, several options are available. The approach should take into consideration the individual patient's risk with persistence of severe hypertension, the likely duration of severe hypertension, and of cerebrovascular or myocardial ischemia with rapid reduction in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/1,8,9,14\">",
"     1,8,9,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatively rapid initial blood pressure reduction (over several hours). We use one of the following agents: oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      (if the patient is not volume depleted) at a dose of 20 mg (or higher if the renal function is not normal); a small dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      (0.2 mg); or a small dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      (6.25 or 12.5 mg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following administration of one of these agents, the patient is observed for a few hours, to ascertain a reduction in blood pressure of 20 to 30 mmHg. Thereafter, a longer acting agent is prescribed (see below) and the patient is sent home to follow up within a few days. The drop in blood pressure may take relatively longer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , and may be too large among patients with hemodynamically significant unilateral renal artery stenosis.",
"   </p>",
"   <p>",
"    We prefer this approach in patients with known aortic or intracranial aneurysms. This may be the optimal approach in most patients, however this is not proven, and it is often not feasible to provide medications and observe for several hours.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure reduction over one to two days. There are no data supporting the use of a particular agent in this setting although we generally do not begin therapy with extended release preparations or with a diuretic alone. Depending on the patient, a calcium channel blocker (but not sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ), beta blocker or angiotensin converting enzyme (ACE) inhibitor or receptor blocker can be started. Examples in these categories are oral nifedipine 30 mg once daily (of the long-acting preparation), oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      XL 50 mg daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      10 mg once daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of agent should take into consideration the type of antihypertensive agent that is most appropriate in the long term (eg, calcium channel blockers and thiazide-like diuretics are preferred over ACE inhibitors and beta blockers as monotherapy in blacks), and underlying conditions that may be favorably or adversely affected by the antihypertensive agent (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"UTD.htm?10/53/11101\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts initiate therapy with two agents or a combination agent, one of which is a thiazide diuretic. The rationale is that most patients with blood pressure",
"    <span class=\"nowrap\">",
"     &ge;20/10",
"    </span>",
"    mmHg above goal will require two or more antihypertensive agents in order to achieve the goal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/1,2,15,16\">",
"     1,2,15,16",
"    </a>",
"    ]. It is unlikely that a diuretic in combination with a modest dose of another agent will cause a dangerous reduction in the blood pressure; however, initiation of two agents simultaneously must be done with close blood pressure follow-up, since the full effects of both agents may not occur for a few days, and adverse consequences may ensue if the blood pressure is lowered too quickly. This is particularly true among patients with cerebrovascular disease in whom more cautious blood pressure reduction is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with severe asymptomatic hypertension is usually managed in the emergency room, since exclusion of acute end-organ damage requires laboratory testing, and the patient may require administration of medications and several hours of observation. However, the patient can often be safely managed in the physician's office if the evaluation and management can be carried out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of a patient who does not have established follow-up is difficult. Rarely, such patients may require admission. In addition, patients at high risk for cardiovascular events (eg, long-standing diabetes, known coronary artery disease or prior stroke), should probably be admitted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiovascular risks of hypertension\", section on 'Additive effects of multiple risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, the patient should be observed for a few hours to ascertain that the blood pressure is stable or improving, and that indeed they are asymptomatic. If so, the patient can be sent home with close follow-up over the subsequent days directed towards evaluation for symptoms related to hypertension or hypotension, and adjustment of medications to achieve the initial blood pressure goal of",
"    <span class=\"nowrap\">",
"     &le;160/100",
"    </span>",
"    mmHg. In reliable patients who can monitor their blood pressure at home, close phone follow-up may substitute for direct physician visits. If the patient does not have a physician, follow-up may need to be in the emergency room or other acute care setting.",
"   </p>",
"   <p>",
"    Over the subsequent weeks and months, the dose and selection of medications should be adjusted as needed to achieve the desired blood pressure goals. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=see_link\">",
"       \"Patient information: High blood pressure emergencies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe hypertension (systolic blood pressure &ge;180 mmHg or diastolic blood pressure &ge;120 mmHg), with no acute signs of end-organ damage, is often called hypertensive urgency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"       \"Initial evaluation of the hypertensive adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there are signs or symptoms of acute end-organ damage, the condition is considered a hypertensive emergency and is treated more aggressively (",
"      <a class=\"graphic graphic_table graphicRef54145 \" href=\"UTD.htm?15/43/16060\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no proven benefit from rapid reduction of the blood pressure in patients with severe asymptomatic hypertension, and myocardial or cerebral ischemia can be precipitated by overly rapid blood pressure lowering.",
"     </li>",
"     <li>",
"      In all patients presenting with severe hypertension, we suggest repeating the blood pressure after rest in a quiet room.",
"     </li>",
"     <li>",
"      We suggest an initial goal of reducing the blood pressure to",
"      <span class=\"nowrap\">",
"       &le;160/100",
"      </span>",
"      mmHg over several hours to days with conventional oral therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The optimal rapidity with which blood pressure is lowered is controversial, and must take into consideration the individual patient's risk for an ischemic event. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For previously treated patients, we suggest adjusting their existing medication regimen, or reinstituting their medications (if nonadherent).",
"     </li>",
"     <li>",
"      For most previously untreated patients, we suggest beginning a low dose of a calcium channel blocker, beta blocker or ACE inhibitor, but not a diuretic alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Suggested initial agents and doses for the average sized adult in these categories are oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      XL 30 mg once daily (of the long-acting preparation), oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      XL 50 mg daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      10 mg once daily. Keep in mind that a recent Cochrane analysis on this topic does not signify any particular agent as preferred for initial therapy in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28246/abstract/17\">",
"       17",
"      </a>",
"      ]. Specifically, there is no evidence from randomized controlled trials that demonstrates that antihypertensive drugs reduce mortality or morbidity in patients with hypertensive emergencies. Furthermore, there is insufficient evidence from randomized trials to determine which drug or drug class is most effective in reducing mortality and morbidity.",
"     </li>",
"     <li>",
"      The choice of agent should take into consideration patient characteristics and comorbid conditions, which influence optimal long-term therapy (",
"      <a class=\"graphic graphic_table graphicRef63628 \" href=\"UTD.htm?10/53/11101\">",
"       table 2",
"      </a>",
"      ). Some physicians begin therapy with two agents (one of which is a thiazide diuretic) in reliable patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"       \"Treatment of hypertension in blacks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all patients, we recommend initial close follow-up (every one to two days). Follow-up is directed towards evaluation for symptoms of either hypertension or hypotension, and attainment of the initial blood pressure goal of",
"      <span class=\"nowrap\">",
"       &le;160/100",
"      </span>",
"      mmHg. In reliable patients who can monitor their blood pressure at home, close phone follow-up may substitute for direct physician visits.",
"     </li>",
"     <li>",
"      In the patient who does not have certain follow-up, particularly patients at high risk for cardiovascular or cerebrovascular disease, we suggest admission to the hospital for initial management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link&amp;anchor=H2#H2\">",
"       \"Cardiovascular risks of hypertension\", section on 'Additive effects of multiple risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Over the course of weeks to months, the dose and selection of medications is modified to achieve desired goals usually with longer acting agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/1\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/2\">",
"      European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/3\">",
"      Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005; 18:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/4\">",
"      Mishra SI, Jones-Burton C, Fink JC, et al. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan, NM. Hypertensive crisis. In: Kaplan's clinical hypertension, 9th ed, Lippincott, Williams, and Wilkins. Philadelphia, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/6\">",
"      Elliott WJ. Hypertensive emergencies. Crit Care Clin 2001; 17:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/7\">",
"      Houston MC. The comparative effects of clonidine hydrochloride and nifedipine in the treatment of hypertensive crises. Am Heart J 1988; 115:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/8\">",
"      Handler J. Hypertensive urgency. J Clin Hypertens (Greenwich) 2006; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/9\">",
"      Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002; 17:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/10\">",
"      Zeller KR, Von Kuhnert L, Matthews C. Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial. Arch Intern Med 1989; 149:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/11\">",
"      O'Mailia JJ, Sander GE, Giles TD. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Ann Intern Med 1987; 107:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/12\">",
"      Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/13\">",
"      Narotam PK, Puri V, Roberts JM, et al. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg 2008; 109:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/14\">",
"      Nielsen PE, Krogsgaard A, McNair A, Hilden T. [Treatment of acute, severe hypertension assessed in a multicentre study. The effects of rest and furosemide and a randomized clinical trial of chlorpromazine, dihydralazine and diazoxide]. Ugeskr Laeger 1981; 143:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/15\">",
"      Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/16\">",
"      Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28246/abstract/17\">",
"      Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 2008; 22:596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3830 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28246=[""].join("\n");
var outline_f27_37_28246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood pressure reduction goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Previously treated hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Untreated hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/43/16060\" title=\"table 1\">",
"      Hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/53/11101\" title=\"table 2\">",
"      Treatment of HTN by underlying disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=related_link\">",
"      Expectant management of severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=related_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=related_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28247="Initial evaluation and management of chest wall trauma in adults";
var content_f27_37_28247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of chest wall trauma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Eric Legome, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Jean M Hammel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28247/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/37/28247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15009011\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest wall, defined here as the bony and muscular structures covering the entire thoracic cavity, protects internal thoracic organs (heart and lungs), mediastinal structures (esophagus and trachea), and major vasculature (aorta and vena cava). Damage to the chest wall may coincide with significant injury to certain of these internal structures and thus, warrants careful evaluation.",
"   </p>",
"   <p>",
"    The evaluation and initial management of chest wall injuries in adults will be reviewed here. Rib fractures, clavicle fractures, internal thoracic injuries, and general trauma management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"     \"Initial evaluation and management of rib fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link\">",
"     \"Clavicle fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009018\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpreting the literature about the epidemiology of chest wall trauma is problematic. Most studies use data from trauma registries, which primarily involve patients admitted to the hospital with significant injuries. Patients with minor injuries or an isolated rib fracture are often discharged, leading to a bias in the literature toward the more seriously injured. As a result, the epidemiology of minor chest wall injuries (eg, muscle contusion and strains) is largely unknown. Many patients with such injuries do not present to the medical system at the time of injury. Therefore, available information is largely retrospective or obtained about patients with other more serious injuries.",
"   </p>",
"   <p>",
"    Nevertheless, available studies provide some insight. Several studies of chest trauma from motor vehicle collisions (MVC) report that rib fractures are identified in nearly two-thirds of admitted patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Sternal fractures are found in up to 8 percent of blunt chest trauma patients and 18 percent of multiple trauma patients with thoracic injuries, and are usually the result of a direct, high-energy blow to the sternum from the steering wheel and column [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Although life-saving in many instances, over-the-shoulder seat belts contribute to these fractures and their incidence has risen with the increased use of these seat belts. The incidence is greater among passengers in older cars where occupants wear seat belts but air bags are not available.",
"   </p>",
"   <p>",
"    Scapular fractures account for only 1 percent of all fractures and less than 5 percent of fractures to the shoulder complex; they occur in up to 3.7 percent of blunt trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. As scapular fractures generally require great force, over 90 percent are associated with other significant injuries, including rib fracture, pneumothorax, and pulmonary contusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Scapular fractures rarely cause blunt aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the reasons are unclear, in one large prospective study scapula fractures were associated with lower mortality compared with similarly injured patients without them [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009025\">",
"    <span class=\"h1\">",
"     ANATOMY, PHYSIOLOGY, AND MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy and physiology of the thorax and the mechanisms of blunt and penetrating thoracic trauma are discussed in detail separately. Elements of particular importance to chest wall trauma are briefly described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Anatomy and mechanism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933688#H4933688\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Anatomy, pathophysiology, and mechanism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chest wall consists primarily of skin, bones (including the thoracic spine, scapulae, clavicles, sternum, and ribs), costal cartilage, and muscles of the chest and back (including the pectoralis major and minor, intercostals, trapezius, latissimus, rhomboids, and paraspinals). Neurovascular bundles comprised of an intercostal nerve, artery, and vein, run along the inferior portion of each rib. Parietal pleura lines the inside of the chest wall.",
"   </p>",
"   <p>",
"    The anterior chest wall contains the sternum and pectoralis major and minor muscles, as well as the clavicle at its superior border. Posteriorly, the scapula provides added protection to the superior thorax. The scapula is a dense bone encased in muscle and significant force is necessary to fracture it. High-speed motor vehicle collisions and falls from height are common mechanisms. Greater force is also necessary to fracture the sternum of a healthy adult. This may occur during a motor-vehicle collision when a driver&rsquo;s chest strikes the steering wheel or column or with sudden forceful restraint from an across-the-chest seat belt [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"    <strong>",
"     Isolated",
"    </strong>",
"    sternal fractures are not closely associated with intrathoracic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest wall injuries that are associated with increased risk of significant intrathoracic or intraabdominal injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Scapula fracture",
"     </li>",
"     <li>",
"      Flail chest",
"     </li>",
"     <li>",
"      Multiple rib fractures (&ge;3) and displaced rib fractures",
"     </li>",
"     <li>",
"      Sternal fracture",
"     </li>",
"     <li>",
"      Posterior sternoclavicular dislocation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The functions of the chest wall are twofold: to assist in the mechanics of respiration and to protect the vital intrathoracic organs. While chest wall structures protect against more devastating injuries, they are commonly injured while doing so. Such chest wall injuries are not usually life-threatening, but can be extremely painful and may lead to significant morbidity if not recognized and treated appropriately.",
"   </p>",
"   <p>",
"    Blunt chest trauma can occur through a variety of mechanisms; common examples include motor vehicle collisions, assaults, and falls. Particularly in the elderly, apparently minor trauma (eg, fall from standing) can cause serious injury. Rib fractures, flail chest, and chest wall contusion can occur from any of the above mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H32#H32\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Flail chest'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009032\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important consideration in the adult with chest wall injuries is the possibility of significant intrathoracic or intra-abdominal injury. The evaluation and management of such internal injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of injuries to the chest wall in patients who have sustained blunt thoracic trauma includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sternal fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H29#H29\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Sternal fracture'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Scapula fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H30#H30\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Scapular fracture'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rib fracture(s) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"       \"Initial evaluation and management of rib fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Costochondral tear",
"     </li>",
"     <li>",
"      Flail chest (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H32#H32\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Flail chest'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intercostal vascular and nerve laceration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link\">",
"       \"Initial evaluation and management of rib fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clavicle fracture and dislocation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link\">",
"       \"Clavicle fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thoracic spine fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12520?source=see_link\">",
"       \"Evaluation of thoracic and lumbar spinal column injury\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Soft tissue injuries, such as lacerations, muscle strains, and contusions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009039\">",
"    <span class=\"h1\">",
"     PREHOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital management of patients with chest trauma varies depending upon patient symptoms and the severity of illness. A patient with concern for underlying pulmonary, cardiac, mediastinal, or major extrathoracic injury is treated according to the principles of advanced trauma life support&trade; (ATLS&trade;), with special attention paid to the airway, breathing, and circulation. Otherwise, alert patients with signs of chest wall injury but no evidence of respiratory or circulatory compromise or significant internal injury are generally taken directly to the emergency department for evaluation with minimal prehospital intervention other than direct transport. Prehospital management of the trauma patient is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009046\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009055\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of the adult with chest wall trauma is based upon the patient's vital signs and clinical presentation, and the mechanism of injury. In general, abnormal vital signs are more predictive of severe injury than mechanism following blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/16\">",
"     16",
"    </a>",
"    ]. Hemodynamically unstable patients are resuscitated in accordance with the basic principles of ATLS&trade;, with the emphasis on assessment and stabilization of the airway, breathing, and circulation. The evaluation and management of the trauma patient, including those with severe blunt or penetrating chest trauma, is discussed separately. The following discussion addresses patients without respiratory distress or hemodynamic instability who have sustained blunt trauma to the chest wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009062\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of chest wall trauma lies in rapidly excluding serious injury to internal structures. Depending upon the presentation, this can be accomplished with a focused history and physical examination or it may require multiple tests, including plain chest x-ray, computed tomography (CT) scans, electrocardiogram, and echocardiography.",
"   </p>",
"   <p>",
"    The initial question is whether the patient is at low or high-risk of internal injury. Vital signs and mental status are the most important factor in making this determination. Additional factors include the patient's chief complaint and general appearance, signs of injury identified on physical examination, and the mechanism of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929690#H1929690\">",
"     \"Initial management of trauma in adults\", section on 'Primary evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While high-energy trauma correlates with increased risk of internal injury, the significance of the mechanism can be difficult to determine. As an example, a young healthy adult with a major mechanism (eg, roll-over motor vehicle collision [MVC]) may have no injuries, while a frail elder patient can sustain life-threatening injuries by simply falling to the ground. Nevertheless, certain mechanisms warrant more extensive evaluation. As an example, patients with significant falls (&gt;3 meters [10 feet]) or high impact collisions are at higher risk of aortic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929661#H1929661\">",
"     \"Initial management of trauma in adults\", section on 'Mechanism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Aortic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trauma patient should be completely undressed so the entire chest and back can be properly examined. Careful inspection is important. Note the patient&rsquo;s respiratory rate and effort; look for asymmetric motion or accessory muscle use during respiration. Inspect the chest wall for signs of injury such as a seat-belt sign or hematoma. Findings such as contusions or an imprint from a steering wheel or an ecchymotic anterior chest raise concern for underlying pulmonary or aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/17\">",
"     17",
"    </a>",
"    ]. Palpate the entire chest wall for areas of tenderness or deformity. Patients with pain and tenderness along the lower ribs, especially when associated with abdominal pain, are at higher risk for intraabdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/18\">",
"     18",
"    </a>",
"    ]. Keep the examination room warm to help prevent hypothermia.",
"   </p>",
"   <p>",
"    Physical findings of chest wall trauma that are consistent with intrathoracic or intraabdominal injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxia or signs of respiratory difficulty (eg, accessory muscle use)",
"     </li>",
"     <li>",
"      Paradoxical movement of a chest segment during respiration (suggesting flail chest)",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Seat belt sign across the chest or abdominal wall",
"     </li>",
"     <li>",
"      Tenderness over multiple rib segments (suggesting multiple rib fractures)",
"     </li>",
"     <li>",
"      Palpable depression or deformity of sternum or multiple rib segments",
"     </li>",
"     <li>",
"      Abdominal tenderness or guarding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with any of these findings need appropriate management and further diagnostic imaging. The hemodynamically stable patient with no concerning examination findings may be observed and discharged, if there is no concern for other injury, or sent to radiology for further evaluation if concerns persist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118186\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial diagnostic study for hemodynamically stable patients with chest trauma is typically a plain chest x-ray (CXR). The CXR provides much useful information while exposing the patient to little radiation and we suggest it be obtained for any patient with concerning chest wall trauma. A CXR is not necessary when injuries are clearly limited to the superficial soft tissues. The use and interpretation of the CXR in patients with blunt chest trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Chest radiograph'",
"    </a>",
"    .) Injuries revealed by CXR are managed accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Specific injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with a significant mechanism of injury (eg, high speed MVC) receive a CT scan of the abdomen and pelvis. If, based on clinical findings, there is any concern for significant intrathoracic injury in such patients, we suggest obtaining a chest CT as well. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118412\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be performed on all patients with significant blunt chest trauma. Patients with minor trauma remote from the central or left side of the chest may not need an ECG, but this should be determined by the clinician after a careful history and examination. ECG findings related to blunt cardiac injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link&amp;anchor=H11#H11\">",
"     \"Cardiac injury from blunt trauma\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009069\">",
"    <span class=\"h1\">",
"     DIAGNOSIS, INITIAL MANAGEMENT, AND DISPOSITION OF SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3120151\">",
"    <span class=\"h2\">",
"     Minor chest wall injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor injuries of the chest wall are usually identified during the physical examination. Patients with such injuries to the chest wall, including bone and muscle contusions, and no signs of other significant injury following an appropriate work-up may be discharged. Discharged patients should be warned to return immediately to the emergency department (ED) for any concerning symptoms, such as shortness of breath. However, among patients with minor chest wall injuries but no rib fracture or underlying pulmonary disease the risk of developing pneumonia appears to be extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28247/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2445769\">",
"    <span class=\"h2\">",
"     Clavicle fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clavicle fractures often complain of pain exacerbated by shoulder movement and deformity of the clavicle. However, deformity may be absent and diagnosis correspondingly more difficult with fractures involving the proximal or distal third of the bone. The diagnosis and management of clavicle fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link\">",
"     \"Clavicle fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118426\">",
"    <span class=\"h2\">",
"     Clinical or radiographic rib fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rib fractures are diagnosed clinically or by chest x-ray (CXR). Examination may reveal focal tenderness along a rib, palpable step-off, crepitus, or diminished breath sounds.",
"   </p>",
"   <p>",
"    If the plain posterior-anterior and lateral CXR are unremarkable in a patient at low-risk for injury, further evaluation of the thorax is generally unnecessary. If the CXR shows an isolated rib fracture or two, the patient can be treated for pain and discharged with appropriate follow-up. Patients with focal tenderness over one or two ribs but no evidence of fracture on CXR can be assumed to have a rib fracture and may be treated with analgesics and follow-up, assuming there are no other injuries of concern. Patients with multiple rib fractures (&ge;3), particularly elders, or displaced rib fractures often warrant admission due to the increased risk of complications (eg, pulmonary contusion). The management of rib fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Initial management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and management of rib fractures\", section on 'Follow-up care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link\">",
"     \"Inpatient management of traumatic rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with clinical or radiographic evidence of one or two rib fractures who are discharged must be warned to return immediately to the ED for any concerning symptoms, such as shortness of breath, increasing pain, or signs of pneumonia. We suggest that such patients be given an incentive spirometer, educated in its proper use, and strongly encouraged to use it regularly in order to prevent atelectasis and pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118570\">",
"    <span class=\"h2\">",
"     Flail chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flail chest occurs when three or more adjacent ribs are each fractured in two places, creating one floating segment comprised of several rib sections and the soft tissues between them (",
"    <a class=\"graphic graphic_figure graphicRef79746 \" href=\"UTD.htm?23/19/23857\">",
"     figure 1",
"    </a>",
"    ). This unstable section of chest wall exhibits paradoxical motion (ie, it moves in the opposite direction of the uninjured, normal-functioning chest wall) with breathing, and is associated with significant morbidity from pulmonary contusion. Abnormal motion can be difficult to detect making the diagnosis difficult, but these patients generally experience significant pain and at least some respiratory difficulty. Patients with flail chest are admitted to the hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H32#H32\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Flail chest'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118419\">",
"    <span class=\"h2\">",
"     Sternal fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sternal fractures usually present with moderate to severe pain localized to the sternum, which can be pleuritic. Palpation reveals tenderness and occasionally bony crepitance or deformity. Anterior chest wall ecchymosis is also common. Sternal fractures are associated with an increased risk of internal injury. Such injuries may include rib fractures, myocardial contusion, hemopericardium, spinal fractures, retrosternal hematoma, hemothorax, pneumothorax, and trauma to major vessels. Therefore, further work-up is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Sternal fracture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2470527\">",
"    <span class=\"h2\">",
"     Sternoclavicular dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sternoclavicular (SC) joint can sublux or dislocate anteriorly or posteriorly. The usual mechanism is a direct, high-velocity blow to the medial clavicle or medial compression of the shoulder girdle. Posterior dislocations can be dangerous, potentially causing damage to the trachea, lung, or subclavian vessels, and warrant careful evaluation including imaging and urgent reduction. The initial evaluation and management of SC dislocations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H2471727#H2471727\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Sternoclavicular dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118440\">",
"    <span class=\"h2\">",
"     Scapular fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with scapula fractures often complain of posterior chest wall pain, which may be exacerbated by shoulder movement. Palpation may reveal tenderness. Scapular fractures involve significant force and should raise suspicion for internal trauma, including intrathoracic injuries, spine fractures, and spleen and liver lacerations. A thorough trauma evaluation is warranted if a scapula fracture is identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2445494\">",
"    <span class=\"h2\">",
"     Internal injuries associated with chest wall trauma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118488\">",
"    <span class=\"h3\">",
"     Blunt aortic and other mediastinal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma patients whose mechanism involves sudden deceleration, such as a fall over 10 feet (3 meters) or a motor vehicle collision at speeds greater than 30 miles (50 km) per hour, are at significant risk for blunt aortic injury. Other mediastinal injuries are uncommon following blunt trauma. The evaluation and initial management of these injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Specific injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118555\">",
"    <span class=\"h3\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax is a common complication of blunt chest trauma, often sustained from a fractured rib. Patients may manifest tachypnea, chest pain, hypoxia, unilateral diminished or absent breath sounds, or unilateral hyperresonance to percussion, depending upon the extent of the pneumothorax. The diagnosis and management of pneumothorax following trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H23#H23\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Pneumothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3118562\">",
"    <span class=\"h3\">",
"     Pulmonary contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary contusion is a relatively common complication of blunt thoracic trauma, but signs may not appear on the initial plain chest radiograph. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Pulmonary contusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15009076\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foremost task when managing patients who have sustained chest wall trauma is to evaluate for intrathoracic, intraabdominal, or other life-threatening injury. Abnormal vital signs, penetrating injury, or altered mental status should automatically prompt a higher level of concern and evaluation in the emergency department. Additional factors to consider include the patient's chief complaint and general appearance, signs of injury identified on physical examination, and the mechanism of injury. (See",
"      <a class=\"local\" href=\"#H15009055\">",
"       'Initial assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15009062\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest wall injuries that are associated with significant intrathoracic or intraabdominal injury include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple or displaced rib fractures",
"     </li>",
"     <li>",
"      Scapula fracture",
"     </li>",
"     <li>",
"      Flail chest",
"     </li>",
"     <li>",
"      Sternal fracture",
"     </li>",
"     <li>",
"      Posterior sternoclavicular dislocation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical findings of chest wall trauma that are consistent with intrathoracic or intraabdominal injury include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypoxia or signs of respiratory difficulty (eg, accessory muscle use)",
"     </li>",
"     <li>",
"      Paradoxical movement of a chest segment during respiration (suggesting flail chest)",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Seat belt sign across the chest or abdominal wall",
"     </li>",
"     <li>",
"      Tenderness over multiple rib segments (suggesting multiple rib fractures)",
"     </li>",
"     <li>",
"      Palpable deformity of sternum or multiple rib segments",
"     </li>",
"     <li>",
"      Abdominal tenderness or guarding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We obtain a screening chest x-ray (CXR) for any patient with concerning chest wall trauma. A CXR is not necessary when injuries are clearly limited to the superficial soft tissues. (See",
"      <a class=\"local\" href=\"#H3118186\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common injuries isolated to the chest wall include muscle strains and contusions and fractures of the ribs, sternum, and clavicle. Patients with multiple or displaced rib fractures or a sternal fracture require a work-up to rule out internal injury and often warrant a period of observation. Provided no significant concomitant injury or comorbidity exists, such patients may then be treated as outpatients with analgesics and appropriate follow-up. Discharged patients must be warned to return immediately to the emergency department for any concerning symptom, such as shortness of breath. (See",
"      <a class=\"local\" href=\"#H15009069\">",
"       'Diagnosis, initial management, and disposition of specific injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with three or more rib fractures, especially elders, are at increased risk for significant complications. The management of rib fractures is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial evaluation and management of rib fractures\", section on 'Initial management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial evaluation and management of rib fractures\", section on 'Follow-up care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/1\">",
"      Gaillard M, Herv&eacute; C, Mandin L, Raynaud P. Mortality prognostic factors in chest injury. J Trauma 1990; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/2\">",
"      Newman RJ, Jones IS. A prospective study of 413 consecutive car occupants with chest injuries. J Trauma 1984; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/3\">",
"      Shorr RM, Crittenden M, Indeck M, et al. Blunt thoracic trauma. Analysis of 515 patients. Ann Surg 1987; 206:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/4\">",
"      Araj&auml;rvi E, Santavirta S. Chest injuries sustained in severe traffic accidents by seatbelt wearers. J Trauma 1989; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/5\">",
"      Knobloch K, Wagner S, Haasper C, et al. Sternal fractures occur most often in old cars to seat-belted drivers without any airbag often with concomitant spinal injuries: clinical findings and technical collision variables among 42,055 crash victims. Ann Thorac Surg 2006; 82:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/6\">",
"      Budd JS. Effect of seat belt legislation on the incidence of sternal fractures seen in the accident department. Br Med J (Clin Res Ed) 1985; 291:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/7\">",
"      Brookes JG, Dunn RJ, Rogers IR. Sternal fractures: a retrospective analysis of 272 cases. J Trauma 1993; 35:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/8\">",
"      McGinnis M, Denton JR. Fractures of the scapula: a retrospective study of 40 fractured scapulae. J Trauma 1989; 29:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/9\">",
"      McLennan JG, Ungersma J. Pneumothorax complicating fracture of the scapula. J Bone Joint Surg Am 1982; 64:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/10\">",
"      Brown CV, Velmahos G, Wang D, et al. Association of scapular fractures and blunt thoracic aortic injury: fact or fiction? Am Surg 2005; 71:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/11\">",
"      Stephens NG, Morgan AS, Corvo P, Bernstein BA. Significance of scapular fracture in the blunt-trauma patient. Ann Emerg Med 1995; 26:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/12\">",
"      Baldwin KD, Ohman-Strickland P, Mehta S, Hume E. Scapula fractures: a marker for concomitant injury? A retrospective review of data in the National Trauma Database. J Trauma 2008; 65:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/13\">",
"      Weening B, Walton C, Cole PA, et al. Lower mortality in patients with scapular fractures. J Trauma 2005; 59:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/14\">",
"      Peek GJ, Firmin RK. Isolated sternal fracture: an audit of 10 years' experience. Injury 1995; 26:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/15\">",
"      Wojcik JB, Morgan AS. Sternal fractures--the natural history. Ann Emerg Med 1988; 17:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/16\">",
"      Kohn MA, Hammel JM, Bretz SW, Stangby A. Trauma team activation criteria as predictors of patient disposition from the emergency department. Acad Emerg Med 2004; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/17\">",
"      Fabian TC, Richardson JD, Croce MA, et al. Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma. J Trauma 1997; 42:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/18\">",
"      Holmes JF, Ngyuen H, Jacoby RC, et al. Do all patients with left costal margin injuries require radiographic evaluation for intraabdominal injury? Ann Emerg Med 2005; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28247/abstract/19\">",
"      Chauny JM, &Eacute;mond M, Plourde M, et al. Patients with rib fractures do not develop delayed pneumonia: a prospective, multicenter cohort study of minor thoracic injury. Ann Emerg Med 2012; 60:726.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13861 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28247=[""].join("\n");
var outline_f27_37_28247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15009076\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009011\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009018\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009025\">",
"      ANATOMY, PHYSIOLOGY, AND MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009032\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009039\">",
"      PREHOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009046\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15009055\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15009062\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118186\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118412\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009069\">",
"      DIAGNOSIS, INITIAL MANAGEMENT, AND DISPOSITION OF SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3120151\">",
"      Minor chest wall injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2445769\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118426\">",
"      Clinical or radiographic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118570\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118419\">",
"      Sternal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2470527\">",
"      Sternoclavicular dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3118440\">",
"      Scapular fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2445494\">",
"      Internal injuries associated with chest wall trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3118488\">",
"      - Blunt aortic and other mediastinal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3118555\">",
"      - Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3118562\">",
"      - Pulmonary contusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15009076\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13861|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23857\" title=\"figure 1\">",
"      Flail chest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=related_link\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12520?source=related_link\">",
"      Evaluation of thoracic and lumbar spinal column injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4376?source=related_link\">",
"      Initial evaluation and management of rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=related_link\">",
"      Inpatient management of traumatic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28248="Etiology and treatment of calcipenic rickets in children";
var content_f27_37_28248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and treatment of calcipenic rickets in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Thomas Carpenter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28248/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/37/28248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcipenic rickets comprises a group of disorders in which supply of calcium or its intestinal absorption is too low to match the calcium demands imposed by bone growth.",
"   </p>",
"   <p>",
"    <br/>",
"    The most common cause of calcipenic rickets is dietary deficiency of vitamin D",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium, which leads to insufficient intestinal absorption of calcium. Alternatively, calcipenic rickets may be caused by decreased vitamin D activity (eg, lack of conversion to the active metabolite or resistance to the active metabolite). Patients with calcipenic rickets have secondary hyperparathyroidism and characteristic changes of the growth plates and metaphyseal bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33082307\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of rickets and diagnostic evaluation to determine the cause of rickets are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, patients with calcipenic rickets are identified by elevated parathyroid hormone (PTH) and normal or low serum inorganic phosphorus (",
"    <a class=\"graphic graphic_algorithm graphicRef79880 \" href=\"UTD.htm?37/6/37997\">",
"     algorithm 1",
"    </a>",
"    ). Serum calcium levels are usually low in calcipenic rickets, but may be normal in some stages of the disease due to a compensatory increase in PTH. Measurement of serum 25-hydroxyvitamin D (25OHD) helps to categorize the disorder into one of the following subcategories, which are discussed in detail in this topic review (",
"    <a class=\"graphic graphic_algorithm graphicRef80602 \" href=\"UTD.htm?10/28/10702\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary vitamin D deficiency (the \"classical\" form of rickets)",
"     </li>",
"     <li>",
"      Dietary calcium deficiency",
"     </li>",
"     <li>",
"      Vitamin D dependent rickets type I (caused by a defect of 1-alpha hydroxylase, the enzyme that converts 25OHD to its active metabolite, 1,25[OH]",
"      <sub>",
"       2",
"      </sub>",
"      D)",
"     </li>",
"     <li>",
"      Hereditary vitamin D resistant rickets (or vitamin D dependent rickets type II, caused by dysfunction of the vitamin D receptor)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic renal failure can also alter vitamin D metabolism and cause calcipenic rickets. This mechanism is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NUTRITIONAL RICKETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional rickets caused by inadequate intake of vitamin D",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium continues to be prevalent in many parts of the world and often is associated with other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/1\">",
"     1",
"    </a>",
"    ]. In Ethiopia, for example, rickets affects a large proportion of children who present with severe infectious diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/2\">",
"     2",
"    </a>",
"    ]. Although infrequent, nutritional rickets can also occur as a result of phosphate deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant's vitamin D status depends upon the amount of vitamin D transferred from the mother prenatally and upon the amount of vitamin D ingested or produced by the skin during exposure to ultraviolet light postnatally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ]. Materno-fetal transfer of vitamin D is mostly in the form of 25-hydroxyvitamin D (25OHD), which readily crosses the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/5\">",
"     5",
"    </a>",
"    ]. The half-life of 25OHD is approximately two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the serum concentration of vitamin D falls rapidly after birth unless additional sources are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H28181880#H28181880\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Perinatal factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D-deficiency rickets typically presents between three months and three years of age, when growth rates (and calcium needs) are high, and exposure to sunlight may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for vitamin D deficiency rickets are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal vitamin D deficiency during pregnancy &ndash; When a woman has very severe vitamin D deficiency during pregnancy, her offspring can have signs of rickets at birth or during the first three months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H28181888#H28181888\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Maternal vitamin D deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breastfeeding &ndash; In infants from developed countries, the main reasons for inadequate vitamin D supply are prolonged breastfeeding without vitamin D supplementation and concomitant avoidance of sun exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. The recommended intake of vitamin D to prevent deficiency is 400 international units (int. units) daily in healthy infants and 600 int. units daily for children 1 to 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/10\">",
"       10",
"      </a>",
"      ]. Human milk typically contains less than 25 int. units of vitamin D per liter [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/11-13\">",
"       11-13",
"      </a>",
"      ] unless the mother receives vitamin D supplementation in high doses (eg, more than 2000 int. units daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H28181902#H28181902\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Exclusive breast feeding'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Skin pigmentation and low sun exposure &ndash; Dark skin is an additional risk factor for developing rickets in breastfed infants because dark-skinned individuals produce less vitamin D in response to sunlight [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/6,8,9\">",
"       6,8,9",
"      </a>",
"      ]. The vitamin D concentration of the breast milk of dark-skinned mothers is less than that of lighter-skinned individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/12\">",
"       12",
"      </a>",
"      ]. Most mothers of breast-fed infants with rickets also are deficient in vitamin D. Thus, all at-risk mothers should be evaluated for vitamin D deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Siblings of infants with rickets should also be considered at high risk for vitamin D deficiency and should be appropriately evaluated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H23365767#H23365767\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Decreased synthesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes &ndash; Other causes of vitamin D deficiency resulting from diminished absorption are cystic fibrosis or other disorders of exocrine pancreatic function, gastrectomy or extensive bowel surgery, celiac disease, inflammatory bowel disease, and other malabsorptive conditions. Certain anticonvulsants and antiretroviral drugs used to treat human immunodeficiency virus (HIV) infection can precipitate vitamin D&nbsp;deficiency by enhancing catabolism of 25OHD and 1,25 dihydroxyvitamin D (1,25[OH]",
"      <sub>",
"       2",
"      </sub>",
"      D). Obesity is associated with low serum concentrations of vitamin D, but the mechanisms and clinical significance of this association have not been established. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H23365759#H23365759\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Causes of vitamin D deficiency'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America, infant formula, cow's milk, and cereals are fortified with vitamin D. All infant formulas in the United States contain at least 400 int.",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonetheless, the diet of exclusively breastfed infants and of partially formula-fed infants does not provide the recommended intake of vitamin D. As a result, vitamin D supplementation is recommended for these infants. Vitamin D supplementation is also recommended for children who consume less than 1000 mL (33 oz) of vitamin D-fortified milk daily, unless they have ample regular exposure to direct sunlight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H722827#H722827\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most nutritional rickets are prevented by adherence to these guidelines. However, infants born to mothers with severe vitamin D deficiency may rarely develop rickets even if they are fed adequate amounts of vitamin D fortified formula and are growing normally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/6\">",
"     6",
"    </a>",
"    ]. An increased total daily intake of up to 800 int. units may be necessary for premature infants, dark-skinned infants, and those who live at latitudes above 40&ordm; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D-deficiency rickets has three stages with increasing severity (",
"    <a class=\"graphic graphic_table graphicRef86780 \" href=\"UTD.htm?14/3/14396\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Stage one is caused by impaired intestinal calcium absorption, resulting in hypocalcemia, whereas serum inorganic phosphorus is normal. Hypophosphatemia develops in stages two and three, coinciding with clinically apparent rickets. Serum calcium is normal in stage two because of a compensatory increase in PTH secretion, but becomes low again in stage three, when the hyperparathyroidism is unable to compensate for the severe restriction in available calcium, and the clinical and radiological findings of rickets are severe. Because later stages of the disorder are characterized by severe secondary hyperparathyroidism, hyperaminoaciduria and hyperphosphaturia may occur.",
"   </p>",
"   <p>",
"    The clinical features of and diagnostic evaluation for hypocalcemic rickets are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used treatment for vitamin D deficiency consists of vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). The following dosing scheme is recommended for treatment of vitamin D-deficiency rickets in children without underlying defects in intestinal absorptive function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &lt;1 month old: 1000 int. units daily",
"     </li>",
"     <li>",
"      Infants 1 to 12 months old: 1000 to 2000 int. units daily",
"     </li>",
"     <li>",
"      Children one year and older: 2000 int. units daily",
"     </li>",
"     <li>",
"      Children with malabsorption, those on medications that impact vitamin D metabolism, and obese children with vitamin D deficiency may require higher replacement doses (two to three times higher than in children without these conditions), followed by higher maintenance dosing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authorities recommend starting treatment with higher doses of vitamin D (eg, 5000 to 10,000 int. units daily for children one year and older) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ], but we suggest the lower doses outlined above to reduce the risk of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment is continued at the above doses until there is radiographic evidence of healing or clear evidence of biochemical correction; thereafter, the dose of vitamin D is reduced to 600 int. units daily. The biochemical evaluation should be repeated within one month of therapy for safety reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we check radiographs for evidence of healing after two to three months of treatment.",
"   </p>",
"   <p>",
"    Expert opinion varies regarding doses for vitamin D replacement in infants and children with serum levels of 25OHD less than 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    but without clinical evidence of rickets. Some authorities recommend the same dosing scheme that is used for children with rickets, as outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ]. In our own practice, we tend to use somewhat lower doses (400 int. units daily in children less than one month of age, and up to 1000 int. units daily for older children). We feel that this reduces the risk of inducing hypercalcemia, especially in children who may not reliably return for biochemical monitoring after one month of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H10576904#H10576904\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Dosing and forms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with elevated levels of PTH, an oral calcium intake calcium supplement should be prescribed to avoid the so-called \"hungry bone\" syndrome (worsening hypocalcemia after the start of vitamin D therapy). The usual recommended dose is 30 to 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental calcium per day in three divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"     4",
"    </a>",
"    ]. This regimen of vitamin D and calcium supplementation should lead to resolution of the biochemical and radiological abnormalities within three months. An additional biochemical parameter of the adequacy of calcium and vitamin D supplementation that may be useful in older children is the reappearance of normal levels of urinary calcium excretion showing that the body's vitamin D and calcium stores have been replenished. If the patient has no detectable calciuria after three months of treatment, continuation of the same treatment regimen for another three months is advisable.",
"   </p>",
"   <p>",
"    Orthopedic consultation usually is not indicated because skeletal deformities regress completely after successful medical therapy. Correction of bow defects is a more chronic process and may take months to years to correct after the radiologic appearance of the growth plates has normalized. Orthopedic intervention may be necessary if deformities do not eventually improve.",
"   </p>",
"   <p>",
"    An alternative treatment protocol is the so-called \"stoss therapy,\" which consists of a high dose of oral vitamin D (600,000 int. units) given on a single day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/22\">",
"     22",
"    </a>",
"    ]. This amount of vitamin D approximately corresponds to a three-month course of 5000 int. units per day and should be sufficient to induce healing of the growth plate within three months. Stoss therapy may be advantageous when compliance with therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    follow-up is anticipated to be a problem [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. However, such high doses of vitamin D can lead to hypercalcemia. Doses of 150,000 or 300,000 int. units appear to be equally effective, and are associated with less risk of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/24\">",
"     24",
"    </a>",
"    ]. Finally, in older children, a modified higher dose approach has been successfully used, particularly when there is concern about adherence to a daily regimen. The regimen consists of weekly doses of 50,000 int. units vitamin D for two to three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum calcium, phosphorus, alkaline phosphatase concentrations, and urinary",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio should be measured four weeks after the start of therapy in children who are being treated for vitamin D-deficiency rickets. At this time point, serum calcium and phosphorus levels should have normalized, and alkaline phosphatase should have started to decrease towards the reference range. The urinary",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio may still be low. These tests should be repeated monthly until doses are adjusted downward to a typical daily replacement amount. This typically occurs by three months of therapy, at which time radiographs can be obtained to document the healing of rachitic lesions. &nbsp;",
"   </p>",
"   <p>",
"    If the radiographs do not show evidence of healing, or biochemical parameters are not improving, the possibility of poor adherence to treatment, malabsorption of vitamin D, or other forms of rickets should be considered. Consideration of an alternate diagnosis is particularly important when the original biochemical profile had borderline values. As an example, modest elevations in serum PTH are occasionally observed in X-linked hyperphosphatemia (XLH), leading to an erroneous diagnosis of calcipenic rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring is also important as to ensure that no toxicity has occurred, particularly if the vitamin D dose was erroneously dispensed or administered. We have encountered hypercalcemia in the setting where high doses were continued for a longer duration than intended due to poor compliance with follow-up visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calcium deficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickets can occur despite adequate vitamin D levels if calcium intake is very low. This problem generally does not occur unless calcium intake is very low because vitamin D increases intestinal calcium absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Most children with calcium deficiency rickets have normal serum 25OHD and high serum 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D concentrations, indicating adequate intake of vitamin D. These children may have an increased vitamin D requirement when measured by their response to vitamin D replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, vitamin D requirements may be higher than expected in children who are calcium-deficient. Indeed, the turnover of vitamin D is accelerated in the setting of vitamin D deficiency. Thus, the two nutrients are inherently linked such that limited availability of one will result in limited supply of the other.",
"   </p>",
"   <p>",
"    Calcium-deficiency rickets was well documented in a randomized, double-blind, controlled trial of 123 Nigerian children with rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/28\">",
"     28",
"    </a>",
"    ]. In this population, the baseline intake of calcium was very low (about 200 mg per day), and the children responded to treatment with calcium, with or without vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/28\">",
"     28",
"    </a>",
"    ]. However, other factors in addition to calcium intake must play a role because control children without rickets had similarly low calcium intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/29\">",
"     29",
"    </a>",
"    ]. Although most of the studies on calcium-deficiency rickets were performed in Africa, similar dietary deficiencies occur in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/26,30-32\">",
"     26,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, rickets does not occur in hypoparathyroidism, perhaps in view of elevated phosphorus levels, or a possible role of PTH in mediating the growth plate lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology of hypocalcemia in infants and children\", section on 'Hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As shown by the study of Nigerian children described above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/28\">",
"     28",
"    </a>",
"    ], calcium-deficiency rickets can be treated by ensuring a daily intake of 1000 mg of calcium and maintenance of vitamin D intake at the recommended daily value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VITAMIN D DEPENDENT RICKETS TYPE I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D dependent rickets type I (VDDR-I), also called pseudovitamin D deficiency rickets or 1-alpha-hydroxylase deficiency, was identified as a unique form of vitamin D-resistant rickets in 1961 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VDDR-I is characterized by early onset of skeletal disease (within the first year of life) and severe hypocalcemia (sometimes with tetany), with accompanying moderate hypophosphatemia. Enamel hypoplasia may occur. These features distinguish VDDR-I from X-linked hypophosphatemic rickets (previously known as X-linked vitamin D-resistant rickets). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'X-linked'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;VDDR-I, an autosomal recessive disorder, is characterized by defective conversion of 25-hydroxyvitamin D (25OHD) to 1,25-dihydroxyvitamin D (1,25[OH]",
"    <sub>",
"     2",
"    </sub>",
"    D) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/34\">",
"     34",
"    </a>",
"    ]. The characteristic biochemical findings of VDDR-I are normal serum levels of 25OHD and low levels of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D (",
"    <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with VDDR-I have inactivating mutations in the CYP27B1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], which encodes the enzyme (25-hydroxyvitamin D 1-alpha-hydroxylase or simply 1-alpha hydroxylase) responsible for the conversion of 25OHD to 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D. Mice with inactivation of the gene encoding 1-alpha hydroxylase mimic the VDDR-I phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for VDDR-I is replacement therapy with 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D (calcitriol), an off-label use of this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/37\">",
"     37",
"    </a>",
"    ]. The dose depends upon the severity of disease and the child's body weight. The initial dose for florid rickets is 1",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    Treatment is continued at this dose until bones are healed. Thereafter, the maintenance dose varies between 0.25 and 1",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    depending on the results of biochemical analyses as described in the next paragraph. The aims of the treatment are to achieve normal serum calcium levels, to maintain PTH levels within normal limits, and to avoid hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/37\">",
"     37",
"    </a>",
"    ]. It is important to maintain adequate intake of dietary calcium (30 to 75",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of elemental calcium).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close supervision is needed during the initial phase of treatment, including a physical examination and biochemical evaluation every two to three weeks. The biochemical evaluation should include measurement of serum calcium, phosphorus, alkaline phosphatase, and PTH levels. Radiographs should show clear improvement after four weeks of therapy and should be repeated after three months, when the growth plates should have regained a normal appearance. Patients may be evaluated at three-month intervals during maintenance therapy. Hand radiographs are performed once per year to check for the reappearance of rachitic changes.",
"   </p>",
"   <p>",
"    Possible side effects of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D therapy include hypercalcemia, hypercalciuria, nephrocalcinosis, and intraocular calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/37\">",
"     37",
"    </a>",
"    ]. Therefore, it is important to check the urinary",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio and kidney function (eg, serum creatinine) at each visit. Renal ultrasound and ophthalmologic consultation (slit lamp examination) should be performed once per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HEREDITARY VITAMIN D RESISTANT RICKETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary vitamin D resistant rickets (HVDRR) has also been called vitamin D dependent rickets type II, and is characterized by end-organ resistance to vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/40\">",
"     40",
"    </a>",
"    ]. It is a very rare form of rickets that has been reported in about 100 cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;HVDRR is an autosomal recessive disorder. It is associated with end&ndash;organ resistance to 1,25-dihydroxyvitamin D (1,25[OH]",
"    <sub>",
"     2",
"    </sub>",
"    D), usually caused by mutations in the gene encoding the vitamin D receptor. The defect in the receptor interferes with the function of the hormone-receptor complex, thereby preventing 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D action [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of HVDRR varies widely, probably reflecting the type of mutation within the vitamin D receptor and the amount of residual vitamin D receptor activity. Affected children usually appear normal at birth but develop rickets within the first two years of life. Alopecia resulting from the lack of vitamin D receptor activity within keratinocytes develops in approximately two-thirds of cases and is a marker of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HDVRR involves a therapeutic trial of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D (calcitriol) and calcium supplementation. The individual response is difficult to predict because the severity of the receptor defect varies among patients. Therapy may start at daily doses of 2 mcg of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D and 1000 mg of elemental calcium. However, administration of extremely high doses of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D (up to 30 to 60",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    and calcium (up to 3 g per day) may be necessary to restore normocalcemia and to mineralize depleted bones.",
"   </p>",
"   <p>",
"    Long-term infusion of calcium into a central vein is a possible alternative therapeutic option for severely resistant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and usually must be maintained for many months. Oral calcium therapy may be sufficient once radiographic healing has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28248/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During treatment, patients should initially be evaluated at least once per week. Serum concentrations of calcium, phosphorus, alkaline phosphatase, creatinine, 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D, and parathyroid hormone (PTH), and the urinary",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio should be measured.",
"   </p>",
"   <p>",
"    If the biochemical parameters do not respond, the dose of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D should be gradually increased to reach serum concentrations of up to 100 times the normal mean value. Failure of therapy should be considered if no biochemical response occurs after three to five months of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=see_link\">",
"       \"Patient information: Vitamin D for babies and children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33081921\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcipenic rickets comprises a group of disorders in which intestinal absorption of calcium is insufficient to match the calcium requirements for bone growth. This may be caused by dietary deficiency of calcium, or by insufficient intestinal absorption of calcium caused by vitamin D deficiency or decreased vitamin D activity (eg, lack of conversion to the active metabolite or resistance to the active metabolite).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcipenic rickets is characterized by elevated parathyroid hormone and normal or low serum inorganic phosphorus concentrations (",
"      <a class=\"graphic graphic_algorithm graphicRef79880 \" href=\"UTD.htm?37/6/37997\">",
"       algorithm 1",
"      </a>",
"      ). Measurement of the serum 25-hydroxyvitamin D (25OHD) level helps to categorize the disorder into one of the following subcategories, which are discussed in detail in this topic review (",
"      <a class=\"graphic graphic_algorithm graphicRef80602 \" href=\"UTD.htm?10/28/10702\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33082307\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional rickets, caused by inadequate intake of vitamin D",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium, continues to be prevalent in many parts of the world and often is associated with other conditions such as infectious disease or generalized malnutrition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nutritional rickets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D-deficiency rickets usually presents between three months and three years of age, when growth rates (and calcium needs) are high, and exposure to sunlight may be limited. The main reasons for inadequate vitamin D supply in infants from Western countries are prolonged breastfeeding without vitamin D supplementation and concomitant avoidance of sun exposure. Vitamin D deficiency may also be caused by conditions that cause malabsorption such as celiac disease, cystic fibrosis, or extensive bowel resection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent vitamin D deficiency, vitamin D supplementation (400 international units [int.",
"      <span class=\"nowrap\">",
"       units]/day)",
"      </span>",
"      is recommended for all breast-fed infants; supplementation should start in the first week of life. Supplements should be continued until the infant is ingesting at least 400 int. units of vitamin D daily through formula, milk, or other food sources. In addition, vitamin D supplementation should be given to all non-breastfed infants who are ingesting less than 1000 mL of vitamin D-fortified formula or milk per day. Children older than one year of age and adolescents should receive 600 int. units of vitamin D daily through diet (eg, 1000 mL vitamin D-fortified milk daily) or supplements (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children with any stage of vitamin D-deficiency rickets should be treated with vitamin D. We use oral vitamin D2 (ergocalciferol) or D3 (cholecalciferol), at the doses shown below. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      1000 int. units daily for infants &lt;1 month old",
"     </li>",
"     <li>",
"      1000 to 2000 int. units daily for infants 1 to 12 months old",
"     </li>",
"     <li>",
"      2000 int. units daily for children one year and older",
"     </li>",
"     <li>",
"      Children with malabsorption, those on medications that impact vitamin D metabolism, and obese children with vitamin D deficiency may require higher doses for vitamin D replacement and higher maintenance doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We also suggest vitamin D replacement for infants and children with serum levels of 25OHD less than 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      but without clinical evidence of rickets (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For these children with subclinical vitamin D deficiency, we use replacement doses of 400 int. units daily in children less than one month of age, and up to 1000 int. units daily for older children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children who are being treated for vitamin D-deficiency rickets, serum calcium, phosphorus, alkaline phosphatase concentrations, and urinary",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio should be measured four weeks after starting therapy. After three months of therapy, these tests should be repeated, and radiographs should be obtained to document healing of rachitic lesions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less commonly, dietary deficiency of calcium may cause nutritional rickets. This is suggested by the presence of rickets in countries where the incidence of hypocalcemic rickets is high, despite ample sunlight and adequate exposure to the sunlight (in the absence of sunscreen), and normal serum concentrations of vitamin D. Because children who are calcium-deficient may have higher than expected requirements for vitamin D, they should be treated with both calcium and vitamin D supplementation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Calcium deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D dependent rickets type I (VDDR-I, or pseudovitamin D-deficiency rickets) is caused by an inherited deficiency of the enzyme 1-alpha-hydroxylase, which is responsible for the conversion of 25OHD to 1,25-dihydroxyvitamin D (1,25[OH]",
"      <sub>",
"       2",
"      </sub>",
"      D). The characteristic biochemical findings of VDDR-I are normal serum levels of 25OHD and low levels of 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D (",
"      <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"       table 2",
"      </a>",
"      ). Treatment is with physiologic doses of 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D (calcitriol). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vitamin D dependent rickets type I'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary vitamin D resistant rickets (HVDRR, or vitamin D dependent rickets type II) is a rare disorder characterized by end-organ resistance to vitamin D that is usually caused by mutations in the gene encoding the vitamin D receptor. The clinical severity and response to treatment with 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D is highly variable. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hereditary vitamin D resistant rickets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/1\">",
"      Fischer PR, Thacher TD, Pettifor JM. Pediatric vitamin D and calcium nutrition in developing countries. Rev Endocr Metab Disord 2008; 9:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/2\">",
"      Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 1997; 349:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/3\">",
"      Holland PC, Wilkinson AR, Diez J, Lindsell DR. Prenatal deficiency of phosphate, phosphate supplementation, and rickets in very-low-birthweight infants. Lancet 1990; 335:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/4\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/5\">",
"      Thandrayen K, Pettifor JM. Maternal vitamin D status: implications for the development of infantile nutritional rickets. Endocrinol Metab Clin North Am 2010; 39:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/6\">",
"      Ward LM, Gaboury I, Ladhani M, Zlotkin S. Vitamin D-deficiency rickets among children in Canada. CMAJ 2007; 177:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/7\">",
"      Robinson PD, H&ouml;gler W, Craig ME, et al. The re-emerging burden of rickets: a decade of experience from Sydney. Arch Dis Child 2006; 91:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/8\">",
"      Beck-Nielsen SS, Jensen TK, Gram J, et al. Nutritional rickets in Denmark: a retrospective review of children's medical records from 1985 to 2005. Eur J Pediatr 2009; 168:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/9\">",
"      Hatun S, Ozkan B, Orbak Z, et al. Vitamin D deficiency in early infancy. J Nutr 2005; 135:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/10\">",
"      Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/11\">",
"      Reeve LE, Chesney RW, DeLuca HF. Vitamin D of human milk: identification of biologically active forms. Am J Clin Nutr 1982; 36:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/12\">",
"      Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child 1985; 139:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/13\">",
"      Hollis BW, Roos BA, Draper HH, Lambert PW. Vitamin D and its metabolites in human and bovine milk. J Nutr 1981; 111:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/14\">",
"      Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80:1752S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/15\">",
"      Wagner CL, Hulsey TC, Fanning D, et al. High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study. Breastfeed Med 2006; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/16\">",
"      Nozza JM, Rodda CP. Vitamin D deficiency in mothers of infants with rickets. Med J Aust 2001; 175:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/17\">",
"      Dawodu A, Agarwal M, Sankarankutty M, et al. Higher prevalence of vitamin D deficiency in mothers of rachitic than nonrachitic children. J Pediatr 2005; 147:109.",
"     </a>",
"    </li>",
"    <li>",
"     Nutrition During Infancy: Principles and Practice, 2nd ed, Tsang RC, Zlotkin SH, Nichols BL, Hansen JW (Eds), Digital Education Publishing, Cincinnati, OH 1997. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/19\">",
"      Fraser D, Kooh SW, Scriver CR. Hyperparathyroidism as the cause of hyperaminoaciduria and phosphaturia in human vitamin D deficiency. Pediatr Res 1967; 1:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/20\">",
"      Kruse K. Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. J Pediatr 1995; 126:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/21\">",
"      Vanstone MB, Oberfield SE, Shader L, et al. Hypercalcemia in children receiving pharmacologic doses of vitamin D. Pediatrics 2012; 129:e1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/22\">",
"      Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr 1994; 125:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/23\">",
"      Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust 2006; 185:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/24\">",
"      Cesur Y, Caksen H, G&uuml;ndem A, et al. Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets. J Pediatr Endocrinol Metab 2003; 16:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/25\">",
"      Pfitzner MA, Thacher TD, Pettifor JM, et al. Absence of vitamin D deficiency in young Nigerian children. J Pediatr 1998; 133:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/26\">",
"      DeLucia MC, Mitnick ME, Carpenter TO. Nutritional rickets with normal circulating 25-hydroxyvitamin D: a call for reexamining the role of dietary calcium intake in North American infants. J Clin Endocrinol Metab 2003; 88:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/27\">",
"      Thacher TD, Fischer PR, Isichei CO, Pettifor JM. Early response to vitamin D2 in children with calcium deficiency rickets. J Pediatr 2006; 149:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/28\">",
"      Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/29\">",
"      Thacher TD, Fischer PR, Pettifor JM, et al. Case-control study of factors associated with nutritional rickets in Nigerian children. J Pediatr 2000; 137:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/30\">",
"      Bergstrom WH. When you see rickets, consider calcium deficiency. J Pediatr 1998; 133:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/31\">",
"      Maltz HE, Fish MB, Holliday MA. Calcium deficiency rickets and the renal response to calcium infusion. Pediatrics 1970; 46:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/32\">",
"      Kooh SW, Fraser D, Reilly BJ, et al. Rickets due to calcium deficiency. N Engl J Med 1977; 297:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/33\">",
"      PRADER A, ILLIG R, HEIERLI E. [An unusual form of primary vitamin D-resistant rickets with hypocalcemia and autosomal-dominant hereditary transmission: hereditary pseudo-deficiency rickets]. Helv Paediatr Acta 1961; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/34\">",
"      Fraser D, Kooh SW, Kind HP, et al. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973; 289:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/35\">",
"      Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/36\">",
"      Kim CJ, Kaplan LE, Perwad F, et al. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:3177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/37\">",
"      Edouard T, Alos N, Chabot G, et al. Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol. J Clin Endocrinol Metab 2011; 96:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/38\">",
"      Dardenne O, Prud'homme J, Arabian A, et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/39\">",
"      Panda DK, Miao D, Tremblay ML, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 2001; 98:7498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/40\">",
"      Malloy PJ, Feldman D. Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am 2010; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/41\">",
"      Sakai Y, Kishimoto J, Demay MB. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 2001; 107:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/42\">",
"      Chen CH, Sakai Y, Demay MB. Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 2001; 142:5386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/43\">",
"      Balsan S, Garab&eacute;dian M, Larchet M, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28248/abstract/44\">",
"      Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J Pediatr 1992; 121:803.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5804 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28248=[""].join("\n");
var outline_f27_37_28248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33081921\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33082307\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NUTRITIONAL RICKETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calcium deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VITAMIN D DEPENDENT RICKETS TYPE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HEREDITARY VITAMIN D RESISTANT RICKETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33081921\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5804|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/6/37997\" title=\"algorithm 1\">",
"      Diagnostic approach in suspected rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/28/10702\" title=\"algorithm 2\">",
"      Approach to calcipenic rickets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/3/14396\" title=\"table 1\">",
"      Stages of vitamin D deficiency rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/34/12845\" title=\"table 2\">",
"      Biochemical findings rickets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=related_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28249="Glucocorticoid effects on the immune system";
var content_f27_37_28249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glucocorticoid effects on the immune system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28249/contributors\">",
"     W Winn Chatham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28249/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28249/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/37/28249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (corticosteroids) have inhibitory effects on a broad range of specific immune responses mediated by T cells and B cells, as well as potent suppressive effects on the effector functions of phagocytes. Because of their inhibitory effects on both acquired and innate immunologic function, glucocorticoids are remarkably efficacious in managing many of the acute disease manifestations of inflammatory and autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of action of glucocorticoids upon the various effector cells of the adaptive and innate immune system will be reviewed here. The effects of glucocorticoids on other specific physiologic systems are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31367?source=see_link\">",
"     \"Glucocorticoid effects on the nervous system and behavior\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF INTRACELLULAR EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids diffuse passively across the cellular membrane and bind to the intracellular glucocorticoid receptor. Binding of the drug to this receptor results in translocation of the complex into the nucleus, where it can interact directly with specific DNA sequences (glucocorticoid responsive elements, or GREs), and other transcription factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effects on gene transcription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binding of the receptor to GREs may result in either enhancement or suppression of transcription of susceptible downstream genes. The antiinflammatory effects of glucocorticoids result from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binding to and blocking promoter sites of proinflammatory genes, such as interleukin (IL)-1alpha and IL-1beta [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recruiting of transcription factors to promoter sequences of genes coding for antiinflammatory gene products including: I-kappa-B (IkBa), IL-1 receptor-II (IL-1RII), lipocortin-1 (annexin I), IL-10, alpha-2-macroglobulin, and secretory leukocyte protease inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of the synthesis of almost all known cytokines (",
"      <a class=\"graphic graphic_table graphicRef68966 \" href=\"UTD.htm?9/9/9371\">",
"       table 1",
"      </a>",
"      ): this is primarily achieved by competing for, or blocking the function of transcription factors, nuclear factor kappa B (NF-kB), and activator protein-1 (AP-1) that are required for transcription of proinflammatory mediators [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/3,5-8\">",
"       3,5-8",
"      </a>",
"      ]. This may be mediated in part by glucocorticoid-induced expression of MAPK phosphatase 1 and consequent dephosphorylation of various proteins that participate in intracellular signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/8\">",
"       8",
"      </a>",
"      ]. These include Jun N-terminal kinase (interfering with production of c-Jun and AP-1), extracellular-signal-related-kinase-1 and -2, and p38 MAP kinase. As mentioned above, glucocorticoids increase the synthesis of IkBa, a protein that traps and thereby inactivates NF-kB [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/3,5\">",
"       3,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effects on post-translational events",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their effects on gene transcription, glucocorticoids also inhibit secretion of inflammatory cytokines by affecting post-translational events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/8\">",
"     8",
"    </a>",
"    ]. The stability of mRNA encoding IL-1, IL-2, IL-6, IL-8, tumor necrosis factor (TNF), and granulocyte-macrophage-colony stimulating factor (GM-CSF) is diminished in the presence of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFECTS ON LEUKOCYTE TRAFFICKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have profound effects on the cellular functions of leukocytes and endothelial cells, resulting in reduced ability of leukocytes to adhere to vascular endothelium and exit from the circulation. Entry to sites of infection and tissue injury is impaired, resulting in suppression of the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Reduction in endothelial adhesion may be due to direct effects of glucocorticoids on expression of adhesion molecules on both leukocytes and endothelial cells, as well as indirect effects due to the inhibitory effects of glucocorticoids on transcription of cytokines, such as IL-1 or TNF, that upregulate endothelial adhesion molecule expression. The normal process of leukocyte-endothelial adhesion during inflammation is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specifically, the administration of glucocorticoids results in a neutrophilic leukocytosis, accompanied by dramatic reductions in circulating eosinophils, monocytes, and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophil migration through the vasculature to sites of inflammation is severely impaired. This, combined with enhanced release of cells from the bone marrow and inhibition of neutrophil apoptosis, results in increased numbers of circulating neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10,13\">",
"       10,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Circulating levels of eosinophils are markedly and rapidly reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/14\">",
"       14",
"      </a>",
"      ]. This is mediated in part by sequestration of eosinophils in extravascular tissues, possibly due to the preferential upregulation of the CXC chemokine receptor 4 (CXCR4) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast to their effects on neutrophils, glucocorticoids (notably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) induce apoptosis of eosinophils [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue accumulation of monocytes and macrophages is reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/17,18\">",
"       17,18",
"      </a>",
"      ], an effect mediated by decreased migration from the vasculature and reduced elaboration of macrophage migration inhibition factor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The numbers of circulating T lymphocytes are rapidly reduced, and B lymphocyte numbers are reduced to a lesser extent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effects on acquired immunity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTS ON INNATE IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innate immune system may be defined as those components of the immune system that are able to respond immediately to an insult without reliance on antibodies or other acquired responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phagocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phagocytes are a critical component of the innate immune response, and glucocorticoids affect the functions of various phagocytic cells:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neutrophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies of neutrophil function indicate that glucocorticoids inhibit neutrophil apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. Neutrophil phagocytic responses or bactericidal activities do not appear to be significantly impaired, although at high doses phagocytic function may be inhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. As a result, the main impact of glucocorticoid treatment on neutrophil function is most likely impairment of migration to sites of inflammation or infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Eosinophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids",
"    <strong>",
"     promote",
"    </strong>",
"    eosinophil apoptosis (the opposite of their effect on neutrophil apoptosis) either directly or by attenuating synthesis of IL-5, a cytokine that promotes eosinophil survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. Glucocorticoids have variable inhibitory effects upon the degranulation of eosinophils that are dependent upon the activating ligand and the glucocorticoid used in the assay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Macrophages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids diminish the production of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    derived eicosanoids and inflammatory cytokines (IL-1, TNF), and also inhibit macrophage phagocytic and microbicidal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10,11,24,25\">",
"     10,11,24,25",
"    </a>",
"    ]. Clearance of opsonized bacteria by the reticuloendothelial system is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigen presentation and expression of class II-HLA molecules by macrophages is downregulated in response to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/27\">",
"     27",
"    </a>",
"    ]. This effect, coupled with the effect of glucocorticoids on dendritic cells, may account for the significant impact of glucocorticoids on acquired immunity. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Dendritic cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11515504\">",
"    <span class=\"h2\">",
"     Mast cells and basophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have been shown in vitro to inhibit both production of cytokines and degranulation by mast cells. The noted inhibition of inflammatory cytokine production by mast cells appears to occur through suppression of gene transcription as described for other leukocytes. The inhibition of mast cell degranulation by glucocorticoids has been shown to be time-dependent, mediated through the upregulation of inhibitory regulators of signaling such as SLAP1 (src-like adapter proten-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effects on proinflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may also impair the generation of inflammatory exudates by decreasing production or increasing degradation of various proinflammatory mediators:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upregulating the synthesis of angiotensin converting enzyme and neutral endopeptidase enzymes that degrade bradykinin, which is a vasodilatory peptide central to the generation of some forms of angioedema [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suppressing production of inflammatory eicosanoids in phagocytic cells by inducing the synthesis of lipocortin-1 (annexin I), macrocortin,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipomodulin, all of which inhibit phospholipase A2 (PLA2)-mediated liberation of arachidonic acid from membrane phospholipids [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/32-36\">",
"       32-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suppressing the synthesis of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase primarily responsible for production of prostaglandins at sites of tissue injury and inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/37\">",
"       37",
"      </a>",
"      ]. This effect primarily results from glucocorticoid suppression of NF-kB transcription. Glucocorticoids do not appear to affect the synthesis of constitutive cyclooxygenase-1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFECTS ON ACQUIRED IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen presenting cells (eg, macrophages and dendritic cells) and both T cells and B cells are affected by glucocorticoids, albeit with different temporal responses and degrees of impact. The differential effects of glucocorticoids on lymphocyte subsets may be an important consideration when formulating treatment regimens for autoantibody mediated diseases or the prevention of graft rejection in organ transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dendritic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In murine models, glucocorticoids decrease the numbers of both circulating and organ-resident dendritic cells; a marked reduction in circulating dendritic cells is also seen in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/38\">",
"     38",
"    </a>",
"    ]. This effect appears to be mediated at least in part by glucocorticoid-induced apoptosis of resident dendritic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD34+ precursor-derived CD14+ dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/39\">",
"     39",
"    </a>",
"    ]. Given the central antigen presenting function of dendritic cells in stimulating naive T cells, treatment with glucocorticoids may impair the development of immunity to newly encountered antigens. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Impact on vaccination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Infection risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy produces a rapid depletion of circulating T cells due to a combination of effects, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhanced circulatory emigration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhibition of IL-2, a principal T cell growth factor, and IL-2 signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired release of cells from lymphoid tissues",
"     </li>",
"     <li>",
"      Induction of apoptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects on T lymphocyte apoptosis depend upon the stage of T cell differentiation and T cell subtype. Certain T cell types, such as immature",
"    <span class=\"nowrap\">",
"     (CD4+/CD8+)",
"    </span>",
"    thymocytes, undergo apoptosis in the presence of glucocorticoids, while others, such as natural killer (NK)1.1 cells, do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/42\">",
"     42",
"    </a>",
"    ]. In keeping with this, thymic atrophy has been described in patients with Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/43\">",
"     43",
"    </a>",
"    ]. The sensitivity of",
"    <span class=\"nowrap\">",
"     CD4+/CD8+",
"    </span>",
"    T cells to glucocorticoid-induced apoptosis is correlated with the absence of expression of Bcl-2, a protein expressed on more mature glucocorticoid-resistant",
"    <span class=\"nowrap\">",
"     CD4+/CD8-",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     CD4-/CD8+",
"    </span>",
"    T cell subsets. While resting mature T cells are generally glucocorticoid-resistant, activated",
"    <span class=\"nowrap\">",
"     CD4+/CD8-/Th1",
"    </span>",
"    subsets of T cells may be moderately susceptible to glucocorticoid-induced apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, due to suppressive effects on expression of fas-ligand, glucocorticoids may actually prolong the survival of",
"    <span class=\"nowrap\">",
"     CD4+/CD8-",
"    </span>",
"    T cells susceptible to fas-mediated apoptosis occurring in response to T cell receptor (TCR) activation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/46\">",
"     46",
"    </a>",
"    ]. Murine models examining the role of Th17 cells in reactive airway disease suggest the subset of Th17 cells may be relatively resistant to the effects of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H5#H5\">",
"     \"Apoptosis and autoimmune disease\", section on 'Triggering apoptosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Effects on T cell selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids play a physiologic role in the positive and negative selection of thymocytes with consequences on development of the T cell repertoire [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/42\">",
"     42",
"    </a>",
"    ]. High levels of glucocorticoids may attenuate negative selection by impairing apoptosis triggered as a consequence of high avidity T cell receptor (TCR)-antigen presenting molecule (MHC class I or II) interactions, the result being survival of autoreactive clones. On the other hand, in the setting of low-avidity TCR interactions, increased ambient glucocorticoid concentrations may raise the activation threshold required for positive selection, the result being deletion of the potentially reactive clones. The extent to which treatment with pharmacologic doses of glucocorticoids impacts the development of the T cell repertoire in humans and any associated clinical significance has not been determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     T cell lineage commitment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids inhibit the acute generation of both Th1 and Th2 derived cytokines by activated T cells, although the inhibitory effect on expression of Th1 cytokines appears to be greater [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, treatment with glucocorticoids is associated with a shift in the relative expression of Th2-derived cytokines relative to Th1 cytokines (",
"    <a class=\"graphic graphic_table graphicRef63847 \" href=\"UTD.htm?16/19/16699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/42\">",
"     42",
"    </a>",
"    ]. Glucocorticoids attenuate peripheral blood mononuclear cell production of IL-12, a cytokine that favors Th1 development, while having minimal effect on production of IL-10, a cytokine that favors Th2 development [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/49\">",
"     49",
"    </a>",
"    ]. Decreased production of IL-12 and associated attenuation of TH1 derived cytokines may potentially favor commitment of undifferentiated T cells to the Th17 lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H11#H11\">",
"     \"The adaptive cellular immune response\", section on 'Cytokine secretion profiles of activated T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     B cells and antibody production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numbers of circulating B lymphocytes are reduced by glucocorticoid administration, but to a much lesser extent than those of T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/51\">",
"     51",
"    </a>",
"    ]. Synthesis of antibodies by B cells remains essentially unchanged following short-term administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/52\">",
"     52",
"    </a>",
"    ]. In fact, glucocorticoids may acutely promote B cell immunoglobulin secretion indirectly via inhibition in the function of CD8+ suppressor T cells. Low-dose glucocorticoid therapy appears to have little, if any effect on antigen-stimulated antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Impact on vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If glucocorticoids are administered chronically over a period of years, however, there may be a decrease in total IgG and IgA, possibly as a consequence of inhibition of T cell help",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased catabolism of generated antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In contrast, synthesis of IgE is often increased, which may be attributable to the enhancing effects of glucocorticoids on IL-4 induced B cell isotype switching to IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Impact on vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of studies have evaluated the ability of patients receiving glucocorticoid therapy to respond to vaccination. Glucocorticoid dose and duration, as well as the patient's underlying disease, appear to be important determining factors in predicting response to vaccination.",
"   </p>",
"   <p>",
"    The majority of available studies evaluated patients receiving low to moderate doses of glucocorticoids for the management of chronic disease (ie, doses of less than 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in children or less than 40 mg per day in adults). Less is known about the impact of higher doses given over extended periods of time.",
"   </p>",
"   <p>",
"    In contrast, severely ill or fragile patients, such as those who recently underwent bone marrow or solid organ transplantation or those with malignancy, may not respond adequately to vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/58\">",
"     58",
"    </a>",
"    ]. As a result, pretransplant immunization should be pursued when possible. The administration of various vaccines in transplant candidates and recipients as well as patients with malignancies is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal vaccine is immunogenic in most patients on glucocorticoid therapy for renal, pulmonary, or rheumatic diseases, although antibody titers may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/54,58-60\">",
"     54,58-60",
"    </a>",
"    ]. As an example, a small study compared pneumococcal vaccination responses in 14 steroid-dependent asthmatics and 14 control asthmatics and found no differences in the strength of response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/60\">",
"     60",
"    </a>",
"    ]. The doses of glucocorticoids taken by these patients ranged from 10 mg to 35 mg daily or every other day.",
"   </p>",
"   <p>",
"    Similar considerations appear to apply to influenza vaccination. Most patients receiving chronic glucocorticoids therapy for rheumatologic or pulmonary disorders generate an adequate antibody response, although some have lower antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The significance of lower immunization-induced antibody titers with regard to infection prevention is unclear, and dose thresholds for glucocorticoid use with regard to vaccination success have not been established.",
"   </p>",
"   <p>",
"    In patients who do show evidence of impaired vaccine response, removal of chronic low dose glucocorticoid treatment may result in improved antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunosuppression due to chronic glucocorticoid use is a contraindication to the administration of live virus vaccines, such as measles, mumps, rubella (MMR), varicella, and vaccinia (small pox). The safety of live virus vaccines in specific patient groups is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"     \"Medical management of immune deficiency\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link&amp;anchor=H11#H11\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Vaccinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IMPACT OF DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some immunologic effects of glucocorticoids are dose-dependent, due primarily to variable affinity of target genomic sites for the complex of glucocorticoid and glucocorticoid receptor. High-affinity genomic sites may be affected by low levels of glucocorticoids, with additional genes affected as the concentration of glucocorticoid increases; administration of high-dose pulse glucocorticoids may result in non-specific general disruption of gene transcription. High-dose pulse glucocorticoids may also have more rapid effects on leukocyte aggregation, possibly as a consequence of effects on the expression of leukocyte adhesion molecules and disruption of calcium flux across membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Low to moderate doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doses of less than 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in children or less than 40 mg per day in adults can be considered low to moderate, as mentioned previously. Equivalent doses of other glucocorticoids are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 3",
"    </a>",
"    ). In the low to moderate dose range, T lymphocytes may be slightly reduced in the circulation, CD4-positive cells more than CD8-positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/65\">",
"     65",
"    </a>",
"    ]. Delayed-type hypersensitivity (DTH) responses may be impaired, resulting in cutaneous anergy, primarily due to the failure of inflammatory cells to be recruited to the site of the reaction. There are isolated case reports of impaired immunoglobulin function with long-term therapy, although this is not believed to be common, and may be an indirect effect mediated by the impact of corticosteroids on T cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Higher doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunologic effects of high-dose, short-term pulse therapy have also been studied. In vitro, lymphocyte proliferation to mitogens was maximally suppressed at concentrations of glucocorticoid that would be achieved by the administration of approximately 1 gram of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/66\">",
"     66",
"    </a>",
"    ]. The acute effects of 1 gram of intravenous methylprednisolone in vivo were evaluated in a small study of patients with RA who were given either one or three daily doses of methylprednisolone (1 gram per dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/67\">",
"     67",
"    </a>",
"    ]. Lymphopenia developed within two hours of the dose, peaked at six hours, and resolved by 24 hours with both regimens. Patients were followed for 16 weeks, during which skin test positivity to PPD was unaffected, serum immunoglobulin levels were unchanged, and primary antibody responses to antigens were normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INFECTION RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoid therapy is associated with a dose-dependent increase in the risk of infection, especially with common bacterial, viral, and fungal pathogens. In addition, the intensity of therapy influences infection risk. Specifically, during high-dose glucocorticoid therapy, there is an immediate risk of infection due to dose-dependent inhibitory effects on phagocytic cell function. This risk should abate once high-dose therapy is complete. With long-term low-dose use, effects on phagocytic cell function are minimal, but there may be some inhibition of adaptive immune responses with increasing duration of therapy. As such, glucocorticoid-sparing therapy is advisable when possible.",
"   </p>",
"   <p>",
"    In contrast to systemic therapy, inhaled and topical glucocorticoids are usually not implicated in increased risk of systemic infections. The side effects of inhaled and topical glucocorticoids are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to glucocorticoid dose and intensity, various patient-specific factors influence infection risk, including the underlying disorder, the presence of concomitant immunosuppressive therapies, and whether the patient is hospitalized. Older patients and those with lower functional status are also at higher risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, patients taking glucocorticoids may not manifest signs and symptoms of infection as clearly, due to the inhibition of cytokine release and associated reduction in inflammatory and febrile responses. This can impair early recognition of infection.",
"   </p>",
"   <p>",
"    Chronic glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in most studies) can lead to an increased risk of serious infections in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of controlled trials in which glucocorticoids or placebo were given, reported that infection occurred significantly more often with steroid therapy (12.7 versus 8.0 percent with placebo, relative risk 1.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/69\">",
"       69",
"      </a>",
"      ]. The infection rates were significantly increased only in patients given an average dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      of more than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or a cumulative dose of greater than 700 mg. A dose-dependence was noted in both the glucocorticoid- and placebo-treated groups, suggesting that the activity of the underlying disease is also a risk factor for infection.",
"     </li>",
"     <li>",
"      Similar findings were noted in a study of 223 patients with lupus who were not receiving other immunosuppressive agents [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/70\">",
"       70",
"      </a>",
"      ]. The risk of infection rose from 1.5-fold at an average",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose below 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to over eightfold in patients receiving doses above 40",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      However, patients receiving higher doses also had more severe underlying disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Types of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common viral (mainly herpes viruses), bacterial (Staphylococcus aureus and others), and fungal (mainly Candida species) pathogens are encountered with greater frequency in a dose-dependent manner during therapy with glucocorticoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes zoster may occur more commonly among patients taking low dose glucocorticoids, although the independent role of glucocorticoids on this infection remains uncertain. A retrospective cohort analysis of over 200 patients with RA found that eight patients treated with glucocorticoids developed zoster compared to only one control [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/72\">",
"       72",
"      </a>",
"      ]. However, people receiving glucocorticoid may have had closer surveillance, potentially leading to more cases of herpes zoster detected.",
"     </li>",
"     <li>",
"      Tuberculosis is a concern in patients receiving moderate to high doses of glucocorticoids for prolonged periods of time. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology of tuberculosis\", section on 'Immune compromise'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Increased risk of reactivation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reactivation of latent Strongyloides stercoralis infection can occur in patients receiving glucocorticoids, leading to a hyperinfection syndrome that can be fatal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link&amp;anchor=H9#H9\">",
"       \"Strongyloidiasis\", section on 'Hyperinfection syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other helminthic or protozoan infections are unusual, except in areas of the world where they are endemic (eg, P. falciparum).",
"     </li>",
"     <li>",
"      Opportunistic infections with organisms of low pathogenicity usually occur only in patients with very significant immunosuppression, such as those receiving prolonged glucocorticoids in addition to other immunosuppressant drugs or underlying immunosuppressive conditions (eg, hematologic malignancy). Pneumocystis carinii (P. jirovecii) pneumonitis is associated with the use of glucocorticoids, both with chronic use of moderate doses and short-term use of high doses. Situations in which prophylaxis for P. jirovecii should be considered are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When used in combination with other immunosuppressive drugs, as in recipients of solid organ transplants, newly acquired infections and reactivation of latent infection with various organisms may occur. These infectious complications are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Measures to reduce risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection risk may be significantly lessened by the use of short-acting preparations (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) given every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10\">",
"     10",
"    </a>",
"    ]. In one retrospective report of 70 patients with various inflammatory conditions treated with alternate day prednisone at mean doses of 45 to 60 mg daily, none developed serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28249/abstract/10\">",
"     10",
"    </a>",
"    ]. Strategies to reduce the side effects of glucocorticoids are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H15#H15\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'Dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11515518\">",
"    <span class=\"h1\">",
"     HETEROGENEITY IN GLUCOCORTICOID SENSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals differ in their susceptibility to the therapeutic and adverse effects of glucocorticoids. The proposed mechanisms responsible for this heterogeneity are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link&amp;anchor=H4#H4\">",
"     \"Glucocorticoid-resistant asthma\", section on 'Mechanisms of glucocorticoid resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have inhibitory effects on a broad range of T cells and B cell responses, as well as potent suppressive effects on the effector functions of phagocytes. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids diffuse across the cell membrane and bind to the intracellular glucocorticoid receptor to form a complex that translocates into the nucleus. This complex interacts with DNA, resulting in altered transcription of various glucocorticoid-responsive genes. Post-translational events are also affected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of intracellular effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid administration results in a neutrophilic leukocytosis, accompanied by dramatic reductions in circulating eosinophils, monocytes, and lymphocytes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effects on leukocyte trafficking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effects on the innate immune system include dose-dependent impaired phagocyte function and attenuated production of proinflammatory mediators. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effects on innate immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids impair a variety of T cell functions and induce T cell apoptosis. B cells are less affected and antibody production is largely preserved, although a mild decrement in IgG and IgA levels may develop in some patients with chronic use. IgE levels may increase. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effects on acquired immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccine responses are preserved in most patients on chronic low-to-moderate doses of glucocorticoids for renal, pulmonary, or rheumatologic diseases, although the titers may be reduced in some individuals. In contrast, vaccine response may not be adequate in patients who are seriously ill, have malignancies, or are immediately post-transplantation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Impact on vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doses of less than 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in children or less than 40 mg per day in adults can be considered low to moderate. In patients with stable chronic diseases, measures of T cell function (such as DTH testing) may be impaired, but immunoglobulin levels are usually normal or only slightly low. High-dose, short-term pulse therapy results in dramatic changes in levels of circulating leukocytes, but relatively intact immunologic functions immediately after administration. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Impact of dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoid therapy is associated with a dose-dependent increase in the risk of infection. Patients are most often affected by common viral, bacterial, and fungal pathogens. Opportunistic infections are less common, and are mainly a concern in patients taking other immunosuppressive agents or with diseases causing immunocompromise. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Infection risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/1\">",
"      Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/2\">",
"      Zhang G, Zhang L, Duff GW. A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-1beta gene. DNA Cell Biol 1997; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/3\">",
"      Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/4\">",
"      Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996; 60:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/5\">",
"      Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/6\">",
"      G&ouml;ttlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med (Berl) 1998; 76:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/7\">",
"      Karin M, Liu Zg, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/8\">",
"      Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/9\">",
"      Tobler A, Meier R, Seitz M, et al. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 1992; 79:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/10\">",
"      Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/11\">",
"      Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/12\">",
"      Fauci AS, Murakami T, Brandon DD, et al. Mechanisms of corticosteroid action on lymphocyte subpopulations. VI. Lack of correlation between glucocorticosteroid receptors and the differential effects of glucocorticosteroids on T-cell subpopulations. Cell Immunol 1980; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/13\">",
"      Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154:4719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/14\">",
"      Andersen V, bro-Rasmussen F, Hougaard K. Autoradiographic studies of eosinophil kinetics: Effects of cortisol. Cell Tissue Kinet 1969; 2:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/15\">",
"      Nagase H, Miyamasu M, Yamaguchi M, et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol 2000; 106:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/16\">",
"      Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156:4422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/17\">",
"      Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004; 50:3783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/18\">",
"      Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 1973; 137:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/19\">",
"      Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther 1989; 250:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/20\">",
"      Jones CJ, Morris KJ, Jayson MI. Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events. Ann Rheum Dis 1983; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/21\">",
"      Herzer P, Lemmel EM. Inhibition of granulocyte function by prednisolone and non-steroid anti-inflammatory drugs. Quantitative evaluation with NBT test and its correlation with phagocytosis. Immunobiology 1980; 157:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/22\">",
"      Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/23\">",
"      Kita H, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Effect of steroids on immunoglobulin-induced eosinophil degranulation. J Allergy Clin Immunol 1991; 87:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/24\">",
"      Rinehart JJ, Sagone AL, Balcerzak SP, et al. Effects of corticosteroid therapy on human monocyte function. N Engl J Med 1975; 292:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/25\">",
"      Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human monocyte function. J Clin Invest 1974; 54:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/26\">",
"      Atkinson JP, Frank MM. Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. Blood 1974; 44:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/27\">",
"      Gerrard TL, Cupps TR, Jurgensen CH, Fauci AS. Hydrocortisone-mediated inhibition of monocyte antigen presentation: dissociation of inhibitory effect and expression of DR antigens. Cell Immunol 1984; 85:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/28\">",
"      Andrade MV, Hiragun T, Beaven MA. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J Immunol 2004; 172:7254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/29\">",
"      Nakamura R, Okunuki H, Ishida S, et al. Gene expression profiling of dexamethasone-treated RBL-2H3 cells: induction of anti-inflammatory molecules. Immunol Lett 2005; 98:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/30\">",
"      Park SK, Beaven MA. Mechanism of upregulation of the inhibitory regulator, src-like adaptor protein (SLAP), by glucocorticoids in mast cells. Mol Immunol 2009; 46:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/31\">",
"      Borson DB, Gruenert DC. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol 1991; 260:L83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/32\">",
"      Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/33\">",
"      Blackwell GJ, Carnuccio R, Di Rosa M, et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980; 287:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/34\">",
"      Hirata F, Schiffmann E, Venkatasubramanian K, et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A 1980; 77:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/35\">",
"      Kim SW, Rhee HJ, Ko J, et al. Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site. J Biol Chem 2001; 276:15712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/36\">",
"      Lew W, Oppenheim JJ, Matsushima K. Analysis of the suppression of IL-1 alpha and IL-1 beta production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. J Immunol 1988; 140:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/37\">",
"      Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000; 165:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/38\">",
"      Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 2003; 12:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/39\">",
"      Woltman AM, Massacrier C, de Fijter JW, et al. Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development. J Immunol 2002; 168:6181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/40\">",
"      Horst HJ, Flad HD. Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol 1987; 68:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/41\">",
"      Paliogianni F, Ahuja SS, Balow JP, et al. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. J Immunol 1993; 151:4081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/42\">",
"      Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol 2000; 18:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/43\">",
"      Hanson JA, Sohaib SA, Newell-Price J, et al. Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/44\">",
"      Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/45\">",
"      Lanza L, Scudeletti M, Puppo F, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 1996; 103:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/46\">",
"      Webster JC, Huber RM, Hanson RL, et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002; 143:3866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/47\">",
"      McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181:4089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/48\">",
"      Franchimont D, Louis E, Dewe W, et al. Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regul Pept 1998; 73:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/49\">",
"      Visser J, van Boxel-Dezaire A, Methorst D, et al. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998; 91:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/50\">",
"      Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/51\">",
"      Slade JD, Hepburn B. Prednisone-induced alterations of circulating human lymphocyte subsets. J Lab Clin Med 1983; 101:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/52\">",
"      Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/53\">",
"      Cupps TR, Gerrard TL, Falkoff RJ, et al. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 1985; 75:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/54\">",
"      Lack G, Ochs HD, Gelfand EW. Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. J Pediatr 1996; 129:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/55\">",
"      Posey WC, Nelson HS, Branch B, Pearlman DS. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978; 62:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/56\">",
"      Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol 2006; 97:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/57\">",
"      Jabara HH, Ahern DJ, Vercelli D, Geha RS. Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 1991; 147:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/58\">",
"      Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/59\">",
"      Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982; 69:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/60\">",
"      Lahood N, Emerson SS, Kumar P, Sorensen RU. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993; 70:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/61\">",
"      Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979; 242:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/62\">",
"      Kubiet MA, Gonzalez-Rothi RJ, Cottey R, Bender BS. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996; 110:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/63\">",
"      Hammerschmidt DE, White JG, Craddock PR, Jacob HS. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest 1979; 63:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/64\">",
"      Youssef P, Roberts-Thomson P, Ahern M, Smith M. Pulse methylprednisolone in rheumatoid arthritis: effects on peripheral blood and synovial fluid neutrophil surface phenotype. J Rheumatol 1995; 22:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/65\">",
"      Haynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest 1978; 61:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/66\">",
"      Fan PT, Yu DT, Targoff C, Bluestone R. Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by \"pulse\" methylprednisolone. Transplantation 1978; 26:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/67\">",
"      Fan PT, Yu DT, Clements PJ, et al. Effect of corticosteroids on the human immune response: comparison of one and three daily 1 gm intravenous pulses of methylprednisolone. J Lab Clin Med 1978; 91:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/68\">",
"      Sakuma Y, Katoh T, Owada K, et al. Initial functional status predicts infections during steroid therapy for renal diseases. Clin Nephrol 2005; 63:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/69\">",
"      Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/70\">",
"      Ginzler E, Diamond H, Kaplan D, et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/71\">",
"      Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28249/abstract/72\">",
"      Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3986 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28249=[""].join("\n");
var outline_f27_37_28249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF INTRACELLULAR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effects on gene transcription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effects on post-translational events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFECTS ON LEUKOCYTE TRAFFICKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTS ON INNATE IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phagocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neutrophils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Eosinophils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Macrophages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11515504\">",
"      Mast cells and basophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effects on proinflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFECTS ON ACQUIRED IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dendritic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Effects on T cell selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - T cell lineage commitment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      B cells and antibody production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Impact on vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IMPACT OF DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Low to moderate doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Higher doses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INFECTION RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Types of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Measures to reduce risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11515518\">",
"      HETEROGENEITY IN GLUCOCORTICOID SENSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/9/9371\" title=\"table 1\">",
"      Cytokine genes with GRE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/19/16699\" title=\"table 2\">",
"      T cell cytokine profiles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 3\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31367?source=related_link\">",
"      Glucocorticoid effects on the nervous system and behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28250="Brugada syndrome";
var content_f27_37_28250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Brugada syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     John V Wylie, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Samuel Asirvatham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/37/28250/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/37/28250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of cases of sudden cardiac arrest (SCA) and sudden cardiac death (SCD), due to ventricular fibrillation (VF), are associated with structural heart disease, particularly coronary heart disease (CHD). SCA in the normal heart is an uncommon occurrence, accounting for 5 percent of cases in an autopsy study of 270 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some causes of SCA in patients with apparently normal hearts have been identified. These include Brugada syndrome (BS), long QT syndrome, preexcitation syndrome, and commotio cordis. BS and the related disorder, sudden unexpected nocturnal death syndrome (SUNDS), will be reviewed here. Other causes of SCA in normal hearts are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECG PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BS is associated with a peculiar pattern on the electrocardiogram (ECG) consisting of a pseudo-RBBB and persistent ST segment elevation in leads V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Isolated cases have been described involving the inferior leads; such patients appear to have a unique mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three different patterns of ST elevation have been described (",
"    <a class=\"graphic graphic_table graphicRef71258 \" href=\"UTD.htm?19/50/20267\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef53908 \" href=\"UTD.htm?36/24/37253\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the classic Brugada type 1 ECG, the elevated ST segment (&ge;2 mm) descends with an upward convexity to an inverted T wave. This is referred to as the \"coved type\" Brugada pattern.",
"     </li>",
"     <li>",
"      The type 2 and type 3 patterns have a \"saddle back\" ST-T wave configuration, in which the elevated ST segment descends toward the baseline, then rises again to an upright or biphasic T wave. The ST segment is elevated &ge;1 mm in type 2 and &lt;1 mm in type 3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moving the right precordial chest leads up to the second or third intercostal space or using bipolar chest leads [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/9\">",
"     9",
"    </a>",
"    ] may increase the sensitivity of detecting these abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. In a study of 98 men with a family member with a type I Brugada ECG, those with a type I Brugada ECG pattern only in high chest leads had a similar rate of cardiac events during &gt;1 year of follow-up as those with type 1 Brugada ECG with standard positioning of chest leads [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the incidence of false-positive results needs to be better defined in larger studies.",
"   </p>",
"   <p>",
"    The widened S wave in left lateral leads that is characteristic of RBBB is absent in most patients with BS. This observation suggests that there is a high takeoff of the ST segment in the right precordium, ie, a \"J\" wave rather than a true RBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QT interval prolongation may be seen in the right precordial leads [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/12\">",
"     12",
"    </a>",
"    ]. The degree of prolongation is usually modest but some patients have genetic abnormalities that cause both BS and long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Sodium channel gene'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transient ECG abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, the characteristic ECG changes are transient. This was illustrated in a series of 43 patients with BS, in whom serial ECGs were obtained over a median follow-up of 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/16\">",
"     16",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 15 patients with a spontaneous type 1 ECG at presentation, 14 had at least one non-diagnostic (type 2, 3 or normal) ECG during follow-up.",
"     </li>",
"     <li>",
"      Among 28 patients whose initial ECG was non-diagnostic, eight developed characteristic type 1 ECG abnormalities during follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, fluctuations in the ECG pattern appear to be common in BS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Provoking factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic ECG abnormalities may be exposed by a sodium channel blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , ajmaline, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , thereby identifying those at risk (",
"    <a class=\"graphic graphic_table graphicRef73611 \" href=\"UTD.htm?20/53/21340\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/3,8,17-19\">",
"     3,8,17-19",
"    </a>",
"    ]. In addition, flecainide can also induce QT prolongation that is primarily seen in the right precordial leads (V1 and V2) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Drug challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pacing, vagal maneuvers, and increased alpha-adrenergic tone also may provoke the typical ECG changes of BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Other factors that can unmask or modulate the Brugada ECG pattern are beta blockers, tricyclic or tetracyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , local anesthetics, fever, hypokalemia, hyperkalemia, hypercalcemia, and alcohol and cocaine toxicity (",
"    <a class=\"graphic graphic_table graphicRef73611 \" href=\"UTD.htm?20/53/21340\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. A",
"    <a class=\"external\" href=\"file://www.brugadadrugs.org/\">",
"     website",
"    </a>",
"    has been established that identifies drugs that have been associated with adverse events in BS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/23\">",
"     23",
"    </a>",
"    ]. The role of genetic predisposition with these factors is not clear, though a case report of bupivacaine-induced ECG changes was associated with an SCN5A mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,24\">",
"     8,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Autonomic tone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Cocaine abuse'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Psychotropic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical significance of drug-provoked ECG changes in the absence of symptoms, family history of BS, or family with Brugada ECG is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Brugada pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic ECG pattern is only one component of the diagnostic criteria for BS. Patients with typical ECG features but no other clinical criteria are said to have the Brugada pattern but not BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of the typical ECG changes of BS has been evaluated in a number of different populations. Studies in heterogeneous populations suggest that the majority of affected individuals are Asian [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following reports illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two reports from Japan, the prevalence was 0.7 and 1.0 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]; 0.12 to 0.16 percent of the Japanese population have type 1 (coved type) ST segment elevation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/25,27,28\">",
"       25,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Finnish cohort, the prevalence of type 2 and 3 ST segment elevation was 0.6 percent; no type 1 patients were found in a screen of over 3000 apparently healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two samples of urban populations in the United States, the prevalence was 0.4 and 0.012 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of the Brugada pattern is much greater in patients who present with apparent idiopathic VF (3 to 24 percent in one series of 37 patients, depending upon the diagnostic criteria used) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada pattern is much more common in men than in women, being as much as nine times higher in one analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/28\">",
"     28",
"    </a>",
"    ], and men had a higher rate of syncope and sudden death in a large prospective registry study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/33\">",
"     33",
"    </a>",
"    ]. Reasons for the prominent male predominance in an autosomal dominant disorder are unclear. Animal models suggest that the impact of testosterone on ion currents, particularly outward potassium currents, may contribute to the increased incidence of clinical manifestations of BS in males [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Age at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;BS is usually diagnosed in adulthood. In two of the larger series of BS patients discussed below, the average patient age was 41 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. BS is rarely diagnosed in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Brugada syndrome in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of BS in childhood were illustrated in a cohort of 30 children diagnosed at 13 referral centers in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/38\">",
"     38",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient age ranged from infancy to 16 years (mean 8 years).",
"     </li>",
"     <li>",
"      Boys (n=17) and girls (n=13) were similarly affected.",
"     </li>",
"     <li>",
"      Twelve patients were diagnosed due to symptoms including unexplained syncope (n=10), aborted sudden death (n=1), and a supraventricular tachycardia. The remaining patients were identified due to family screening (n=17) or a suspicious ECG (n=1).",
"     </li>",
"     <li>",
"      Five children were treated with ICDs, and four were treated with hydroquinidine. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Quinidine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      During a mean follow up of 37 months, one child died suddenly, and two received an appropriate ICD shock. All three of these patients initially presented with symptoms and had a spontaneous type I ECG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'ECG patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fever was a prominent trigger of events. Five of the 10 patients presenting with syncope had fevers at the time of their initial event and the patient who died during follow up was febrile at the time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in children with BS clinical manifestations and arrhythmic events are uncommon, but arrhythmias may be more likely during febrile episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Potential reasons for delayed presentation include the impact of hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and the progressive structural degradation of myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the data are limited, the optimal approach to the management of children with BS is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors may contribute to the clinical manifestations of BS including right ventricular abnormalities, mutations in the cardiac sodium channel gene SCN5A, autonomic tone, and the use of cocaine and psychotropic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BS demonstrates autosomal dominant inheritance with variable expression. Genetic analysis has led to the identification of causative mutations in the SCN5A gene, encoding subunits of a cardiac sodium channel. Reasons for the variable expression of BS are not completely understood, although compound heterozygosity had been described in one family [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second region on the same chromosome (chromosome 3), has been identified as potentially causative of BS, although a specific gene at this locus has not been characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sodium channel gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in SCN5A, the gene that encodes the alpha subunit of the cardiac sodium channel gene, have been found in 18 to 30 percent of families with BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,36,42,43\">",
"     8,36,42,43",
"    </a>",
"    ]. The gene locus is on chromosome 3p21-24.",
"   </p>",
"   <p>",
"    The SCN5A mutations seen in BS are \"loss of function\" mutations and result in a variety of abnormalities in sodium channel activity including failure of expression, alterations in the voltage and time dependence of activation, and accelerated or prolonged recovery from inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, mutations may explain the ability of sodium channel blockers to expose the ECG changes in some patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/3,8,17-19\">",
"     3,8,17-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The defective myocardial sodium channels reduce sodium inflow currents, thereby reducing the duration of normal action potentials. In addition, a prominent transient outward current, called I(to), in the right ventricular epicardium further shortens the action potential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between sodium channel abnormalities and ST segment elevation is not fully understood. The ventricular myocardium is composed of at least three electrophysiologically distinct cell types: epicardial, endocardial, and M cells. The ST segment elevation and T wave inversions seen in the right precordial leads in BS are thought to be due to an alteration in the action potential in the epicardial and possibly the M cells, but not the endocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/5,44-46\">",
"     5,44-46",
"    </a>",
"    ]. The resulting dispersion of repolarization across the ventricular wall, which is most pronounced in the right ventricle, results in a transmural voltage gradient that is manifested in the electrocardiogram as ST segment elevation.",
"   </p>",
"   <p>",
"    The means by which the SCN5A mutation may predispose to ventricular tachyarrhythmias is discussed below, but like the ST segment elevation, VT and VF may be caused by heterogeneity of the cardiac action potential, both across the three layers of myocardial cells and within the epicardium itself.",
"   </p>",
"   <p>",
"    Related disorders &mdash; Mutations in the SCN5A gene have also been associated with other electrophysiologic abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated AV conduction defect",
"     </li>",
"     <li>",
"      Congenital long QT syndrome type 3 (LQT3)",
"     </li>",
"     <li>",
"      Congenital sick sinus syndrome",
"     </li>",
"     <li>",
"      Familial dilated cardiomyopathy with conduction defects and susceptibility to atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences in clinical manifestations are probably due to differences in the electrophysiologic abnormalities induced by the specific mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. Certain SCN5A mutations have been associated with an \"overlap\" syndrome, with affected patients exhibiting sick sinus syndrome or complete heart block as well as BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology of atrioventricular block\", section on 'Familial disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 3'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link&amp;anchor=H6106301#H6106301\">",
"     \"Manifestations and causes of the sick sinus syndrome\", section on 'Childhood and familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the mutations in BS are found at sites other than those known to contribute to the long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/42,47\">",
"     42,47",
"    </a>",
"    ]. One exception is a 1795insD mutation (insertion of aspartic acid) in the C terminus, which can cause both the long QT and BS as a result of its interaction with a heterogeneous physiologic substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In another family, the mutation was associated with BS, long QT syndrome, and a conduction defect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for an overlap between BS and LQT3 comes from a report of 13 patients with LQT3 who received intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/49\">",
"     49",
"    </a>",
"    ]. Although shortening of repolarization and the QT interval occurred in 12 of these patients, six (46 percent) developed ST segment elevation in V1 through V3, compatible with BS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Additional loci",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since only a minority of affected families have an identified abnormality of SCN5A, it is possible that additional genetic abnormalities may produce the phenotypic characteristics of BS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac calcium channel gene &mdash; In a series of 82 probands with a clinical diagnosis of BS, seven individuals (8.5 percent) were found to have mutations in the alpha1 or beta2 subunit of the cardiac L-type calcium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/52\">",
"       52",
"      </a>",
"      ]. Three of these patients had a unique phenotype in that in association with the typical ECG findings of BS, they also had shortened QT intervals (&le;360 msec). The relationship of this disorder to the usual form of BS and to short QT syndrome remains to be defined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H9#H9\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Short QT syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A locus on chromosome 3p22-25 has been identified in a large family with an autosomal dominant syndrome similar to BS (RBBB and ventricular arrhythmias) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/53\">",
"       53",
"      </a>",
"      ]. The mutation is also associated with progressive conduction disease. Compared to patients with SCN5A mutations, affected members of this family had a good prognosis, with a very low incidence of SCD. Also in contrast to mutations in the sodium channel gene, characteristic ECG changes were not exposed by infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      A specific disease-causing gene at this locus has not yet been identified, which limits full characterization of this disorder and its relationship to the usual form of BS.",
"     </li>",
"     <li>",
"      Other sodium channel mutations - Other mutations that decrease the sodium channel current have been identified in isolated kindreds with BS. These include a mutation in SCN1B, an accessory subunit that interacts with the sodium channel, and is also associated with conduction system disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/54\">",
"       54",
"      </a>",
"      ], and a mutation in GPD1-L, a gene that affects trafficking of the sodium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;BS is not usually associated with structural heart disease. Standard cardiac testing, including echocardiography, stress testing, and cardiac magnetic resonance imaging often reveal no abnormalities. However, it is probably more accurate to categorize BS as a disorder that occurs in hearts that are apparently normal, since there is some evidence that subtle structural or microscopic abnormalities occur, including dilation of the right ventricular outflow tract and localized inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/40,56-59\">",
"     40,56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supporting a pathogenic role of fibrosis in BS, a mouse model of heterozygous SCN5A knockout revealed age-dependent fibrosis and marked slowing of conduction velocity in the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/56\">",
"     56",
"    </a>",
"    ]. Similarly, evaluation of an explanted heart from a transplant recipient with BS revealed microscopic fibrosis and conduction abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence of microscopic abnormalities in BS comes from a series of 18 patients who underwent endomyocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/40\">",
"     40",
"    </a>",
"    ]. Although noninvasive evaluation was normal in each patient, all had evidence of microscopic structural abnormalities, including signs of RV myocarditis in 14. The ECG changes resolved at follow-up in 8 of the 14 patients with signs of RV myocarditis, raising the possibility that the BS ECG seen in these patients at presentation may have been a manifestation of RV myocarditis rather than an intrinsic cardiac ion channel abnormality.",
"   </p>",
"   <p>",
"    Patients with spontaneous type 1 ECGs were found to have significant enlargement of the right ventricular outflow tract on cardiac MRI compared with patients with drug-induced type 1 ECGs and controls as well as mildly lower left and right ventricular ejection fractions. The differences were not large enough to aid in diagnosis but provide further evidence of subtle structural abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Arrhythmogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant clinical manifestations of BS are ventricular arrhythmias, although there is some evidence that there may also be an increased rate of atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ventricular arrhythmias and phase two reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias may result from the heterogeneity of myocardial refractory periods in the right ventricle. This heterogeneity arises from the presence of both normal and abnormal sodium channels in the same tissue, and from the differential impact of the sodium current in the three layers of the myocardium (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Sodium channel gene'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/44,45,61\">",
"     44,45,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the epicardium, the juxtaposition of myocytes with different refractory periods can produce the triggers that initiate sustained arrhythmias (eg, closely-coupled premature beats) via a unique type of reentry called phase two reentry. In cardiac myocytes with defective sodium channels, initial depolarization is blunted (phase zero), and the counterbalancing effect of I(to) (phase 1) may be more significant. This phenomenon is more dramatic in the epicardium where I(to) currents are greater. In combination, this results in less initial depolarization, and reduced activation of the calcium channels that maintain the depolarized state during phase two. Thus, phase two of the cardiac action potential can be dramatically shortened.",
"   </p>",
"   <p>",
"    The cells with impaired sodium channel function may fail to propagate the action potential, resulting in localized conduction block. However, due to the abbreviation of phase two, these same cells have a much shorter refractory period and recover excitability before the surrounding cells. The combination of localized conduction block and a shortened refractory period provides the substrate for localized reentry, which, in this case, is referred to as phase two reentry. The closely-coupled ventricular premature beats that result from phase two reentry may precipitate sustained ventricular arrhythmias. Optical mapping studies have supported this mechanism of initiation of polymorphic VT and VF in a canine model of BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/62\">",
"     62",
"    </a>",
"    ]. This mechanism is also seen in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    -induced arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/63\">",
"     63",
"    </a>",
"    ] and is similar to the mechanism of arrhythmogenesis during myocardial ischemia.",
"   </p>",
"   <p>",
"    Other factors also may be important. Subtle structural abnormalities (eg, interstitial fibrosis or inflammation) in combination with reduced sodium currents could produce localized delay of impulse conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/56\">",
"     56",
"    </a>",
"    ]. The possible significance of conduction delay is less well established than action potential heterogeneity, and the issue is complicated by the possibility of overlap with other arrhythmia syndromes, particularly arrhythmogenic right ventricular cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Relation to ARVC'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BS may also be at increased risk of atrial arrhythmias, most notably atrial fibrillation (AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. The incidence of AF is higher in BS patients than in control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/64\">",
"     64",
"    </a>",
"    ], and the presence of AF has been associated with increased disease severity and a higher risk of VF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between BS and AF is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 59 patients with BS and 31 matched controls, over three years of follow-up, AF occurred in 12 (20 percent) of the BS patients but none of the control subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/64\">",
"       64",
"      </a>",
"      ]. There was a significant correlation between a history of AF and inducibility of sustained ventricular arrhythmia on EP testing.",
"     </li>",
"     <li>",
"      In a series of 73 BS patients, AF occurred in 10 (14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/66\">",
"       66",
"      </a>",
"      ]. Patients with AF had a higher incidence of syncope (60 versus 22 percent of patients without AF), and VF (40 versus 14 percent).",
"     </li>",
"     <li>",
"      In a series of 57 patients with BS, patients with a history of VF had more frequent AF, prolonged atrial conduction times, and increased atrial size [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with a diffuse myocardial nature of the sodium channel abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Relation to ARVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada ECG pattern can be an early subclinical manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/45\">",
"     45",
"    </a>",
"    ]. ARVC is genetic disorder, usually autosomal dominant, that primarily involves the right ventricle, as the right ventricular myocardium is typically replaced by fat, with scattered residual myocardial cells and fibrous tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between ARVC and the Brugada ECG pattern is suggested by a report of 96 victims of SCD who were &le;35 years and had a baseline ECG available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/68\">",
"     68",
"    </a>",
"    ]. Right precordial ST segment elevation with or without RBBB was present in 13 (14 percent); at autopsy all but one had ARVC. However, this study was from southern Italy, where ARVC is an important cause of SCA. Furthermore, mutations in SCN5A have not been described in ARVC.",
"   </p>",
"   <p>",
"    Patients with ARVC often have abnormalities in the right ventricle that can be seen on echocardiography or cardiac magnetic resonance imaging. In contrast, the vast majority of patients with BS do not have apparent structural heart disease on routine imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Autonomic tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An imbalance between sympathetic and parasympathetic tone may be important in the pathogenesis of BS, as suggested by the nocturnal occurrence of the associated tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/69\">",
"     69",
"    </a>",
"    ] and the alteration of typical ECG changes by pharmacologic modulation of autonomic tone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for the role of autonomic dysfunction comes from a study of 17 patients with BS who underwent scanning with iodine-123-metaiodobenzylguanidine (MIBG), a radiolabeled guanethidine analog that is actively taken up by sympathetic nerve terminals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/21\">",
"     21",
"    </a>",
"    ]. A segmental reduction in MIBG uptake was seen in 8 of the 17 patients, but in none of 10 controls.",
"   </p>",
"   <p>",
"    Augmentation of ST elevation &ge;0.05mV in leads v1-v3 during recovery from exercise is seen in some BS patients and has been associated with worse arrhythmic outcomes. In a study of 93 patients with BS, 37 percent had augmentation of ST elevation in exercise recovery, and during follow-up 44 percent of these patients versus 17 percent of patients without ST augmentation had arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/70\">",
"     70",
"    </a>",
"    ]. The mechanism may be a response to parasympathetic reactivation during recovery from exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a retrospective review of 111 patients with BS suggest that fever is a trigger for ECG changes and cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/71\">",
"     71",
"    </a>",
"    ]. In 24 of these patients with ECGs recorded during both fever and normothermia, fever was associated with BS-type ECG changes. Fever was present in 4 of 22 patients with cardiac arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cocaine abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG findings of BS can be transiently induced by cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/72\">",
"     72",
"    </a>",
"    ]. Cocaine acts like a class I antiarrhythmic agent, producing local anesthetic effects via sodium channel blockade in the heart; this could explain the relation to the Brugada pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Psychotropic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that block cardiac sodium channels have been associated with a transient Brugada pattern on the ECG, including overdoses with neuroleptic drugs or cyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In one report, a Brugada pattern was seen in 15 of 98 cases (15.3 percent) of a cyclic antidepressant overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/74\">",
"     74",
"    </a>",
"    ]. One patient with the Brugada pattern and one without died of refractory ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;BS is not yet well defined and establishing the diagnosis is often difficult. Both ECG and clinical features are important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7,8,75\">",
"     7,8,75",
"    </a>",
"    ]. The appearance of typical ECG changes alone is considered to represent an idiopathic Brugada ECG pattern but not the BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Genetic testing may also be useful in establishing the diagnosis. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Role of genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a consensus report from the Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology, it was proposed that type 1 BS should be strongly considered in patients who meet the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appearance of type 1 ST segment elevation (coved type) (",
"      <a class=\"graphic graphic_waveform graphicRef53908 \" href=\"UTD.htm?36/24/37253\">",
"       waveform 2",
"      </a>",
"      ) in more than one right precordial lead (V1 - V3) in the presence or absence of a sodium channel blocker, plus at least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;a) Documented ventricular fibrillation",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;b) Self-terminating polymorphic ventricular tachycardia (VT)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;c) Family history of sudden cardiac death at &lt;45 years",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;d) Type 1 ST segment elevation in family members",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;e) Electrophysiologic inducibility of VT",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;f) Unexplained syncope suggestive of a tachyarrhythmia",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;g) Nocturnal agonal respiration",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Type 2 and type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consensus report proposed that the diagnosis of BS should be strongly considered in patients with a type 2 or type 3 Brugada ECG who meet both of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appearance of type 2 or type 3 ST segment elevation (saddle-back type) (",
"      <a class=\"graphic graphic_waveform graphicRef53908 \" href=\"UTD.htm?36/24/37253\">",
"       waveform 2",
"      </a>",
"      ) in more than one right precordial lead under baseline conditions, with conversion to type 1 following challenge with a sodium channel blocker (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Drug challenge'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      One of the features (a-g) described above",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug-induced conversion of type 3 to type 2 ST segment elevation is considered inconclusive for the diagnosis of BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all patients with a type 2 or type 3 Brugada ECG need to undergo drug challenge. In particular, we suggest that drug challenge is not necessary in patients who have documented VF, self-terminating polymorphic VT, unexplained syncope strongly suggestive of a tachyarrhythmia, or nocturnal agonal respiration (clinical features a, b, f, and g). Most such symptomatic patients will receive an implantable cardioverter-defibrillator regardless of the results of drug testing.",
"   </p>",
"   <p>",
"    Thus, the main indication for drug challenge is in patients with clinical features (c) and (d), which reflect findings in the family. If the drug challenge is positive, EP testing should be considered. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Role of EP testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The utility of lead v3 and the necessity of having more than one lead positive in the diagnosis of BS was called into question by at study of 186 patients with spontaneous or drug-induced type 1 Brugada ECGs. Among 376 ECGs, lead v3 provided no additional diagnostic information in any patient, and patients with ECGs with only one lead with a diagnostic pattern had similar outcomes to patients with 2 or 3 diagnostic leads. The authors of this report, including all three Brugada brothers, have called for revision of the diagnostic criteria to exclude lead v3 and to include patients with one diagnostic lead (v1 or v2) in the diagnosis of BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Drug challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with the Brugada type 2 or type 3 ECG pattern, the Brugada type 1 ECG pattern can occasionally be unmasked by sodium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , ajmaline, pilsicainide) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,17-19\">",
"     8,17-19",
"    </a>",
"    ]. The reported sensitivity of pharmacologic challenge with these drugs has been variable, ranging from 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/18\">",
"     18",
"    </a>",
"    ] to as low as 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended doses by the second consensus conference on BS were [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      &ndash; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over 10 minutes intravenously or 400 mg PO",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      &ndash; 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over 10 minutes intravenously",
"     </li>",
"     <li>",
"      Ajmaline &ndash; 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over five minutes intravenously",
"     </li>",
"     <li>",
"      Pilsicainide &ndash; 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over 10 minutes intravenously",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The test should be performed under continuous ECG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. Indications for termination are development of a diagnostic type 1 Brugada ECG, a &ge;2 mm increase in ST segment elevation in patients with a type 2 Brugada ECG, the development of ventricular premature beats or other arrhythmias, or widening of the QRS &ge;30 percent above baseline.",
"   </p>",
"   <p>",
"    A variety of other drugs have been associated with a Brugada-like ECG; it is not clear if a genetic predisposition is involved with these drugs (",
"    <a class=\"graphic graphic_table graphicRef73611 \" href=\"UTD.htm?20/53/21340\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Provoking factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Exclusion of confounders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confounding factors that could account for either the ECG findings or syncope should be excluded. These include atypical right bundle branch block, left ventricular hypertrophy, early repolarization, acute myocardial infarction, acute pericarditis, and the ECG changes sometimes seen in the right precordial leads in well-trained athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Role of genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for BS (BS) is commercially available and can be useful in confirming the diagnosis. However, the genetic and clinical heterogeneity of BS can limit the test's utility as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic testing typically involves sequencing SCN5A, the gene encoding the alpha subunit of the cardiac sodium channel. However, only 15 to 30 percent of patients diagnosed with BS have mutations in SCN5A [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/77\">",
"       77",
"      </a>",
"      ]. This may reflect variations in the testing procedure since mutations in non-coding regions or alterations in splice sites are not always examined even though they can lead to abnormal sodium channel activity. In addition, there is evidence that mutations in other genes can give rise to this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Additional loci'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all patients with documented Brugada SCN5A mutations have BS. In one study, the average penetrance among 24 patients in four genotyped families was only 16 percent (one Brugada patient in each family) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of these issues, we advise that genetic testing for BS be performed in conjunction with specialists who have expertise in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All clinical manifestations of BS are related to life-threatening ventricular arrhythmias. Sudden cardiac arrest may be the first and only clinical event in BS, occurring in as many as one-third of patients. Arrhythmic events generally occur between ages 22 and 65 and are more common at night than in the day and during sleep than while awake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/3,69\">",
"     3,69",
"    </a>",
"    ]. SCA in Brugada patients is usually not related to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/68\">",
"     68",
"    </a>",
"    ]. Stored electrograms from implantable cardioverter-defibrillators (ICDs) have found that frequent spontaneous premature ventricular beats, which are identical in morphology to those that initiate VF, are often seen before the onset of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical risk factors for SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one analysis of 200 symptomatic and asymptomatic patients with BS, male sex and a family history of SCD were identified as risk factors for subsequent SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36\">",
"     36",
"    </a>",
"    ]. However, neither characteristic had a high specificity (26 percent for male sex and 65 percent for family history). The increased risk of male sex has been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk stratification usually begins with determining the presence or absence of associated symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Previous SCA or syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a previous history of SCA and those with a history of syncope (unexplained syncope suggestive of a tachyarrhythmia) are at increased risk for subsequent arrhythmic events compared to asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36,37,79,80\">",
"     36,37,79,80",
"    </a>",
"    ]. This was demonstrated in a review of 334 patients with the Brugada pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/79\">",
"     79",
"    </a>",
"    ]. Of these patients, 71 had presented after cardiac arrest (group A), 73 after a syncopal episode (group B), and 190 with ECG findings alone (group C). During a mean follow-up of 33 months, a new arrhythmic event (SCD or VF) occurred in 62 and 19 percent of group A and B patients, while only 8 percent of group C patients had a first arrhythmic event (",
"    <a class=\"graphic graphic_figure graphicRef80714 \" href=\"UTD.htm?43/41/44701\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A later study from the same group identified risk factors for SCD or VF among patients with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/37\">",
"     37",
"    </a>",
"    ]. Among 547 patients with an ECG diagnostic of type 1 BS and no prior cardiac arrest; 124 had at least one prior syncopal episode and 302 had a family history of SCD. The ECG was diagnostic spontaneously in 391 and only after administration of an antiarrhythmic drug in 156. EP testing was performed at the discretion of the clinician in 408 patients, 163 of whom had an inducible sustained ventricular arrhythmia. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On multivariate analysis, inducible sustained ventricular arrhythmia and a history of syncope were adverse predictors.",
"     </li>",
"     <li>",
"      At a mean follow-up of 24 months (range 1 to 160 months), 45 patients (8.2 percent) had SCD or VF. Patients with a previous history of syncope, inducible sustained ventricular arrhythmia, and a spontaneously abnormal ECG had a 27.2 percent probability of SCD or documented VF. The lowest probability (0.5 percent) was seen in patients lacking all of these features, while patients with one or two features had an intermediate risk (eg, 4.1 percent in patients with syncope and a spontaneously abnormal ECG who were noninducible) (",
"      <a class=\"graphic graphic_table graphicRef68496 \" href=\"UTD.htm?38/8/39051\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Syncope was also identified as a risk factor for subsequent arrhythmic events in the report of 200 patients cited above, with a sensitivity of 36 percent and a specificity of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36\">",
"     36",
"    </a>",
"    ]. The combination of syncope and spontaneous ST segment elevation in leads V1 to V3 identified a subgroup with a particularly high risk for subsequent SCD (hazard ratio 6.4).",
"   </p>",
"   <p>",
"    The largest series of BS patients was reported in the FINGER (France, Italy, Netherlands, Germany) Registry of 1029 patients (654 asymptomatic). In this population, history of SCD conferred an 11 times higher risk of arrhythmic event and history of syncope, a 3.4 times higher rate than asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cardiac arrest is much lower in asymptomatic patients, although subgroups of asymptomatic patients with increased risk can be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36,37,79,80\">",
"     36,37,79,80",
"    </a>",
"    ]. In a review of 547 patients with the type 1 Brugada ECG pattern, 422 of whom were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/37\">",
"     37",
"    </a>",
"    ], among the asymptomatic patients, two features were important determinants of arrhythmic risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a type 1 ECG abnormality spontaneously versus only after drug challenge (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Drug challenge'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Inducible ventricular tachyarrhythmia on EP testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a mean follow-up of 24 months, the following probabilities of arrhythmic events (SCD or documented VF) were reported (",
"    <a class=\"graphic graphic_table graphicRef68496 \" href=\"UTD.htm?38/8/39051\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a spontaneous type 1 ECG, event rates for those with positive and negative EP testing results were 14 and 1.8 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with the type 1 ECG abnormality only after drug challenge, event rates for those with positive and negative EP testing results were 4.5 and 0.5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the FINGER study, neither spontaneous type 1 ECG nor positive EP studies were predictive of arrhythmic outcomes (0.8 versus 0.4 percent for spontaneous ECG and 1.1 versus 0.4 percent for positive EPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/81\">",
"     81",
"    </a>",
"    ]. The overall event rate for asymptomatic patients was quite low (0.5 percent per year).",
"   </p>",
"   <p>",
"    A low risk of an arrhythmic event (5 percent by age 41) among asymptomatic patients who had ST elevation only with sodium channel blocker administration was also noted in the study of 200 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many truly asymptomatic patients, and particularly those with only a drug-induced type 1 BS ECG, close clinical follow-up may be sufficient for management given the low overall risk of arrhythmic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Role of EP testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of EP testing in patients with known or suspected BS depends largely upon the presence or absence of associated symptoms. Patients with a Brugada ECG pattern and certain high-risk clinical features (ie, a history of SCA, sustained ventricular tachyarrhythmias, or unexplained syncope) are known to have an increased risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/3,5,37,45,79,82\">",
"     3,5,37,45,79,82",
"    </a>",
"    ]. EP testing may provide additional information, but because such patients already have an indication for ICD therapy, test results are unlikely to impact management decisions. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Use of an ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of EP testing in asymptomatic patients remains an area of investigation and debate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The report of 547 patients described above demonstrated that abnormal EP test results (inducible VT or VF) predict an increased risk of life-threatening arrhythmias in asymptomatic patients with type 1 Brugada ECG abnormalities, particularly if one of the type 1 ECG is spontaneous rather than drug-induced. However, although patients with inducible VT or VF had a several-fold increase in arrhythmic events compared to those who were not inducible, the positive predictive value of EPS was low.",
"   </p>",
"   <p>",
"    As stated above, the largest study of BS patients (the FINGER registry) showed no independent predictive value of EPS in 369 asymptomatic patients who underwent EPS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the report of 200 symptomatic and asymptomatic patients cited above, among the 86 patients who underwent EP testing, a positive study had a sensitivity and specificity of 66 and 34, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36\">",
"     36",
"    </a>",
"    ]. Several factors may have contributed to the failure to detect a benefit from EP testing in this cohort: the number of patients who underwent EP testing was small; the population was not restricted to higher-risk patients with type 1 ECG abnormalities, and 49 percent of the patients who did have type 1 abnormalities had this finding only after drug challenge. Thus, the overall population was at lower risk than in the study of 547 patients in which all patients had type 1 ECG abnormalities, 71 percent of which occurred spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though recommended in the consensus statement on BS from 2005 (see below), reports from groups other than the Brugada brothers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/36,80,81\">",
"     36,80,81",
"    </a>",
"    ] have not confirmed the utility of EP testing in asymptomatic patients, and thus it remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9195608\">",
"    <span class=\"h2\">",
"     Other risk stratification models",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 43 patients with BS, the presence of late potentials on signal-averaged electrocardiogram (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    ) was significantly predictive of arrhythmic events. Patients with late potentials had a significantly higher arrhythmic event rate over 34 month follow-up compared with those without late potentials (72.4 versus 14.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Risk stratification summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for risk stratification for SCD in BS have been addressed in reports from several major societies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/European",
"      </span>",
"      Society of Cardiology",
"      <span class=\"nowrap\">",
"       (ACC/AHA/ESC)",
"      </span>",
"      guidelines for the management of ventricular arrhythmias and the prevention of SCD included the following comments and recommendations with regard to risk stratification [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/86\">",
"       86",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A history of syncope together with spontaneous ST segment elevation is included as a predictor of SCA. This risk factor is also included as an indication in the 2008 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society",
"      <span class=\"nowrap\">",
"       (ACC/AHA/HRS)",
"      </span>",
"      guidelines for device-based therapy. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'ICD therapy summary'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is agreement that patients with spontaneous ST-segment elevation have a worse prognosis than individuals with ST-segment elevation only after pharmacologic drug challenge. Clinical monitoring for the development of a spontaneous ST-segment elevation pattern is reasonable for the management of patients with ST-segment elevation induced only with provocative pharmacological challenge with or without symptoms.",
"     </li>",
"     <li>",
"      Family history is not endorsed as a risk factor. It should NOT be assumed that asymptomatic individuals with the characteristic ECG but without family history are at low risk, or that family members of an individual with SCD are at increased risk.",
"     </li>",
"     <li>",
"      The evidence is less well established for the use of EP study to risk-stratify patients with a spontaneous ST elevation with or without mutation in the SCN5A gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast, the second consensus conference on BS recommended an approach with greater reliance on EP testing; this approach was endorsed by the Heart Rhythm Society and the European Heart Rhythm Association (",
"      <a class=\"graphic graphic_algorithm graphicRef79568 graphicRef61362 \" href=\"UTD.htm?39/56/40833\">",
"       algorithm 1A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"       8",
"      </a>",
"      ]. EP testing was recommended in most asymptomatic patients and, in symptomatic patients, only for assessment of supraventricular arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pharmacologic therapy has been tried, the only therapy with proven efficacy in preventing sudden death is an implantable cardioverter-defibrillator (ICD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no proven pharmacologic treatments for preventing SCD in BS, although there are data suggesting benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    . In a report of 63 patients, an ICD was implanted in 35, pharmacologic therapy with beta blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was administered in 15, and 13 were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/87\">",
"     87",
"    </a>",
"    ]. During a 34 month follow-up, the incidence of arrhythmic events was similar in the three groups, but there were no deaths in the ICD group compared to mortality rates of 26 and 31 percent in the other two groups. All deaths were due to SCD. It was concluded that amiodarone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta-blockers do",
"    <strong>",
"     NOT",
"    </strong>",
"    protect patients with BS against SCD.",
"   </p>",
"   <p>",
"    Other antiarrhythmic drugs may be deleterious, particularly sodium channel blockers. As noted above, a sodium channel blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , ajmaline, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , can transiently induce the characteristic type 1 ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/3,8,17-19\">",
"     3,8,17-19",
"    </a>",
"    ]. In addition, sodium channel blockade can induce ventricular premature beats or ventricular tachycardia in patients with BS, particularly in symptomatic patients (six of 10 in one report), and T wave alternans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Drug challenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Quinidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above observations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and hydroquinidine (which are also sodium channel blockers) may be beneficial in patients with BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. This effect may be mediated by blockade of I(to), the transient outward current, that increases heterogeneity and may promote ventricular premature beats that act as the trigger for",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    was illustrated in a report in which EP testing was performed on 25 patients with BS (15 symptomatic and 10 asymptomatic) before and after treatment with quinidine bisulfate (mean dose 1483&plusmn;240",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/89\">",
"     89",
"    </a>",
"    ]. Ventricular fibrillation was inducible in all patients at baseline but in only three patients after three to seven days of quinidine therapy. Quinidine treatment was continued in 19 patients for a mean of 56 months. None of these patients had an arrhythmic event, although two had non-arrhythmia-related syncope. Side effects occurred in 36 percent and resolved after cessation of therapy. Quinidine can also attenuate ST segment elevation in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,44\">",
"     8,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar benefits have been noted with hydroquinidine, including a reduction in defibrillator discharges in four patients who had received an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these encouraging findings, there is not enough clinical experience with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    or related agents to recommend their use in preference to an ICD. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'ICD therapy summary'",
"    </a>",
"    below.) A multicenter trial of quinidine for asymptomatic patients is underway.",
"   </p>",
"   <p>",
"    However, antiarrhythmic drugs may have a role in patients with an ICD who continue to have frequent discharges.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is usually the drug of choice but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    or hydroquinidine may be an alternative in patients with BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/89,91,92\">",
"     89,91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines include the following recommendations regarding treatment of electrical storm in BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       Isoproterenol",
"      </a>",
"      is reasonable for treatment of electrical storm in BS.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      might be reasonable treatment of electrical storm in BS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Use of an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICD implantation can prevent SCD in patients with BS. However, selecting which patients should receive an ICD is challenging. The arrhythmic risk varies among BS patients, and ICD implantation carries some risk, including a relatively high rate of inappropriate shocks (6 to 9 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,87,93,94\">",
"     8,87,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the study of 63 patients cited above, there were no deaths in the 35 patients receiving an ICD compared to mortality rates of 26 and 31 percent among those treated pharmacologically or not treated, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/87\">",
"     87",
"    </a>",
"    ]. However, these patients represent a high-risk cohort, as all had a spontaneous type 1 ECG and 41 had a history of syncope or SCA. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Clinical risk factors for SCD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Benefit from an ICD was also documented in a review of 690 patients with BS in a multicenter registry; 258 received an ICD because of perceived high risk of SCD due, for example, to a history of symptoms or a family history of SCD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a Brugada ECG pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. A sustained ventricular arrhythmia was induced during EP testing in 77 percent. At a mean follow-up of 2.5 years, 69 patients (27 percent) had at least one appropriate ICD discharge.",
"   </p>",
"   <p>",
"    The role of the ICD in BS patients with a lower risk profile is less clear. The issue was addressed in a heterogeneous series of 220 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/93\">",
"     93",
"    </a>",
"    ]. Although all patients had a type 1 ECG, this abnormality was spontaneous in 62 percent and induced with sodium channel blockade in the remaining 38 percent. In addition, more than half of these patients (114) were asymptomatic at presentation, and the asymptomatic patients received ICDs on the basis of an abnormal EP study (99 patients), or a family history of SCD or nonsustained VT (15 patients). At a mean follow-up of 38 months, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate ICD shocks occurred in 8 percent of the overall population (2.6 percent per year). Total arrhythmic events over the three years were significantly more common in patients who had a history of SCA or syncope prior to ICD implantation (22 and 10 percent respectively, compared to 4 percent among those who were asymptomatic).",
"     </li>",
"     <li>",
"      45 patients (20 percent) experienced inappropriate shocks.",
"     </li>",
"     <li>",
"      The overall complication rate was 28 percent, which included the inappropriate shocks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in this heterogeneous cohort of BS patients, including a significant percentage of asymptomatic patients and patients with a provocable (as opposed to spontaneous) type 1 ECG, overall event rates were relatively low, but were significantly higher in patients with a history of syncope or SCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     ICD therapy summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the high incidence of SCD in selected patients with BS, major societies have reached the following conclusions regarding the indications for an ICD in patients with BS.",
"   </p>",
"   <p>",
"    The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities included the following statements regarding ICD therapy in BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/95\">",
"     95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement supporting ICD implantation in all BS patients with a prior cardiac arrest.",
"     </li>",
"     <li>",
"      The weight of",
"      <span class=\"nowrap\">",
"       evidence/opinion",
"      </span>",
"      supports ICD implantation in BS patients who have had a history of syncope.",
"     </li>",
"     <li>",
"      The weight of",
"      <span class=\"nowrap\">",
"       evidence/opinion",
"      </span>",
"      supports ICD implantation in BS patients with a history of VT that did not result in cardiac arrest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all of the above settings, the guidelines stated that ICD implantation should only be considered in patients who have a reasonable expectation of survival with a good functional capacity for more than one year.",
"   </p>",
"   <p>",
"    The implications of a positive family history of SCD are uncertain, and the 2008 guidelines did not address the prognostic significance of SCD in a family member with BS. As noted above, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines noted that family history is not reliable risk factor. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Risk stratification summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We generally agree with this approach, with one caveat regarding syncope: other causes of syncope, such as typical vasovagal events, bradycardia, or neurologic causes, must be excluded before proceeding to ICD implantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The second consensus conference on BS recommended a somewhat more aggressive approach; this approach was endorsed by the Heart Rhythm Society and the European Heart Rhythm Association [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, ICD use may be too expensive in some countries. In such patients, the consensus conference concluded that relatively high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    (1200 to 1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,89\">",
"     8,89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Quinidine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Investigative approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other, still investigative approaches have been evaluated in patients with BS who are at risk for SCD. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal radiofrequency ablation to prevent the ventricular premature beats that trigger",
"      <span class=\"nowrap\">",
"       VT/VF.",
"      </span>",
"      In an initial report that included three patients with BS who had episodes of VF or polymorphic VT, there was no recurrence of symptomatic ventricular arrhythmia at a mean follow-up of 17 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      , which is a phosphodiesterase inhibitor that impairs platelet aggregation and is approved for the treatment of intermittent claudication. Possible benefit in BS may be mediated by an increase in calcium current and reduction in I(to) due to an increase in heart rate. In a case report of a 67 year-old man with BS who had daily early morning episodes of VF, the episodes were completely prevented by cilostazol, recurred when the drug was discontinued, and were again prevented when the drug was restarted [",
"      <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUDDEN UNEXPECTED NOCTURNAL DEATH SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sudden unexpected nocturnal death syndrome (SUNDS, also called sudden unexpected death syndrome or SUDS) has been described in young, apparently healthy males from Southeast Asia; this syndrome has several names including lai tai (death during sleep) in Thailand, bangungut (to rise and moan in sleep followed by death) in the Philippines, and pokkuri (unexpected SCD at night) in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A low serum potassium may contribute to SCA in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"     8",
"    </a>",
"    ]. It has been suggested that a high carbohydrate meal may precipitate SCA, perhaps by increasing the secretion of insulin which drives extracellular potassium into cells.",
"   </p>",
"   <p>",
"    A relationship to BS was initially suggested by the observation that a majority of patients with SUNDS have the ECG manifestations of BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/99\">",
"     99",
"    </a>",
"    ]. This association was confirmed by the finding that these patients have mutations in the same cardiac sodium channel gene, SCN5A, that is abnormal in BS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, it has been concluded that SUNDS and BS are phenotypically, genetically, and functionally the same disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/8,100\">",
"     8,100",
"    </a>",
"    ]. Thus, the management of these patients should be the same as that for classic BS (",
"    <a class=\"graphic graphic_algorithm graphicRef79568 graphicRef61362 \" href=\"UTD.htm?39/56/40833\">",
"     algorithm 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The DEBUT trial evaluated the role of an ICD compared with beta blockers in 66 patients who were considered definite or probable SUNDS survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/37/28250/abstract/101\">",
"     101",
"    </a>",
"    ]. The trial was prematurely terminated after a mean follow-up of 24 months because of four deaths in the beta blocker arm, compared with none in the ICD arm; seven patients in the latter group had recurrent VF that was appropriately terminated by the ICD. Similar benefits had been noted in a pilot study of 20 patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9195408\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brugada Syndrome (BS) is a cause of sudden cardiac death (SCD) in patients with structurally normal hearts. Sudden unexpected nocturnal death syndrome (SUNDS) has been described in young males from Southeast Asia and appears to be the same disorder as BS.",
"     </li>",
"     <li>",
"      BS is diagnosed in patients with typical ECG findings (covered ST segment elevation in leads v1-v3) plus at least one or more additional criteria including a personal or family history of syncope, ventricular arrhythmias, or similar ECG findings in other family members. The stereotypical ST segment changes of BS may be provoked in susceptible patients by sodium channel blocking agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      and ajmaline.",
"     </li>",
"     <li>",
"      Patients with BS and prior syncope or documented ventricular arrhythmias are at high risk for SCD and an ICD is indicated for secondary prevention.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      has shown promise in small studies to reduce the risk of recurrent ventricular tachyarrhythmias and is the subject of ongoing research.",
"     </li>",
"     <li>",
"      Management of asymptomatic patients with typical ECG findings of BS is controversial. A current consensus statement recommends that an electrophysiology study be used to risk stratify these patients, but more recent data have not supported this practice, and it remains controversial.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/1\">",
"      Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/2\">",
"      Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/3\">",
"      Atarashi H, Ogawa S, Harumi K, et al. Characteristics of patients with right bundle branch block and ST-segment elevation in right precordial leads. Idiopathic Ventricular Fibrillation Investigators. Am J Cardiol 1996; 78:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/4\">",
"      Brugada J, Brugada P. What to do in patients with no structural heart disease and sudden arrhythmic death? Am J Cardiol 1996; 78:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/5\">",
"      Alings M, Wilde A. \"Brugada\" syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999; 99:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/6\">",
"      Potet F, Mabo P, Le Coq G, et al. Novel brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J Cardiovasc Electrophysiol 2003; 14:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/7\">",
"      Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002; 23:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/8\">",
"      Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/9\">",
"      Batchvarov VN, Govindan M, Macfarlane P, et al. Diagnostic utility of bipolar precordial leads during ajmaline testing for suspected Brugada syndrome. Heart Rhythm 2010; 7:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/10\">",
"      Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001; 22:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/11\">",
"      Miyamoto K, Yokokawa M, Tanaka K, et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 2007; 99:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/12\">",
"      Pitzalis MV, Anaclerio M, Iacoviello M, et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 2003; 42:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/13\">",
"      Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/14\">",
"      Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002; 105:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/15\">",
"      Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 2002; 110:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/16\">",
"      Veltmann C, Schimpf R, Echternach C, et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J 2006; 27:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/17\">",
"      Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998; 9:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/18\">",
"      Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/19\">",
"      Hong K, Brugada J, Oliva A, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004; 110:3023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/20\">",
"      Mizumaki K, Fujiki A, Tsuneda T, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/21\">",
"      Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/22\">",
"      Darbar D, Yang T, Churchwell K, et al. Unmasking of brugada syndrome by lithium. Circulation 2005; 112:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/23\">",
"      Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009; 6:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/24\">",
"      Vernooy K, Sicouri S, Dumaine R, et al. Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm 2006; 3:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/25\">",
"      Miyasaka Y, Tsuji H, Yamada K, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 2001; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/26\">",
"      Matsuo K, Akahoshi M, Nakashima E, et al. Clinical characteristics of subjects with the Brugada-type electrocardiogram:. J Cardiovasc Electrophysiol 2004; 15:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/27\">",
"      Atarashi H, Ogawa S, Harumi K, et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome. Idiopathic Ventricular Fibrillation Investigators. J Am Coll Cardiol 2001; 37:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/28\">",
"      Matsuo K, Akahoshi M, Nakashima E, et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of four decades. J Am Coll Cardiol 2001; 38:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/29\">",
"      Junttila MJ, Raatikainen MJ, Karjalainen J, et al. Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. Eur Heart J 2004; 25:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/30\">",
"      Monroe MH, Littmann L. Two-year case collection of the Brugada syndrome electrocardiogram pattern at a large teaching hospital. Clin Cardiol 2000; 23:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/31\">",
"      Patel SS, Anees S, Anees SS, Ferrick KJ. Prevalence of a Brugada pattern electrocardiogram in an urban population in the United States. Pacing Clin Electrophysiol 2009; 32:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/32\">",
"      Remme CA, Wever EF, Wilde AA, et al. Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricular fibrillation. Eur Heart J 2001; 22:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/33\">",
"      Benito B, Sarkozy A, Mont L, et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol 2008; 52:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/34\">",
"      Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/35\">",
"      Bai CX, Kurokawa J, Tamagawa M, et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005; 112:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/36\">",
"      Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/37\">",
"      Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/38\">",
"      Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007; 115:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/39\">",
"      Skinner JR, Chung SK, Nel CA, et al. Brugada syndrome masquerading as febrile seizures. Pediatrics 2007; 119:e1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/40\">",
"      Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 2005; 112:3680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/41\">",
"      Cordeiro JM, Barajas-Martinez H, Hong K, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006; 114:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/42\">",
"      Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/43\">",
"      Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000; 102:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/44\">",
"      Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/45\">",
"      Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999; 33:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/46\">",
"      Nagase S, Kusano KF, Morita H, et al. Longer repolarization in the epicardium at the right ventricular outflow tract causes type 1 electrocardiogram in patients with Brugada syndrome. J Am Coll Cardiol 2008; 51:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/47\">",
"      Desch&ecirc;nes I, Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res 2000; 46:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/48\">",
"      Clancy CE, Kass RS. Defective cardiac ion channels: from mutations to clinical syndromes. J Clin Invest 2002; 110:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/49\">",
"      Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000; 102:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/50\">",
"      Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005; 46:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/51\">",
"      Smits JP, Koopmann TT, Wilders R, et al. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J Mol Cell Cardiol 2005; 38:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/52\">",
"      Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/53\">",
"      Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 2002; 105:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/54\">",
"      Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel &beta;1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/55\">",
"      London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007; 116:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/56\">",
"      van Veen TA, Stein M, Royer A, et al. Impaired impulse propagation in Scn5a-knockout mice: combined contribution of excitability, connexin expression, and tissue architecture in relation to aging. Circulation 2005; 112:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/57\">",
"      Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005; 112:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/58\">",
"      Takagi M, Aihara N, Kuribayashi S, et al. Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent arrhythmogenic substrates in patients with the Brugada syndrome. Eur Heart J 2001; 22:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/59\">",
"      Papavassiliu T, Wolpert C, Fl&uuml;chter S, et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/60\">",
"      Papavassiliu T, Veltmann C, Doesch C, et al. Spontaneous type 1 electrocardiographic pattern is associated with cardiovascular magnetic resonance imaging changes in Brugada syndrome. Heart Rhythm 2010; 7:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/61\">",
"      Ha&iuml;ssaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/62\">",
"      Aiba T, Shimizu W, Hidaka I, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study. J Am Coll Cardiol 2006; 47:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/63\">",
"      Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 1993; 87:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/64\">",
"      Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004; 25:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/65\">",
"      Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/66\">",
"      Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008; 51:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/67\">",
"      Toh N, Morita H, Nagase S, et al. Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography. Heart Rhythm 2010; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/68\">",
"      Corrado D, Basso C, Buja G, et al. Right bundle branch block, right precordial st-segment elevation, and sudden death in young people. Circulation 2001; 103:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/69\">",
"      Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/70\">",
"      Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. J Am Coll Cardiol 2010; 56:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/71\">",
"      Amin AS, Meregalli PG, Bardai A, et al. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med 2008; 149:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/72\">",
"      Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000; 75:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/73\">",
"      Rouleau F, Asfar P, Boulet S, et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/74\">",
"      Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/75\">",
"      Gussak I, Bjerregaard P, Hammill SC. Clinical diagnosis and risk stratification in patients with Brugada syndrome. J Am Coll Cardiol 2001; 37:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/76\">",
"      Richter S, Sarkozy A, Paparella G, et al. Number of electrocardiogram leads displaying the diagnostic coved-type pattern in Brugada syndrome: a diagnostic consensus criterion to be revised. Eur Heart J 2010; 31:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/77\">",
"      Miura D, Nakamura K, Ohe T. Update on genetic analysis in Brugada syndrome. Heart Rhythm 2008; 5:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/78\">",
"      Kakishita M, Kurita T, Matsuo K, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000; 36:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/79\">",
"      Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/80\">",
"      Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005; 111:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/81\">",
"      Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation 2010; 121:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/82\">",
"      Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/83\">",
"      Brugada P, Brugada R, Brugada J. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005; 112:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/84\">",
"      Priori SG, Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005; 112:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/85\">",
"      Huang Z, Patel C, Li W, et al. Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm 2009; 6:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/86\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/87\">",
"      Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/88\">",
"      Morita H, Morita ST, Nagase S, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003; 42:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/89\">",
"      Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/90\">",
"      Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/91\">",
"      Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/92\">",
"      M&aacute;rquez MF, Salica G, Hermosillo AG, et al. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/93\">",
"      Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/94\">",
"      Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/95\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/96\">",
"      Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/97\">",
"      Kirschner RH, Eckner FA, Baron RC. The cardiac pathology of sudden, unexplained nocturnal death in Southeast Asian refugees. JAMA 1986; 256:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/98\">",
"      Gotoh K. A histopathological study on the conduction system of the so-called \"Pokkuri disease\" (sudden unexpected cardiac death of unknown origin in Japan). Jpn Circ J 1976; 40:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/99\">",
"      Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/100\">",
"      Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002; 11:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/37/28250/abstract/101\">",
"      Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107:2221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1020 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28250=[""].join("\n");
var outline_f27_37_28250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9195408\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECG PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transient ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Provoking factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Brugada pattern",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Age at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Brugada syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sodium channel gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Additional loci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Arrhythmogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ventricular arrhythmias and phase two reentry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Relation to ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Autonomic tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Psychotropic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Type 2 and type 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Drug challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Exclusion of confounders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Role of genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CLINICAL MANIFESTATIONS AND RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical risk factors for SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Previous SCA or syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Role of EP testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9195608\">",
"      Other risk stratification models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Risk stratification summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Quinidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Pharmacologic therapy summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Use of an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - ICD therapy summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Investigative approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUDDEN UNEXPECTED NOCTURNAL DEATH SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9195408\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1020|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/7/7295\" title=\"algorithm 1A\">",
"      Management Brugada syndrome-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/40/1679\" title=\"algorithm 1B\">",
"      Management Brugada syndrome-II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1020|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/41/44701\" title=\"figure 1\">",
"      Outcome Brugada Syndrome by presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1020|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/50/20267\" title=\"table 1\">",
"      ST elevation patterns Brugada",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/53/21340\" title=\"table 2\">",
"      Drugs that can induce Brugada-like ECG patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/8/39051\" title=\"table 3\">",
"      First SCD risk Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1020|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 1\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/24/37253\" title=\"waveform 2\">",
"      Brugada ST patterns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_37_28251="Congenital anomalies in IDM";
var content_f27_37_28251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common congenital anomalies in infants of diabetic mothers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        System",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        Anencephaly with or without herniation of neural elements, arrhinencephaly, microcephaly, holoprosencephaly, neural tube defects (meningomyelocele and other variants).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        Transposition of the great vessels with or without ventricular septal defect (VSD), VSD, coarctation of the aorta with or without VSD or patent ductus arteriosus, atrial septal defect, single ventricle, hypoplastic left ventricle, pulmonic stenosis, pulmonary valve atresia, double outlet right ventricle truncus arteriosus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        Duodenal atresia, imperforate anus, anorectal atresia, small left colon syndrome, situs inversus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary",
"       </td>",
"       <td>",
"        Ureteral duplication, renal agenesis, hydronephrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal",
"       </td>",
"       <td>",
"        Caudal regression syndrome (sacral agenesis), hemivertebrae.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Single umbilical artery.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Tyrala, EE. Obstet Gynecol Clin North Am 1996; 23:221; and Reece, EA, Homko, CJ. Semin Perinatol 1994; 18:459.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28251=[""].join("\n");
var outline_f27_37_28251=null;
var title_f27_37_28252="Normal respiratory rate and heart rate in children";
var content_f27_37_28252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric respiratory rate and heart rate by age*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Respiratory rate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Median (1st-99th percentile)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Median (1st-99th percentile)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-3 months",
"       </td>",
"       <td>",
"        43 (25-66)",
"       </td>",
"       <td>",
"        143 (107-181); term newborn at birth: 127 (90-164)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-6 months",
"       </td>",
"       <td>",
"        41 (24-64)",
"       </td>",
"       <td>",
"        140 (104-175)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-9 months",
"       </td>",
"       <td>",
"        39 (23-61)",
"       </td>",
"       <td>",
"        134 (98-168)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-12 months",
"       </td>",
"       <td>",
"        37 (22-58)",
"       </td>",
"       <td>",
"        128 (93-161)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-18 months",
"       </td>",
"       <td>",
"        35 (21-53)",
"       </td>",
"       <td>",
"        123 (88-156)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-24 months",
"       </td>",
"       <td>",
"        31 (19-46)",
"       </td>",
"       <td>",
"        116 (82-149)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-3 years",
"       </td>",
"       <td>",
"        28 (18-38)",
"       </td>",
"       <td>",
"        110 (76-142)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-4 years",
"       </td>",
"       <td>",
"        25 (17-33)",
"       </td>",
"       <td>",
"        104 (70-136)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-6 years",
"       </td>",
"       <td>",
"        23 (17-29)",
"       </td>",
"       <td>",
"        98 (65-131)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-8 years",
"       </td>",
"       <td>",
"        21 (16-27)",
"       </td>",
"       <td>",
"        91 (59-123)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-12 years",
"       </td>",
"       <td>",
"        19 (14-25)",
"       </td>",
"       <td>",
"        84 (52-115)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-15 years",
"       </td>",
"       <td>",
"        18 (12-23)",
"       </td>",
"       <td>",
"        78 (47-108)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-18 years",
"       </td>",
"       <td>",
"        16 (11-22)",
"       </td>",
"       <td>",
"        73 (43-104)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The respiratory and heart rates provided are based upon measurements in awake, healthy infants and children at rest. Many clinical findings besides the actual vital sign measurement must be taken into account when determining whether a specific vital sign is normal in an individual patient. Values for heart rate or respiratory rate that fall within normal limits for age may still represent abnormal findings that are caused by underlying disease in a particular infant or child.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011; 377:1011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28252=[""].join("\n");
var outline_f27_37_28252=null;
var title_f27_37_28253="Window period acute HBV";
var content_f27_37_28253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Window period of acute HBV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 177px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the serologic findings during the window period of acute hepatitis B virus infection. The disappearance of HBsAg (hepatitis B surface antigen) is followed by the appearance of anti-HBs. In some patients, however, anti-HBs may not be detectable until after a window period of several weeks to months. At this time, neither HBsAg nor anti-HBs can be detected, the serologic diagnosis may be made by the detection of IgM antibodies against hepatitis B core antigen (IgM anti-HBc).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28253=[""].join("\n");
var outline_f27_37_28253=null;
var title_f27_37_28254="Etiology of in-toeing";
var content_f27_37_28254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Primary diagnosis in 202 children referred for evaluation of in-toeing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 301px; background-image: url(data:image/gif;base64,R0lGODlhzwEtAfcAAP///wCZZmYzZpmZmf8AAAAz/wAAAAAzmWZmZgAmGY+PjwAmcri4uNbW1ojPuBAQEPDw8LiguES0j49pj4CAgEBAQHBwcAAJBgCPX7vJ/93x6+vr6yKnetbJ1sDAwABfP+Dg4GBgYIWFhSYmJgB8UpnWwrvk1tDQ0DMZMxGgcP+7u0wmTCAgIExMTKOjo3p6eiJO/2aF/zOthd3k/8LCwhkMGURp/6CgoP+IiIVchbCwsKOFo/X19XJycgA5JgByTJmt/1BQUABMMwAcE/8iIgADDwCFWWbCo38AAAATDDNc/78AADAwMP9mZv9ERIig///MzD8AAOvk6wAv7+749QAZTAAMJl8vXwkJCQYDBrvJ5JCQkHpOev+ZmfXx9QBWORFB/wBCLBwcHP/u7lW7mcKtwlIpUgAfnwApz3BBcAAvHyYTJhMTEz8fP2aFwgAGH+7x/3x8fA8AAP8zM62trQAs3wATXwBpRv/d3d8AADNcrVksWRMJEwAJL3fJrQAmvzkcOQAMP18AAO7x+MzW6wAZf8zr4B8AAAwGDO8AAODW4AAPT0RptDk5OZ8AAAAjr8zW/5l3mf+qqiJOp1ZWVpmt1v8REardzMzMzIigz19fX/9VVWlpaS8vL0JCQo8AAB8PH3eS/wAcj1V3/3eSyS8AAK2SrU8AAAAWb28AAKq7/0YjRq8AABFBoM8AACwWLN3k8QAjaVV3uwAGEwAfX8y7zP93dwAWQgATOQAshQAJHAApfAAcVgADCQAsLAAPLwAvj6q73QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADPAS0BAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnStRBYGFBFTQ3csXJw4CgAngYJg3ol2BhxUW7su4sUscRCAufpg4ccLJjjNrHgmZ4F8Cc6AA+By6SWA8AyFbAj0GT+A5Y4gAJmJ3DgFLokmLLuwEsJMxowM7ca3XLvDNyJMn/AwYCgHRTZw4h+4EAObRRMbEHizQtaTKvJtM/wcQ3boKyNrn4HAuaXT1Jk3Ix1dOvz72gV0iA1BBJD/iyNfhUB0ATojXG2BdgCcQfP7tB6AK8AmEQxMNCrifJa6hZt+Gm3Um0HibSPccACFa155n1eFhSRdNzAHAGAQkSABwicEHYnV5obfdjQI5MccmHAaZmYcSAhZacKBBB5iGSBIApAqrydbFGLbRdpd8SB7Jm2/AmUYAEQNKcp2QZJYp4YAlbTKfhWa2aSabIh04B2oqnujmnXjmqeeefPbp55+ABtpTF4HlBcVq8zlhp6CM3tmgQLbYAiMeKqDZ6KVmEgrYYE1ISgAetGEqqpuEQnEoARRuomkXo7YaJGZEgP8qiST6uWqrZqoC0IUlx40WHxGzunjrsI19tuJAsaG2KrHMNuvss9BGK+201FZr7bVfeYDttmsZwO23Z3kL7rhiiUvuuV2Zi+66WKlLkRYHsCtvT+4iBAsjBxwwSSUAwCuQv/MGjFO9B+mhxyAAZHIAIQADLPDDMxFcECEHICyQLKRMku8k8OpxQCuEJLxxyAdUMokbEKcsksQEVRLvQG640fABWgDAiBuEgAwAKbIAcEDPKgf9EcsDUWwxABjPLFDMLuerr881Cy31RkQPNMnBIjNccb8vx5xzyAPRPPXYGFUt0L0b8zuIxxx3jbLC+aIsNtl0T2R23XivdHfefJv/tHffgIf0d+CEczR44YhfdPhApDAC88cha6FH4sxmAANDGRRA0uI+H+A4AINUTArKjERN+VhAKFFAATA8kVMMri+U+eYUZfI5LKK7Ucnnp4uVeexP2IATHGDMgLnmI3GeMO9uQM6xx1j37tUoMRhk+epAAGCD6gVUH4PwAMCQvUAzFAAJAJnDAcPqMJxfABAwxNA6AOXPkPn6YIyyeigCASE8EGAQyBOUUL7VKQEOs5sB9wqQASAgLwbVY93qYmBAhyjPdgaphO4mpwd+Sa8r88sc6wAAhuypIoA2EF7mZvA9gYiPIDaoHvUIAgP+FWAULnRd/TKXgfD9D3lKUAUA/4iXvRIOpHyqmN0olCAQBjpQIBAEQAFcJ78ZlK+HDLkg7wQyiFbAohIcDMYHuzLD/sGggKsrwAxsoEM1tjB84xNIBoqnRjhQcIJSxOL8dog8NqJPc5AIoABtoIrLQcIGaQTC7F6YxycCIIoMBEDwmojFhXDOaQeAxUAyQQrQQe9oY8yKKgrAP0lezogD8WP9nnC5OcbRhTD4IRwAoIQIYjGGklTj7LTnutmFopT0Yx0VmQiH9ykRh5Bg4AoVaEtJgi+SWQxlclLHvl6ub4SqVOMM1qcEVA7EgT1UIPua+ccCqM5+feyl5sBwvoHEAAyznKMEFQnI9a2vh4gEQy3z6P9MSjZEedJsliqYSJFkGs9wigsouEQ4RY8AVCAPVSjEIhpRiQqMohZNHEYz6qZtgo+C7EQfQXOyUY6WCQ6qE14x4RCK6tmgkgNLqEnLVMsWlo+lMfAfT0o6Uw6l8JEfLQA7YZAB1R2wIBUwgFKXytSmOlWpVJNpTzeExtWBr385ZaISXlm2qELEAx7QAQXGaoAQVOCsZw3CWMe6BbCCYKqOeaNAiDeD1NFSiF7NCMtA4AEKWKACTFCqHGZhhSoYtgq8WAAtfPGDH3xACJAVgg8SkIALGOABFQgBBXRwArjKRa6S5B9KzTnLvHZ1ICAQawUeYIAoCAIJS1gCYJBQBUz/Om0BCQiAbnfLW90a4QdfEEICkmAAJoRgC5317J8qOhADgOAGIWBBa5HAijwUqlCssIJt84Xb3nr3uxj4gRDUkATMUiC5ys0Tc3VgAQPI4RSfcMV15wuYJWh3u939rn6/a4QP+KC8QbgBBNLrpofqIAQPKEUqDEDfBtf3vrbN734n7F0jfEENxd3CWwksJM4dOMGfsC4BZOtg+ibCANs9gIQpzGLeYuADGK6AgDm8ocGBgAIsOAQSRFziHhMAxfjNbYuH3NsXJ6Cs2qKxcvbmgSAYQBAk9rGUDQCMIBP5yr01ghCSwIIZK1kzZrsBC95gAPlK+cwEiMICrIzlNu/2/wMJeAAFNvxlxrAMAhR4QCDOUAA7pALNZ1Yzm91MaBL4oKx0rjNdCIZnPf8hjWiQQyIA7eMoxGLQhCa0EQ4dgkQrGi712oKj05jGQDiC0j2mLaYzrWlOe/rTbFGXmAPxaFKn8QylQHWJVR1hIbP615uW84Bh3RZxnaACb+CzrW1dhCjr+rpIuMWqf51pEsT5BsSONQQsUIRCTGHZyy6EIJ5NX/tOm9qZvkMSKoDebJvlsouoA7jBXQcD8JjcDz43ujMtBANQYNjuFgsEnPyIeRvcDkjAd6FcMQt971vTCWBBkgP+FR08YBGFMLjB/yAHhRcKyJhc8cPR/YULWADgFP/PCgRCUISCa1zjfTi1x3/s8JFDnAntTnlVTsCCRXz75Ro/QxRmTgA55KLXNk96v7egc6tswQCiADrQp1AEMytc0CH3ddIfToIkBAHlTW/KytmABZdLXeOoGLfHsX5brW993xhQAwtyHvakgIAJI1AAJ4qAhrNrvN6TVvgpaIH0tyf9Cw/Adt2V4oEHeGIAkG9BH37ud3Av4hMe53XbDb/1H1yAAotHyg0MoAnIm34Edqj8vP9wiMzXNuuc3zoJhhACsIf+JxTAQhxMb3oFYEHZqrf1G1ih8E/8ovCxtzkGhsAE299+JyFgw+55b/oe8D34thbF0PFtbtgnf+s+aP7/830SAjEogPrUp8QbKI99qt8b1d3f/PfB/wC6j58mEKiA+dGP/k4sAvukZgdq92x50AvIN382JwT1d383AQFMsH/8R30KwAZRB4AFUAeShm8gx11uh4AP9wELyIAz4YAQGIHUFwcG0HcWaGoaeIAeOHIgaH8iuBL6d34myH+aUATsp3pn0Hrkdgi74H0vmHQxOIMvUX42eIP81wiBYIEF8AbORmlsp2IdOIT7hngyaIQkgYRKaIIKIAYZB4CFcArkNoUiZ4UPF37Op4UiYQFskIRdyH9xgAW1FnxTYG/PJgivx4Fo+HZqyIYmcQO6F4dKmIPyhn1+9myaR4V9+HYJ/xAEgEgSHmAA00eIN+gJfQCAkaaIe8iIjZh0yxcCkRgSJ/AApWeJXSgGqACAMadr2SWEnzhyRnABijeKHOGAj4eKXSgCZYd9uKZr8eeJsWhzJGAAWWiLExEEI6CLhLh3Kqh6zQZ/ECaMwwiDD7CGyBgRW/CGzEiIkreDUiduqHZisFiNaVgB2XgRJ0CJ3WiJqBd89fZ+U1aO5ohuywd66TgREMAClNCOluh7wOd3CIdqG3iG9UhtJHABE5ePDxEEneCPqGh9z3h2rIdqpbBmfHiQNgeC2MiQBqEDWACHENmF6geOL/cGModmbGeQGvlragCJHskQEPAAnDCSuuh/PP+4fSp5aRnZkg+HARegAyrTAAgwEA3wAgehAAyAEQygABvRlAPBAC4QEQ5pk7o4gRV4dlRndVKmeSzpk+l2jbaiAAiwlBuAAA2gEUQ5EC6wlAahlA+xlgYBlQxBlwphly+Qlg8BkiJplV2IghMJdGkHaF5ZhWDJai85li+AABtwlnqJEXLJAxawAUnplhZhl0zplABwlBAxkzXpl7pICTrodxgYeF0pbT15mPaokK6iAC6gAArgmABAlgigADxAlERJAwiwmAjgAgiAACIAAGf5myJwm0UJADSgmcD5mzQwmyLwm1P5AkspmZhAAxbwmwywlhvwnAhABwAAlQ1wnRb/0JxH+ZtFCZ68yQC6CZ3fqZltCREWsIygyYxMWHmXh2bx95Wq6WYfwAId+SeuSZQMgJYM8AI8wAMikJ1lKRAL6gIv0JhoORBniQlyKQKYwKBLyQAWMJtOSZQbQANICaKz6Z0CsZaQBwAgYAENAJUWsJTWKZneuZYsapkDoZs8AJU8gAA88BAngAUiMJ/M+IVhKHWP4INSlp+GuZ+ElgD4KCquCQAD8JsN4AJT+Z0uIJcAEKF0iZYgQJsIQANrmaIDEaEeCpdnuQGS2QAiQJ7PqQAgsJYv0JyzSQNNeaYMaqcyGpuMWaPcyZhQyQADABEV0AJA2o1zWIdAN3xntgS6/yB/SopuxfhqgvKkw7miBsoD0omlWqqcUxqcOQqmRUkHJJqlaUkHSGmme8oAIrChBDEAV1qUJwoCBOqULfqdFiCZGXqetGqZL+CdmOCnTmmhe8mNhcqMhnh22odmIKefj4plPiCKTlqlvpmWtGmbmpqWW9oA4bmbX7qWFkBn5pmXs2mWe5qjbkmbL/CmRbmdv+md4Cmezbmei9mem3mdZTmg3LoBTSmmD8ECp1is9JmJUud+Z7asSdqsWAaUCykvmBCcY/qYCBGeO/qUSAkRovoQWyAGAOuPqnh2iShlRpeaCMtqQoCOQhOhCiECo3oR+KqiITGTPbCx7ciLZqdxkf9mmiWGdcw6skOGAUmwsMhIAfIps93ojFLHgpWGkTvLsy32ASabjjBLtP6IiSZpaz0oZYMnskxLaD97KXCZEJg5EVjaFEIrtRD5jokahfTFa0u7tRTmtF5Lo3OpmSWqqw4xtkzBAjFrtu0IkEA3hj7GtgfrtkPWtYzytQgRtgKhuBF7nE1xAxrLt/4okS93h/J4XZ+AC1pLuFhWso2iANw5levZm9/5AtdZnB5qnlSqmXE6nMBpnE/hr5ILkS2wfi83kCXWfW3LufoFlJLKJ7C5mXsqEDZaoAeaqXYLAK8pEHEqoQhAoY4LUU81vdRbvdZ7vdi7VGwwuyOJkxrHcT3/pruDy7sUFgbQGiio+qF9qq+aGaDJu7wAEKddap6g6hRBQKjc649Y+XKt6GAFuLnkO2RGIJboS64b0KsA8KvsK5zjKaMOW6D1SgMu4KndGr12ZwB9mb+oCJhBl2slBmS7G8DelQBMV8DC6ae/uZj6ap6BGqbX6QIHDJwNfJ2LWb9MQQGNoMEjKZpVuzrR6GAgPL4irF93wAKRqLc6PJL1aXDi6GBASI1DfGUXcIyhpwPbm8QQKaQGB3gOJmghHMW7Zb5sGAL4i8X+eKgGtwgJ12BeLMRg3Fsk8ABs+AA/asYQeazgVpENJgi8AMVv3GJDIJQzqAORa8cQ2QgCC24o/9lgqvbFf/wF5/snCUoQB+yeCPCtm+mwXBEC/WjII9mx4CZ0jFxbjvzGAwwoRLmgAoGgtQkAOcoDdDCVCgCxWkHHnjySNAtuBDtfjqBdpfzGgWzCAiECq3vCsOwCyekVVnzLNmm0yyaA5ebLbvzHvCUEkdwnXxu88Oub35qXz1mcWmEBucjMEEm1y1aa82VuvwzGJGDEgIKq5tnKNYrMwbmmWoHE5DySaGtrgYB510WO6wzGU/zOcgu/qzyZNFDPF4oVIIAF+WyTfmtrRUpfKBbQUewDJcwnqbybBGHQ3+mdrAzOWHEDD/nQI0m5wkd811XR00zNbwaTz8fJJm2Ttf+7g6JAhtd1kRY9xEbAXOnFApU40/7ovWlkudelZjs9xElAxe4GAgYg1BBNgbb2sYFhaUktwhj9fDowtFB9xilIajdbKKlQBVcdwF8A04tHAWXc1f7Iw6SGtLNF1i3t0rrVzs9XAZ/J1ofchLdmpAQQbWUdwAbwn9lmy3qdxWBIalAYGPYV2OSbAECbck592DaJxqvTxCNmBY7Nuz7QpGHnAVxN2e2Ix/FYX7qw2ZwLyaGHw6Jtk4icRrj7Y6hNuD/wtGFnAWvd2u0IyuALGAYw2257yotXAXur2/6YywXQvwYQC3NN17rl0z2Fz8btj3snb6KcZlXQ3M49BJEdcE//Pd0jac5Vh93aTdeQXXcQ8N3gfbapN5ingAvl7dJh4NkpB9rrPZIACXhIYAXxTc1CQN8UZ9/3DZESqcb73d9/LASs2nRbPeAjKXlF+gmzgOBvXNt1p9YO3r2L8AYLRuFgbOFhh+EZrr9s8AZyYAAeHsUg3nQiPuLtiIJKleJDbNchntsuHpox7txuBt0cFQRsMAJAHuQj0AgtUORGfuSU0ANKvuRMHtSt3QgoruNtxuMZVQGAsAJYnuUrAAgo0OVe/uVrUANiPuZkjgjWK+RoDuSecORs3gKcwORw3gN1jN9YkARSjmVUblEVsAIC0Od+/ueAHuiCPuh/fgVafugr/7AKX77oXU7mji7m1vvjaR7knXDkbGAAd35leS5Re07onv7poB7qoj7qAmAGiK7lbfDlBuADmU5km65QnU7qsj7rtF7rhL4GQ9Dqru4UAWACBKEBHBAADvARDiABHBLrtp7syr7sgt4GF4ABuj5km75bGrASvU4QfmDsIFHsHBIEbcDs4B7utW4GWfAD0S7tIHHt1u7rA0EGw77t2m4fFIAC4l7v9u7pV8AHQnDu6P4R1+4AHBDsMkAFAEAGupUCABAAJcABR2ACwa7wAHAEu1UCAOAHu2UIGiADunUEAJDxu8XuAFAC1G7wATDwAK9bMqDxAXAJAGACKRAAKUDxxf/uAAq/WxzP7Rsy7/e+8zwvAKCgBvzeYhjw6v/OARpABTEP8NUuEAFABgIR8wBwCQg/EEcgAwnP8gJBBhyvASlgCGSg7eouEBIw7A4w8AAgAw6g9Bog7BFv7Ckw7CWQAlQA8CAf8gEw9/FeHzrf83wP7oCQBNAe9BS24h3x79rOASVwBBw/ENe+9rylAQ7w8gHAAQBw8kdABQ+vWwtP8Qlf92Mf8bx1BDhv+Gu/9AEA+dpeAip/+jgv7/Te97Bv62ZgACQg+CxG+Bxh+AKB+ErP+OwO9QKx9izvB5Q/EDGv9QRBBk5vCGEPAJ9f9gQvEKPv69z+9pUv9zjPAX4Q9az/n/f0sQVrEPviL+tXgAhfYPu3b9sbQe3ZT/EScPCdLxAOr1uU//6TzwFIj/JU4PG6BRAaDHEIICOACQAJAUhwkJBMAIglHEhIeBDARAAmUgRIUeIixYsQCWrAqNDkSZQpVa5k2dLlS5gxY3qoIcDmTZw5de7k2dPnT6BBb9bwAdHoUaRJlS5l2tTpU6hRkX4IItPqVaxZtW7l2tXrV640hY4lW9ZsUBRDMEhl29btW7hHhVAAW9fuXbx59e5lCSLLWcCBBftccYFEXMSJFcOdy9fxY8iRJd81MNjy5bNXsnxY3NnzZ6QJdEwmXdr0ackP9mBm3bonn6KgZc+Om8AD/2rcuXXvjllhhWvgwF8NoV3ceFQDEEqXBGsiAG/o0bmGABTc+uVVF4wc5979KAYDpplLJ1+eNAUU19UDNpPljnf43H8wyXvEqEcJBgMc0WCUv/4jAOCgISpSuMQEggLAbyIOStgoAAecA0AD/fy4iAOCZKDCPA5506Gm9UIU6go+wojvxOKo4usIGRaiyDmSQCIjQA1SMMQBDi4EoCMALklhIRk0WMjChCQkgwwADEnBBBw1KNCjDqNE7QRERLTypzUSQHFL2YQw4EswwxRzTDJvU8iBB3NkaMIAYkwowYgKNEGGEvo7SoM1MzJIAkMkbDAhCSQC6U8pCy3NgCuuVP80pzYuWItLSBcTDa/+LgHADzUb6o+kFgGY8aQjOEhhQx4VylOhGY1E0pCDSiLUUFghY+K3RRdt74dIc03sAhDykkCkTNkUaKP/jBKyv4YySjDYhUTq8zkKIbLQVShjtXavENKr9corEPlCV3DfMuKBa8s1V7otQNn2SlDUCPddtu6o4Fx66z2NynVFBCSJR+H1t6kw6LJ3YIIdUy1f9cww4LB/G15qiNEKlnhisCpoA2HrNOPMYY6RSo5ikEPGioI1MA6OqI5ThugO+vZCMwCQLo3ZPhv1FPnmyfA1ubW0+lXZ4TAs2KsEBU2CCCQqAqDCjwAlQAhnqB87eGfsDPv/OWWI95IhWZNK6m/pI0qIOWqy8wqiOqoH22Ozqzs2Iry9ODr6zJk5GmjOgjYse++vblA3bcFKbLtjFfdacsJSx0uohLBbpJNvyLmCAFHAARtu8I7VuIGvT2u09KOTCtSgBMc/j/z0q5i4uPKyGt0O84bB63WvaAMg8s4zLaTCIA1R912mdFkn61bYHf6g5d9xniCClpZ/SYAOoAOBcuGBIlGI4h1WY4vkc7tJCpQ6EMAr5xWKYIKEzgeg/ITYNwl6k9SXSfy6LK4eqCyzj/3j7nGDP/zxdcV98lOI+1byv/ShDzU3ANH9eNIon+kvXIXrH2rgN4Ec2GQHAOCCTbgA/4BI2CQHXjhfBARQBgFkMA2KAMAOblKG9TEvIVK4yQ7Uh0ENxpCDHmQhAmmowQ6kQQBpgGEJBaCIDAogEvSTQhJNAQDxqZCFMJncahyoE4UxTILwGsLmKmjB6E0AfeKTAv0AEIERAiAHEYgAF6InvjBuUCE7yIEOzafAG0YCAIo4ovu48EQEnlGBaWBeGdJAQjeesY4JoV8k9KiINHQAjuuTI0yydcWcdOtbW4QXCcj1RTDqkIZlDKALayg/M+5ggxEQogA+OEA8oq98J1yeF0wpgA0GUn2jTIgApCA/KYQwB2WgHxdguD5ilrKSL/FAlTB5k3Zx0l8+CAEoQ+m8Uf+KzwuK3GYCGalMGtYCAKZ4pQzTt8gbMq8WvlweCreZg1xGz3yLJOQZD0nA9LlxfI7cI/RSucyXsGB1mNxXBKUZKQzwypqm+R42femFDH4whDYpAyqVuT4PltMkkMTlDW/CvOU10YPx3KgQdxDEIRYRjy9kohOheFGZMPCZhdHiQXX1gXktVKdRgsADzHBFjdn0XUmI2E6NWh6SXRFlQgXXHVhwVKiSZ3pWFN5wDMrULSXAi1Hl6m5CUDLhZed1WI3UDx6gnK6mFTdTZd3a3kPWXCVAYGqV2BoV0kGboM+FK4TiIgv1VdYJDq5lPStdCyY+AZjTmArxggC8YIoNTkD/noVia9rWQJzBRkquhp0Y+/CaAynQ8LE7KIMCYQVYqkEws5D6AQvQylmCGRCietyrItyYwTQmhEy75W1vffvbL4XApzsj3mq5lIStwnZgBhSkScpA2joO01AUaGC+rmdcLn3gqcotWPk6MAEvQNScXkiDFMoQXXEWqqerwFj+sIuihJqJu/VCrCsBIFIBgNd8T4RoCrtZqBs4c10FfS+KwpDT+SYYMhXQVq2yWOATkcAAs1NwhfdyAgNQlVvegvCJNmthEOuFurVaaoe984XthljFdoEAC9BmpZ6Z2DtGuIB8V3xjr3ggCxpWD01l7J0ECA3HQ/aKBap7naD+mDso/34tkZ2MFQgwocHXgY2SuUOCC5zgyVvOCoZ/ep3LWdk4GBjCXLl85phsARGJCo5YxWwcHyAYzXN+SRD+5hq3vjlFhaVzn1vS4hdjhkQm0vNssGxjPycaJSd4AK0w495CgwYDSTCzoi1tkhtk4cuWUW2kQZOAal5a1CexAB/YLJjietozPmBCk0c96hDwYTDdwp6qPfMBPr9a11EGK2CiaevO4FrLuiY2AHgNGAIDWzESRnSxR93TKQvlwcpODJaT62xdM3qgQUkyteNibWyHW9tjKbG33wLucIv7AdvuSYzNfe4LXDvdxWZ0oHfi43e7Bd3zTjeje62TtW0s32zZN/+/+82Ef+NEsAOXygcMIG+DYzvKNTi1TcLM8KjgutkRDzcEgsAHqroO41HxwQOGzXGOh0DTAmjPW0feFAwkoNUopzkAbmAAQPCh1i9nCgmSEAJX19zgjOYXz5nygQtUWugcB0EFhlBTowcAAyXf+NI5ToELCNzoJBhCBYJudZp74AFquGq+v5B0sKc9IR6/gMsHboQEsODkak+7DsZedluf3QJfp/vS2a51YJMg7lXvO9h1wIIEQL3QGAiDAZRe+L5DgAIGCAPeZYz0ClAY8ptPCAiCcAEhWP69P0gCCwjP+cJ7oAJJADyEfxB3iKNe9qpnfYdf/wAK8F32u6d96I3/e4cE4F73uyc+AFR/gTCMVagY+EDpbzD84kcfBCEwgBrcvkUS+OACFShq9L3PEghsgQVJCIPi28b8ITzAApr/fvtZcgLhDuELyk8Z89VggCDE3v37V4kO4i8E8wsXI/iA+2OCLYA+/ktAlPA/FrgAH/gA+oOUOwiDIcC/G2A/BcxAmDiBLagAA0gCH/iCACwOI5jACmQCC+g+DVxBrPCALQgCFjCABAjBH4jAxMCAH/gAIUiAC3iACqAAHUBAFhxCKvIACgiBCngAAxiCBAgDIRCCH4jCEcTBKNTBHUyAL2GCIABCDCRCL6wLDzDCI6wAMlRC3iLDCthCIPQAIfxCPDd8QziMQzmcQzqsQzu8QzzMQz3cQz7sQz/8Q0AMREEcREIsREM8RERMREVcREZsREd8REiMREmcxMgICAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Normal/physiological/habitual\" in-toeing represents a diagnosis made on the basis of normal walking for the age of that child, or where the child in-toes as a result of habit. The three terms were used interchangeably in the notes. In all of these eventualities, there is no pathology to identify. \"Foot pathology\" represents pes planus, metatarsus adductus or pronation of the forefoot. \"Other\" represents leg-length discrepancy, reduced peroneal power, or in-toeing after an ankle injury.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blackmur JP, Murray AW. Do children who in-toe need to be referred to an orthopaedic clinic? J Pediatr Orthop B 2010; 19:415. Copyright &copy; 2010&nbsp;Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28254=[""].join("\n");
var outline_f27_37_28254=null;
var title_f27_37_28255="Oblique shaft fracture of second metacarpal";
var content_f27_37_28255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique shaft fracture of second metacarpal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a displaced oblique fracture though the proximal shaft of the 2nd metacarpal. This fracture warrants orthopedic referral for reduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josh Bloom, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_37_28255=[""].join("\n");
var outline_f27_37_28255=null;
      